WO2006067446A1 - Pyridine carboxamide derivatives for use as anticancer agents - Google Patents

Pyridine carboxamide derivatives for use as anticancer agents Download PDF

Info

Publication number
WO2006067446A1
WO2006067446A1 PCT/GB2005/004986 GB2005004986W WO2006067446A1 WO 2006067446 A1 WO2006067446 A1 WO 2006067446A1 GB 2005004986 W GB2005004986 W GB 2005004986W WO 2006067446 A1 WO2006067446 A1 WO 2006067446A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
alkyl
methyl
mmol
compound
Prior art date
Application number
PCT/GB2005/004986
Other languages
French (fr)
Inventor
Lynsie Almeida
Brian Aquila
Don Cook
Scott Cowen
Les Dakin
Jayachandran Ezhuthachan
Stephanos Ioannidis
John W Lee
Stephen Lee
Paul Dermot Lyne
Timothy Pontz
David Scott
Mei Su
Xiaolan Zheng
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Limited filed Critical Astrazeneca Ab
Priority to JP2007547642A priority Critical patent/JP2008525406A/en
Priority to MX2007007574A priority patent/MX2007007574A/en
Priority to CA002589773A priority patent/CA2589773A1/en
Priority to DE602005013819T priority patent/DE602005013819D1/en
Priority to BRPI0519181-5A priority patent/BRPI0519181A2/en
Priority to EP05820952A priority patent/EP1831198B1/en
Priority to AU2005317870A priority patent/AU2005317870A1/en
Publication of WO2006067446A1 publication Critical patent/WO2006067446A1/en
Priority to IL183527A priority patent/IL183527A0/en
Priority to NO20072784A priority patent/NO20072784L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the invention relates to chemical compounds, of pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body.
  • the invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their Use in the manufacture of medicaments of Use in the production of an anti-cancer effect in a warm-blooded animal such as man.
  • Ras, Raf, MAP protein kinase/extracellular signal -regulated kinase kinase (MElC), extracellular signal -regulated kinase (ERK) pathway plays a central role in the regulation of a variety of cellular functions dependent upon cellular context, including cellular proliferation, differentiation, survival, immortalization and angiogenesis (reviewed in PeyssonnaUx and Eychene, Biology of the Cell, 2001, 93, 3-62).
  • Raf family members are recruited to the plasma membrane upon-binding to guanosine triphosphate (QtP) loaded Ras resulting in the phosphorylation and activation of Raf proteins.
  • QtP guanosine triphosphate
  • Rafs Activated Rafs then phosphorylate and activate MEKs, which in turn phosphorylate and activate ERKs.
  • ERKs translocate from the cytoplasm to the nucleus resulting in the phosphorylation and regulation of activity of transcription factors such as EIk-I and Myc.
  • the Ras/Raf/MEK/ERK pathway has been reported to contribute to the tumorigenic phenotype by inducing immortalisation, growth factor-independent growth, insehsitivity to growth-inhibitory signals, ability to invade and metastasis, stimulating angiogenesis and inhibition of apoptosis (reviewed in Kolch et al., Exp.Rev. MoI.
  • ERK phosphorylation is enhanced in approximately 30% of all human tumours (Hoshino et al., Oncogene, 1999, 18, 813-822). This friay be a result of overexpression and/or mutation of key members of the pathway.
  • Raf serine/threonine protein kinase isoforrtts have been reported Raf-1 /c-Raf, B-Raf and A-Raf (reviewed in Mercer and Pritchard, Biochim. Biophys. Acta, 2003, 1653, 25-40), the genes for which are thought to have arisen from gene duplication. All three Raf genes are expressed in most tissues with high-level expression of B-Raf in neuronal tissue and A-Raf in urogenital tissue. The highly homologous Raf family members have overlapping but distinct biochemical activities and biological functions (Hagemann and Rapp, Expt. Cell Res. 1999, 253, 34-46).
  • B-Raf The most frequent mutation in B-Raf (80%) is a glutamic acid for valine substitution at position 600. These mutations increase the basal kinase activity of B-Raf and are thought to uncouple Raf/MEK/ERK signalling from Upstream proliferation drives including Ras and growth factor receptor activation resulting in constitutive activation of ER ⁇ C. Mutated B-Raf proteins are transforming in N1H3T3 cells (Davies et al., Nature, 2002,
  • AstraZeneca application WO 00/55120 discloses certain amide derivatives which are inhibitors of the production of cytokines such as TNt 1 , in particular of TNF ⁇ , and various interleukins, in particular IL-I .
  • the present invention provides a compound of formula (I):
  • Ring A is phenyl of a monocyclic 5 of 6 ftiembefed fully-unsatufated heterocyclic ring; wherein said phenyl or heterocyclic ring may be optionally fused to a five or six membered carbocyclyl or heterocyclyl forming a bicyclic ring; and wherein if said heterocyclyl or heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 5 ;
  • R 1 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci- ⁇ alkyl, C 2- ealkenyl, C 2-6 alkynyl, C
  • R 2 is selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C
  • R 3 is selected from halo, hydroxy, cyano, methyl, methoxy or hydroxymethyl;
  • R 4 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C
  • Ci -6 alkyl 2 carbamoyl
  • Ci -6 alkoxycarbonyl jV-(C] -6 alkyl)sulphamoyl
  • N,7V-(Ci. 6 alkyl) 2 sulphamoyl Ci -6 alkylS(O) a wherein a is 0 to 2
  • Ci -6 alkoxycarbonyl jV-(C] -6 alkyl)sulphamoyl
  • N,7V-(Ci. 6 alkyl) 2 sulphamoyl jV-(C] -6 alkyl)sulphamoyl
  • G is selected from halo, ttitfo, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C
  • R 6 , R 7 , R 10 , R", R 14 , R 15 , R 18 , R 19 , R 22 and R 23 are independently selected from a direct bond, -O-, -N(R 26 )-, -C(O)-, -N(R 27 )C(O)-, -C(O)N(R 28 )-, -S(O) 5 -, -SO 2 N(R 29 )- or -N(R 30 )SO 2 -; wherein R 26 , R 27 , R 28 , R 29 and R 30 are independently selected from hydrogen or Cualkyl and s is 0-2;
  • R 5 , R 9 , R 13 , R 17 , R 21 and R 25 are independently selected from Cualkyl, Cualkanoyl, Cualkylsulphonyl, Cualkoxycarbonyl, carbamoyl, /V-(C i -6 alkyl)carbamoyl, N,N-(Ci- 6 alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
  • R 20 and R 24 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, tfifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-niethyl-N-ethylamino, acetylamin ⁇ , iV-methylcarbamoyl, jV-ethylcarbamoyl,
  • Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from k 5 ;
  • R is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci -6 alkyl, C 2-6 alkenyl,
  • R 6 alkyl 2 sulphamoyl, Cualkylsulphonylamino, carbocyclyl-R 6 - or heterocyclyl-R 7 -; wherein R 1 may be optionally substituted on carbon by one or more R 8 ; and wherein if said heterocyclyl contains an -MH- moiety that nitrogen may be optionally substituted by a group selected from R 9 ;
  • H is selected from 0-4; wherein the values of R 1 may be the same or different;
  • R 2 is selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci ⁇ alkyl, C 2-6 alkenyl, C 2-6 alkyiiyl, Cualkoxy, Ci-r,alkanoyl, C
  • R is selected from halo, hydroxy, cyatto, methyl, methoxy or hydroxyniethyl; R is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C
  • R 6 , R 7 , R 10 , R n , R 14 , R 1S , R 18 , R 19 , R 22 and R 23 are independently selected from a direct bond, -O-, -N(R 26 )-, -C(O)-, -N(R 27 )C(O)-, -C(O)N(R 28 )-, -S(O) 8 -, -SO 2 N(R 29 )- or
  • R 26 , R 27 , R 28 , R 29 and R 30 are independently selected from hydrogen or
  • Ci- G alkyl and s is 0-2;
  • R 5 , R 9 , R 13 , R 17 , R 2t and R 25 are independently selected from Cualkyl, Ci -6 alkanoyl,
  • R 20 and R 24 are independently selected from halo, nitro, cyano, hydroxy, trifiuoromethoxy, trifiuoroirtethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamiiio, ethylamino, diniethylamino, diethylamino, jV-methyl-jV-ethylamino, acetylamino, TV-r
  • alkyl includes both straight and branched chain alkyl groups. References to individual alkyl groups such as “propyl” are specific for the straight chain version only and references to individual branched chain alkyl groups sUch as 'isopropyl' are specific for the branched chain version only, for example, "C
  • halo refers to fluoro, chloro, bromo and iodo.
  • Ring A may be a "monocyclic 5 or 6 membered fully unsaturated heterocyclic ring".
  • a "monocyclic 5 or 6 membered fully unsaturated heterocyclic ring” is fully unsaturated, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH 2 - group can optionally be replaced by a -C(O)- and a ring sulphur atom may be optionally oxidised to form the S-oxides.
  • Examples of a "monocyclic 5 or 6 membered fully unsaturated heterocyclic ring” are pyridyl, pyrazolyl, thienyl, isoxazolyl, furanyl, 1 ,3-thiazolyl, pyrimidinyl and pyrrolyl.
  • Ring A may also be phenyl or a monocyclic 5 or 6 membered fully unsaturated heterocyclic ring; "wherein said phenyl or heterocyclic ring may be optionally fused to a five or six membered carbocyclyl or heterocyclyl forming a bicyclic ring".
  • said bicyclic ring is a bicyclic ring containing 8, 9 or 10 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH 2 - group can optionally be replaced by a -C(O)- and a ring sulphur atom may be optionally oxidised to form the S-oxides.
  • bicyclic ring examples include indolyl, 2,3-dihydrobenzofuranyl, imidazo[l ,2-a]pyridinyl, benzimidazolyl and 2- oxoindolinyl.
  • a "heterocyclyl” is a saturated, partially saturated of unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, " unless otherwise specified, be carbon or nitrogen linked, wherein a -CH 2 - group can optionally be replaced by a -C(O)- and a ring sulphur atom may be optionally oxidised to form the S-oxides.
  • heterocyclyl examples and suitable values of the term "heterocyclyl" are niorpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, pyrazolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1 ,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, N-methylpyitolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, pyridine-N-oxide and quinoline-7
  • heterocyclyl is a saturated, partially saturated or unsaturated, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a -CH 2 - group can optionally be replaced by a -C(O)-and a ring sulphur atom may be optionally oxidised to form the S-oxides.
  • a “carbocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CM 2 - group can optionally be replaced by a -C(O)-. Particularly “carbocyclyl” is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms.
  • Suitable values for "carbocyclyl” include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl.
  • a particular example of “carbocyclyl” is phenyl.
  • Cualkanoyloxy is acetoxy.
  • C ⁇ -6 alkoxycarbonyl include methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbortyl.
  • Examples of "Ci -6 alkoxy” include methoxy, ethoxy and propoxy.
  • Examples of "C]. 6 alkanoylamino” include formamido, acetamido and propionylamino.
  • -6 alkylS(O) a wherein a is 0 to 2" include methylthio, ethylthio, rnethylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl.
  • -6 alkanoyl” include propionyl and acetyl.
  • Examples of 'W-(Ci - 6 alkyl)amino” include methylamino and ethylamino.
  • -6 alkyl) 2 amino” include di-W-methylamino, di-(N-ethyl)amino and
  • N-ethyl-N-methylamiho examples of “C 2-6 alkenyl” are vinyl, allyl and 1 -propenyl.
  • Examples of “C 2-6 alkynyl” are ethynyl, 1-propynyl and 2-propynyl.
  • . 6 alkyl)sulphamoyl are N-(methyl)sulphanioyl and N-(ethyl)sulphamoyl.
  • Examples of ⁇ W-(Cj -6 alkyl) 2 sulphanioyl” are jV,N-(dimethyl)sulphamoyl and N-(methyl)-N-(ethyl)sul ⁇ hamoyl.
  • Examples of 'W-(Ci -6 alkyl)carbamoyl are jV-(Cualkyl)carbamoyl, methylaminocarbonyl and ethylaminocarbonyl.
  • .6alkyl) 2 carbamoyl” are N,W-(Cualkyl) 2 carbamoyl, diitiethylaminocarbonyl and methylethylaminocarbonyl.
  • . 6 alkylsulphonyl” are mesyl, ethylsulphonyl and isopropylsulphonyl.
  • Examples of “C ⁇ -6 alkylsulphonylamino” are mesylamino, ethylsulphonylamino and isopropylsulphonylamino.
  • -6 alkoxycarbohylamino” are methoxycarbonylamino and f-butoxycarbohylamino.
  • . 6 alkoxy)sulphamoyl” are N-(methyl)-N-(methoxy)sulphanioyl and N-(ethyl)-jV-(propoxy)sulphamoyl.
  • Example of ⁇ W,N-(C ⁇ -6 alkyl) 2 ureido are N,N'-dimethylureido and N-methyl-N'-propylureido.
  • . 6 alkyl) 2 ureido” are N'N'-diethylureido and N'-methyl-N'-propylureido.
  • -6 alkyl)-N',N'-(Ci -6 alkyl) 2 ureido" are N-(methyl)-N'-ethyl-N'-isopropylureido and N-ethyl-N'N'-diethylureido.
  • Examples of W-(Ci -6 alky I)-N-(C ⁇ -6 alkoxy)amino are N-(methyl)-N-(propoxy)amino and N-methyl-N-methoxyamino.
  • a suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid.
  • a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
  • an alkali metal salt for example a sodium or potassium salt
  • an alkaline earth metal salt for example a calcium or magnesium salt
  • an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation
  • a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxye
  • Some compounds of the formula (I) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess B-Raf inhibitory activity.
  • the invention further relates to any and all tautomeric forms of the compounds of the formula (I) that possess B-Raf inhibitory activity.
  • Ring A is a monocyclic 5 or 6 membered fully-unsaturated heterocyclic ring; wherein if heterocyclic ring contains an - ⁇ tt- moiety that nitrogen may be optionally substituted by a group selected from R 5 .
  • Ring A is phenyl fused to a five or six membered carbocyclyl or heterocyclyl forming a bicyclic ring; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 5 .
  • Ring A is a heterocyclic ring fused to a five or six membered carbocyclyl or heterocyclyl forming a bicyclic ring; wherein if said heterocyclyl or heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 5 .
  • Ring A is carbocyclyl. Ring A is phenyl.
  • Ring A is heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R 5 .
  • Ring A is pyridyl
  • Ring A is pyrazolyl; wherein said pyrazolyl may be optionally substituted on nitrogen by a group selected from R 5 .
  • Ring A is thienyl
  • Ring A is imidazo[l,2-a]pyridinyl.
  • Ring A is indolyl.
  • Ring A is 2,3-dihydrobenzofuranyl. Ring A is isoxazoiyl.
  • Ring A is benzimidazolyl.
  • Ring A is 2-oxoindolinyl.
  • Ring A is furanyl
  • Ring A is 1,3-thiazolyl. Ring A is pyrimidinyl.
  • Ring A is pyttolyl.
  • Ring A is phenyl, pyridyl, pyrazolyl, thienyl, indolyl, 2,3-dihydrobenzofuranyl, ittiidazo[l,2-a]pyridinyl, isoxazoiyl, benzimidazolyl, 2-oxoindolinyl, furanyl, 1,3-thiazolyl, pyrimidinyl and pyitolyl; wherein said pyrazolyl, indolyl, pyrrolyl may be optionally substituted on nitrogen by a group selected from R 5 ; wherein
  • R 5 is selected frotti Ci-ealkyl.
  • Ring A is phenyl, pyridyl, pyrazolyl, thienyl, indolyl, 2,3-dihydrobenzofuranyl and imidazo[l,2-a]pyridinyl; wherein said pyrazolyl may be optionally substituted on nitrogen by a group selected from R 5 ; wherein R 5 is C ⁇ -6 alkyl.
  • Ring A is phenyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, l-methylpyrazol-5-yl, ⁇ - ⁇ - butylpyrazol-5-yl, thien-2-yl, thiert-3-yl, ilidol-2-yl, 1 -methylindol-2-yl, indol-4-yl, indol-5-yl, indol-6-yl, indol-7-yl, 2,3-dihydrobeiizofuran-7-yl, imidazo[l ,2-a]pyridin-2-yl, isoxazol-3-yl, pyrrol-2-yl, benzimidazol-6-yl, l-methyl-2-oxoindolih-5-yl, furan-2-yl, l,3-thiazol-5-yl, pyrimidili-4-yl and l-methyl
  • Ring A is phenyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, l -methylpyrazol-5-yl, thien-2-yl, thien-3-yl, indol-5-yl, indol-6-yl, 2,3-dihydrobenzofurati-7-yl or imidazo[l,2-a]pyridinyl. Ring A is not pyridyl.
  • Ring A is not pyrid-4-yl.
  • R is a substituent on carbon and is selected from halo, cyano, hydroxy, stilphanioyl, C
  • R 8 is selected from halo, cyano, hydroxy, C
  • R 6 , R 7 , R 18 and R 19 are independently selected from a direct bond, -O-, -S(O) 8 - or -N(R 30 )SO 2 -; wherein R 30 is selected from hydrogen and s is 2;
  • R 2 ' is selected from C ⁇ -6 alkyl
  • R 20 is selected from cyano or hydroxy.
  • R 1 is a substituent on carbon and is selected from halo, cyano, Ci ⁇ alkyl, C 2-6 alkynyl, C
  • R 8 is selected from halo, cyano, hydroxy, N,N-(C
  • R 2 l is C 1-6 alkyl.
  • R 1 is a substituent on carbon and is selected from fluoro, chloro, bromo, iodo, cyano, hydroxy, sulphamoyl, methyl, ethyl, isopropyl, sec-butyl, /-butyl, 2-ttiethylbut-2-yl, 3- methylbut-2-yl, l,l-dimethylprop-2-yn-l-yl, l,l-dimethylbut-2-yn-l-yl, 3,3-dimethylbut-l- yn-l-yl, 3-methylbut-l-yn-l-yl, methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, 7V,N-dimethylamiho, ⁇ N-diethylamino, methylthio, mesyl, f-butoxycarbonylamino, N-methylsulphamo
  • R 6 , R 7 , R 18 and R 19 are independently selected from a direct bond, -O-, -S(O) 5 - or - ⁇ (R 30 )SO 2 -; wherein R 30 is selected from hydrogen and s is 2; R 21 is selected from methyl or ethyl; R 20 is selected from cyano or hydroxy.
  • R 1 is a substituent on carbon and is selected from fluoro, chloro, bromo, iodo, cyano, methyl, isopropyl, t-butyl, 3-methylbut-l-yn-l-yl, 3,3-dimethylbut-l -yii-l-yl, methoxy, propoxy, isopropoxy, isobutoxy, dittiethylamino, methylthio, mesyl, jV.N-dimethylsulphamoyl, mesylamino, cyclopropyl-R 6 - or azetidin-1-yl-R 7 -; wherein R 1 may be optionally substituted on carbon by one or more R 8 ; R 8 is selected from fiuoro, cyano, hydroxy, dimethylamino or piperazin-1-yl-R 19 -; wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from
  • R 6 , R 7 and R 19 are independently selected from a direct bond, -S(O) 5 - or -K(R 30 )SO 2 -; wherein R 30 is hydrogen and s is 2; R 2 ' is methyl or ethyl.
  • R 1 is a substituent on carbon and is selected from fluoro, chloro, bromo, iodo, cyano, hydroxy, sulphamoyl, methyl, trifluoromethyl, 1 -cyano- 1-metliylethyl, methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, TV.N-dimethylamin ⁇ , difluoromethylthio, jV.jV-dimethylsulphanioyl, f-butyl, mesyl, cyclopropylaminosulphonyl, azetidin-1-ylsulphonyl, teti-ahydrofumn-2-ylmethylai ⁇ iinosulphottyl, ⁇ V-niethyl-jV-(2,3-dihydi-oxypropyl)sulphaiiioyl, mesylamino, morpholinosulphonyl
  • R is a substitue ⁇ t oh carbon and is selected from fl ⁇ oro, chloro, bromo, iodo, cyano, methyl, t-butyl, trifluoromethyl, dimethylaminomethyl, 1 -methyl- 1-cyattoethyl, A- methylpiperazin-1-ylmethyl, 4-ethylpiperazin-l-ylmethyl, 3-hydroxy-3-methylbut-l-yn-l -yl, 3,3-dimethylbut-l-yn-l -yl, methoxy, propoxy, isopropoxy, isobutoxy, dimethylamino, difluoromethylthio, jV,N-dimethylsulphamoyl, mesyl, cyclopropylaminosulphonyl, azetidin-1- ylsulphonyl or mesylamirio.
  • R 1 is a substituent on carbon aiid is selected from 1 -methyl- 1-cyahoethyl.
  • R 1 is a substituent on carbon and is selected from trifluoromethyl. ri Is selected from 0-2; wherein the values of R may be the same or different. n is 0. tt Is 1. n is 2; wherein the values of R 1 may be the same or different.
  • R 2 is hydrogen
  • R 3 is selected from halo, methyl or methoxy.
  • R 3 is selected from halo or methyl.
  • R 3 is selected from fluoro, chloro, methyl or methoxy.
  • R 3 is selected from fluoro, chloro or methyl.
  • R 3 is fluoro.
  • R 3 is chloro.
  • R 3 is methyl
  • R 3 is methoxy
  • R 3 is not chloro.
  • R is selected from halo, cyano, hydroxy, amino, carbamoyl, ureido, Ci-ealkyl,
  • R 16 is selected from halo, hydroxy, amino, C
  • R l ? and R 25 are independently selected from Ci -6 alkyl and Cualkoxycarbonyl;
  • R 24 is methyl or phenyl.
  • R 4 is selected from halo, cyano, amino, Cj -6 alkyl, Ci -6 alkoxy, N-(C
  • R 15 is a direct bond.
  • R is selected from fluoro, chloro, bromo, cyano, hydroxy, amino, carbamoyl, ureido, methyl, ethyl, propyl, prop-1-ynyl, methoxy, ethoxy, propoxy, isopropoxy, acetyl, hiethylamino, ethylamino, propylamino, isopropylamino, butylamino, dimethylamitto, N- methyl-7V-ethylamino, jV-methyl-N-propylamino, formylamino, acetylamino, propanoylamino, 2,2-dimethylpropanoylamino, 7V-methylcarbamoyl, methoxycarbonyl, N,jV-dimethylsUlphamoyl, mesylamino, cyclopropyl-R 14 -, cyclobutyl-R 14 -, piperazin
  • R 16 is selected from fluoro, hydroxy, amino, methoxy, niethylamino, jV.N-dimethylamirto, cyclopropyl-R 22 -, 1,3-dioxolanyl-R 23 -, imidazolyl-R 23 -, morpholino-R 23 -, piperazinyl-R 23 -, piperidihyl-R 23 - or pyrrolidinyl-R 23 -; wherein R l 6 may be optionally substituted on carbon by one or more R 2 ; and wherein said piperazinyl or pyrrolidinyl may be optionally substituted on nitrogen by a group selected from R 25 ;
  • R 14 , R 15 , R 22 and R 23 are independently selected from a direct bond, -N(R 26 )- or -C(O)N(R 28 )-; wherein R 26 and R 28 are hydrogen; R 17 and R 25 are independently selected from methyl and f-butoxycarbonyl;
  • R 24 is methyl or phenyl.
  • R is selected from fluoro, chloro, bromo, cyano, amino, methyl, methoxy, niethylamino, acetylamino, iV-inethylcarbamoyl or morpholino.
  • R is selected from fluoro, chloro, bromo, cyano, hydroxy, amino, carbamoyl, ureido, methyl, ethyl, methoxy, methylamino, isopropylamino, morpholino, 2-
  • Ring A is phenyl, pyridyl, pyrazolyl, thienyl, indolyl, 2,3-dihydrobeiizofuranyl, imidazotl,2-a]pyridinyl, isoxazolyl, benzimidazolyl, 2-oxoindolinyl, furanyl, 1,3-thiazolyl, pyrimidinyl and pyrrolyl; wherein said pyrazolyl, indolyl, pyitolyl may be optionally substituted on nitrogen by a group selected from R 5 ;
  • R is a substituent oh carbon and is selected from halo, cyano, hydroxy, sulphamoyl, C
  • R 2 is hydrogen;
  • R 3 is selected from halo, methyl or methoxy;
  • R is selected from halo, cyano, hydroxy, amino, carbamoyl, ureido, C
  • R 4 may be optionally substituted on carbon by one or more R ; and wherein if said heterocyclyl contains art -NH- moiety that nitrogen may be optionally substituted by a group selected from R ;
  • R 5 is selected from Ci -6 alkyl; m is selected from 0-2; wherein the values of R may be the same or different;
  • R 6 , R 7 , R 18 and R 19 are independently selected from a direct bond, -O-, -S(O) 5 - or -N(R 30 )SO 2 -; wherein R 30 is selected from hydrogen and s is 2;
  • R 8 is selected from halo, cyano, hydroxy, C
  • R 14 , R 15 , R 22 and R 23 are independently selected from a direct bond, -N(R 26 )- or -C(O)N(R 28 )-; wherein R 26 and R 28 are hydrogen; R 16 is selected from halo, hydroxy, amino, C
  • R 2 is selected from C h alky!
  • R 20 is selected from cyano or hydroxy
  • R 24 is methyl or phenyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not:
  • Ring A is phenyl, pyridyl, pyrazolyl, thienyl, indolyl, 2,3-dihydrobenzofuranyl and imidazotl,2-a]pyridinyl; wherein said pyrazolyl may be optionally substituted on nitrogen by a group selected from R 5 ;
  • R is a substituent on carbon and is selected from halo, cyano, Ci-ealkyl, C 2 - 6 alkynyl, C
  • R 2 is hydrogen
  • R 3 is selected from halo or methyl;
  • R is selected from halo, cyano, amino, C
  • m is selected from 0-2; wherein the values of R 4 may be the same or different;
  • R 5 is Ci -6 alkyl
  • R 6 , R 7 and R 19 are independently selected from a direct bond, -S(O),- or -N(R 30 )SO 2 -; wherein R 30 is hydrogen and s is 0-2;
  • R 8 is selected from halo, cyano, hydroxy, /V,/V-(C!- 6 alkyl) 2 amino or heterocyclyl-R 19 -; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R ; R 15 is a direct bond;
  • R 21 is Cualkyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not:
  • Ring A is phenyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, l-methylpyrazol-5-yl, 1-/- butylpyrazol-5-yl, thien-2-yl, thien-3-yl, indol-2-yl, l-methylindol-2-yl, indol-4-yl, indol-5-yl, indol-6-yl, indol-7-yl, 2,3-dihydrobenzofuran-7-yl, imidazo[l,2-a]pyridin-2-yl, isoxazol-3-yl, pyrrol-2-yl, benzimidazol-6-yl, l-methyl-2-oxoindolin-5-yl, furan-2-yl, l ,3
  • R 2 is hydrogen
  • R 3 is selected from fiuoro, chloro, methyl or methoxy
  • R is selected from fiuoro, chloro, bromo, cyano, hydroxy, amino, carbamoyl, ureido, methyl, ethyl, methoxy, methylamilio, isopropylamino, morpholiiio, 2- (dimethylamino)ethylamino, 2-(hydroxy)ethylamino, 2-(amino)ethylamino, 3-(pyrrolidin-1 - yl)propylamino, jV-methylcarbamoyl, acetylamino, 2-hydroxyacetylamino, trifluoromethyl, mesylamino, 2,2-dimethylpropanoylamino, 3-methoxypropanoylamino, cyclobutylcarbonylamino, cyclopropylamino, 2,3-dihydroxypropylamino, 1,3-dihydroxyprop- 2-ylamino, 1 -methylpiperazin-4-y
  • Ring A is phenyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, l-methylpyrazol-5-yl, thien-2-yl, thien-3-yl, indol-5-yl, indol-6-yl, 2,3-dihydrobenzofUran-7-yl or imidazo[l,2-a]pyridinyl;
  • R is a substittient on carbon and is selected from fluoro, chloro, bromo, iodo, cyano, methyl, t-butyl, trifluoromethyl, dimethylaminoniethyl, 1 -methyl- 1 -cyattoethyl, 4- methylpiperazin- 1 -ylmethyl, 4-ethylpiperazin- 1 -ylniethyl, 3-hydroxy-3-methylbut- 1 -yn- 1 -yl, 3,3-diniethylbut-l-yn-l -yl, methoxy, propoxy, isopropoxy, isobutoxy, dimethylamino, difluoroniethylthio, ⁇ jV-dimethylsulphamoyl, mesyl, cyclopropylaminosulphonyl, azetidin-1- ylsulphoiiyl or mesylamino; n is selected from
  • R 2 is hydrogen
  • R 3 is selected from fluoro, chloro or methyl
  • R is selected from fluoro, chloro, bromo, cyano, amino, methyl, methoxy, niethylaniino, acetylaniin ⁇ , jV-methylcarbamoyl or morpholino; m Is selected from 0-2; wherein the values of R 4 may be the same or different, or a pharmaceutically acceptable salt thereof.
  • preferred compounds of the invention are any one of the Examples or a pharmaceutically acceptable salt thereof.
  • preferred compounds of the invention are any one of:
  • Process a) and Process b) Amines and acids may be coupled together in the presence of a suitable coupling reagent.
  • Standard peptide coupling reagents known in the art can be employed as suitable coupling reagents, or for Example carbonyldiimidazole and dicyclohexyl-carbodiimide, optionally in the presence of a catalyst such as dittiethylaminopyrldine or 4-pyrrolidinopyridine, optionally in the presence of a base for Example triethylamine, pyridine, or 2,6-di-o%/-pyridines such as 2,6-lutidine or 2,6-di-fe/V-butylpyridine.
  • Suitable solvents include diniethylacetamide, dichloromethane, benzene, tetrahydrofuran and dihiethylformaniide.
  • the coupling reaction may conveniently be performed at a temperature in the range of -40 to 40 °C.
  • Suitable activated acid derivatives include acid halides, for Example acid chlorides, and active esters, for Example pentafluorophenyl esters.
  • the reaction of these types of compounds with amines is well known in the art, for Example they may be reacted in the presence of a base, such as those described above, and in a suitable solvent, such as those described above.
  • the reaction may conveniently be performed at a temperature in the range of -40 to 40 0 C.
  • Pg is an acid protecting group, for example such as those described herein below.
  • aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under friedel Crafts conditions; and the introduction of a halogeno group.
  • an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under friedel Crafts conditions
  • Lewis acid such as aluminium trichloride
  • modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenatioii with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heatihg; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
  • a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a rnethoxycarbohyl, ethoxycarbonyl or /-butoxycarbonyl group, an arylmethoxycarbohyl group, for example benzyloxycarbottyi, or an aroyl group, for example benzoyl.
  • the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an acyl group such as a /-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydr ⁇ genation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
  • a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamiiie, or with hydrazine.
  • a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkaiioyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl.
  • the deprotection conditions for the above protecting groups will necessarily vaty with the choice of protecting group.
  • an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a f-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a base such as sodium hydroxide
  • a f-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • the protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
  • the compounds defined in the present invention possess anti-cancer activity which is believed to arise from the B-Raf inhibitory activity of the compounds. These properties may be assessed, for example, Using the procedure set out below. B-Raf in vitro ELlSA assay
  • the reaction Utilized 2.5 nJVl B-Raf, 0.15 ⁇ M MEKl and 10 ⁇ M adenosine triphosphate (ATP) in 40 niM 7V-(2-hydroxyethyl)piperaziiie-N'-(2- ethanesulfonic acid hemisodium salt (HEPES), 5 hiM 1 ,4-dithio-t)L-threitol (DTT), 10 mM MgCl 2 , 1 mM ethyleliediamihetetraacetic acid (Et)TA) and 0.2 M NaCl (Ix HEPES buffer), with or without compound at various concentrations, in a total reaction volume of 25 ⁇ l in 384 well plates.
  • HEPES niM 7V-(2-hydroxyethyl)piperaziiie-N'-(2- ethanesulfonic acid hemisodium salt
  • DTT 5 hiM 1 ,4-di
  • the compounds of the present invention When tested in the above in vitro assay, the compounds of the present invention exhibited activity less than 30 ⁇ M. for example the following results were obtained:
  • a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore, in association with a pharmaceutically-acceptable diluent or carrier.
  • the composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
  • compositions may be prepared in a conventional manner using conventional excipients.
  • the compound of formula (I) will normally be administered to a warm-blooded animal at a unit dose within the range 1 -1000 mg/kg, and this normally provides a therapeutically-effective dose.
  • a daily dose in the range of 10-100 mg/kg is employed.
  • the daily dose will necessarily be varied depending Upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
  • a compound of the formula (1), or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use in a method of treatment of the human or animal body by therapy.
  • the compounds defined in the present invention are effective anti-cancer agents which property is believed to arise from their B-Raf inhibitory properties. Accordingly the compounds of the present invention are expected to be useful in the treatment of diseases or medical conditions mediated alone or in part by B-Raf , i.e. the compounds may be used to produce a B-Raf inhibitory effect in a warm-blooded animal in need of such treatment.
  • the compounds of the present invention provide a method for treating cancer characterised by inhibition of B-Raf, i.e. the compounds may be Used to produce an anti- cancer effect mediated alone or in part by the inhibition of B-Raf.
  • Such a compound of the invention is expected to possess a wide range of anti-cancer properties as activating mutations in B-Raf have been observed in many human cancers, including but not limited to, melanoma, papillary thyroid tumors, cholangiocarcinomas, colon, ovarian and lung cancers. Thus it is expected that a compound of the invention will possess anti-cancer activity against these cancers. It is in addition expected that a compound of the present invention will possess activity against a range of leukaemias, lymphoid malignancies and solid tumours such as carcinomas and sarcomas in tissues such as the liver, kidney, bladder, prostate, breast and pancreas.
  • such compounds of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the skin, colon, thyroid, lungs and ovaries. More particularly such compounds of the invention, or a pharmaceutically acceptable salt thereof, are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with B-Raf, especially those tumours which are significantly dependent on B-Raf for their growth and spread, including for example, certain tumours of the skin, colon, thyroid, lungs and ovaries. Particularly the compounds of the present invention are useful in the treatment of melanomas.
  • a compound of the formula (t), or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use as a medicament According to a further aspect of the Invention there is provided the Use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of a B-Raf inhibitory effect in a warm-blooded animal such as man. According to this aspect of the invention there is provided the Use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for Use in the production of an anti-cancer effect in a warm-blooded animal such as man.
  • a method for producing a B-Raf inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined above.
  • a method for producing an anti-cancer effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined above.
  • a method of treating melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries, in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined herein before.
  • a pharmaceutical composition which comprises ⁇ compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined herein before in association with a pharmaceUtically-acceptable diluent or carrier for use in the production of a B-Raf inhibitory effect in a warm-blooded animal such as man.
  • a pharmaceutical composition which comprises a compound of the formula (J), or a pharmaceutically acceptable salt thereof, as defined herein before in association with a pharmaceutically-acceptable diluent or carrier for Use in the production of an anti-cancer effect in a warm-blooded animal such as man.
  • a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined herein before in association with a pharmaceutically-acceptable diluent or carrier for use in the treatment of melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries in a warm-blooded animal such as man.
  • the B-Raf inhibitory treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy.
  • Such chemotherapy may include one or more of the following categories of anti-tumour agents :- (i) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, lnelphalan, chlorambucil, busulphaii and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside and hydroxyurea; antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin
  • cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene), oestrogen receptor down regulators (for example fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LMRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example ttiegestrol acetate), aromatase inliibitors (for example as anastrozole, letrozole, vorazole and exelnestane) and inhibitors of 5 ⁇ -reductase such as finasteride;
  • antioestrogens for example tamoxifen, toremifene, raloxifene, droloxifene and i
  • Agents which inhibit cancer cell invasion for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function);
  • inhibitors of growth factor function include growth factor antibodies, growth factor receptor antibodies (for example the anti-erbb2 antibody trastuzumab [Herceptin +M ] and the anti-erbbl antibody cetuximab [C225J) , farnesyl transferase inhibitors, MEK inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inliibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as N-(3-chloro-4-fluoropliertyl)-7-methoxy-6-(3- ttiorpholinopropoxy)quinazolin-4-amine (gefitinib,
  • antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, (for example the anti-vascular endothelial cell growth factor antibody bevacizumab [Avastin tM ], compounds such as those disclosed in International Patent AppHcations WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compounds that work by other mechanisms (for example linomide, inhibitors of integrin ⁇ v ⁇ 3 function and atigiostatin);
  • vascular endothelial growth factor for example the anti-vascular endothelial cell growth factor antibody bevacizumab [Avastin tM ]
  • compounds that work by other mechanisms for example linomide, inhibitors of integrin ⁇ v ⁇ 3 function and atigiostatin
  • antisettse therapies for example those which are directed to the targets listed above, such as IStS 2503, an anti-ras antisense;
  • gene therapy approaches including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCAl or BRCA2, Gt)]EPT (gene-directed enzyme pro-drug therapy) approaches such as those Using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy;
  • immunotherapy approaches including for example ex-vivo and in-vivo approaches to increase the ininiuttogenicity of patient tumour cells, such as transfectioli with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches Using transfected immune cells such as cytokine-transfected dendritic cells, approaches Using cytokine-traiisfected tumour cell lines and approaches using anti-idiotypic antibodies;
  • Cell cycle inhibitors including for example CDlC inhibitiors (eg flavopiridol) and other inhibitors of cell cycle checkpoints (eg checkpoint kinase); inhibitors of aurora kinase and other kinases involved in mitosis and cytokinesis regulation (eg mitotic kinesins); and histone deacetylase inhibitors; and
  • endothelin antagonists including endothelin A antagonists, endothelin B antagonists and endothelin A and B antagonists; for example ZD4054 and Zt)161 1 (WO 96 40681 ), atrasentan and YM 598.
  • Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.
  • Such combination products employ the compounds of this invention within the dosage range described hereinbefore and the other pharmaceUtically-active agent within its approved dosage range.
  • the compounds of formula (1) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of In vitro and in vivo test systems for the evaluation of the effects of inhibitors of B-Raf in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
  • temperatures are given in degrees Celsius ( 0 C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25°C;
  • Example 55 The following compounds were prepared by the procedure in Example 1 Using 5- amino-2-methyl-7V-pyridiri-3-ylbenzamide (Method 68) or 5-amino-2-chloro-N-(5- fluoropyridin-3-yl)benzamide for (Method 79) Example 55 and the appropriate SM. In some cases, further purification was required (supercritical fluid, Gilson reverse phase preparatory HPLC or colurnh chromatography utilizing an ISCO system).
  • Example 121 Using 5- amino-2-chloro-jV-pyridin-3-ylbenzamide (Method 76) and the appropriate SM with the exception of Example 157 which was prepared from 2-chloro-5- ⁇ [3-(trifiuoromethyl)benzoyl] amino) benzoic acid (Method 224) and 7V-(5-aminopyridin-2-yl)acetamide. In some cases, further purification was required (supercritical fluid, Oilson reverse phase preparatory HPLC or column chromatography utilizing an ISCO system).
  • Example 158 jV-f6-Acetylpyfidin-3-yl)-2-chloto-5- ⁇ f3-ftfifluofomethyl)betizoyl1aminolbelizamide
  • Example 166 The following compounds were prepared by the procedure in Example 166 using 5- amino-2-flUoro-/V-pyriditt-3-ylbenzamide (Method 75) and the appropriate SM. In some cases, further purification was required (supercritical fluid, Gilson reverse phase preparatory HPLC or column chromatography utilizing an ISCO system).
  • Example 183 The following compounds were prepared by the procedure in Example 183 using the appropriate SMs. In some cases, further purification was required (supercritical fluid, Gilson reverse phase preparatory HPLC or column chromatography utilizing an ISCO system).
  • N-(5-BromopyHdin-3-yl)-5- ⁇ t3-(l-cyano-l -methylethyl)benzoyl]amino ⁇ -2- methylbenzamide (Example 192; 256mg, 0.54mmol), 1 //-pyrazol-4-ylboronic acid (l25mg, 0.64mmol), Cs 2 CO 3 (352mgl .08mmol) and Pd(PPh 3 ) 4 (62mg, 0.054mmol) were put in a microwave tube, dioxane (4ml) and water (I mI) were added.
  • the tube was heated in microwave (Smith, Personal Chemistry tM ) and heated at 180 0 C for 2000 seconds, the solution was filtered, and separated between EtOAc and water. Organic layer was dried and evaporated Under reduced pressure.
  • the crude product was purified by reverse phase HPLC (5-75% MeCN/H 2 O, 15 min) and the title compound (75.6 mg, 30%) was collected by evaporation.
  • the resulting reaction mixture was warmed to 80 °C and was allowed to stir for 12 h before being cooled and diluted with EtOAc ( ⁇ 100 ml).
  • the organic phase was poured into a separator funnel and washed with saturated aqueous NaMCO 3 ( ⁇ lOO ml).
  • the organic extract was dried with MgSO 4 , filtered, and concentrated in vacuo to yield the crude product, which was purified on a 40 g SiO 2 column using MeOH/EtOAc (1 :10) as eluent giving 144 mg (77%) of the title compound as a white solid.
  • Example 193 N- (5-bromopyridin-3-yl)-2-methyl-5- ⁇ t3-(trifluoromethyl)benzoyl]amino) benzamide
  • Example 193 N-(5-bromopyridin-3-yl)-5- ⁇ [3-(l-cyano-l-methylethyl)benzoyl]amino) -2- methylbenzamide
  • Example 192 N-(5-bromopyridin-3-yl)-2-chloro-5-t(3,5- dimethylbehzoyl)amino]beiizamide
  • Example 219 further purification was required (supercritical fluid, Gilson reverse phase preparatory HPLC or column chromatography utilizing an ISCO system).
  • Example 341 The following compounds were prepared by the procedure in Example 341 and the appropriate SM. In some cases, further purification was required (supercritical fluid, Gilson reverse phase preparatory HPLC or column chromatography utilizing an ISCO system).
  • Examples 345-351 The following compounds were prepared by the procedure in Example 344 using the appropriate SMs. In some cases, further purification was required (supercritical fluid, Gilson reverse phase preparatory HfLC or column chromatography utilizing an ISCO system).
  • Examples 353-356 the following compounds wefe prepared by the procedure in Example 352, using N- (5-aminopytidin-3-yl)-2-methyl-5- ⁇ t3-(trifluoromethyl)betizoyl]amino] benzamide (Example 244), and the appropriate SM. In some cases, further purification was required (supercritical fluid, Gilson reverse phase preparatory Hl 3 LC or column chromatography utilizing an ISCO system).
  • Example 358 the following compound was prepared by the procedure in Example 357, using N-(6- aminopyridin-3-yl)-5- ⁇ t3-(l-cyano-l-methylethyl)benzoyl]amino ⁇ -2-methylbenzamide (Example 202) and the appropriate SM. Further purification was required (column chromatography utilizing an ISCO system). Ex Compound NMR M/z SM
  • N-(5- aminopyfidin-3-yl)-2-methyl-5- ⁇ t3-(trifluofomethyl)behzoyl]amiho ⁇ betizamide (Example 244; 200 mg, 0.482 mmol).
  • Pyridine 5.0 ml
  • acetyl chloride 0.044 ml, 0.603 mmol.
  • the reaction was allowed to stir to for 12 h at room temperature before being poured over -50 ml of saturated aqueous NaHCO 3 .
  • the resulting mixture was poured into a separator funnel and extracted with -50 ml of EtOAc.
  • Example 202 The following compound was prepared by the procedure In Example 359, using N-(6- aminopyridin-3-yl)-5- ⁇ t3-(l -cyano-l-methylethyl)benzoyl]amino) -2-methylbenzamide (Example 202) and the appropriate SM. In some cases, further purification was required (supercritical fluid, Gilson reverse phase preparatory Hl 3 LC or column chromatography utilizing an ISCO system).
  • reaction mixture was stirred for 12 h at 40 °C.
  • reaction was quenched with 10% NaOH and extracted with EtOAc.
  • the organics were dried with NaCl(sat) and then Na 2 S ⁇ 4( S ) and removed Under reduced pressure.
  • the residue was purified directly by column chromatography (5% MeOH in EtOAc) to give 70 mg of product (73%).
  • Method 85 the following compound was prepared by the procedure of Method 84, using the appropriate starting material.
  • Methyl 5-amino-2-methylbenzoate A solution of methyl 2-niethyl-5-nitrobenzoate (Method 86; 3.4 g) and 10% palladium oh carbon (672 nig) in MeOH (20 ml) was treated with H 2 for 48 h. The reaction mixture was then filtered through diatomaceous earth and washed with MeOH (20 ml) and EtOAc (10 ml). The solvents were removed under reduced pressure to give a brown oil (2.7 g). M/z 165.
  • reaction mixture was extracted with EtOAc (2 x 250 ml) and the combined organic phase was dried with MgSO 4 and concentrated in vacuo to yield the crude reaction product which was purified on 120 g SiO 2 Using hexanes/EtOAc 10:1 as eluent giving 3.70 g of the title compound as a yellow oil (76 %) m/z 447.
  • reaction mixture was extracted with EtOAc (2 x 50 ml) and the combined organic phase was dried with MgSO 4 and concentrated in vacuo to yield the crude reaction product which was purified on 40 g SiO 2 using hexanes/EtOAc 2:1 as eluent giving 0.270 g of the title compound as a colourless oil (71 %) m/z 182.
  • Triethylamine (0.718 g, 7.40 mmol) was then added and the reaction was allowed to warm to 25 °C with stirring over 1 h before being quenched with NaHCO 3(sa t) (250 ml).
  • the reaction mixture was then extracted with EtOAc (2 x 50 ml) and the combined organic phase was dried with MgSO4 and concentrated in vacuo to yield the crude reaction product which was purified on 40 g SiO 2 using hexanes/EtOAc 10:1 as eluent giving 0.262 g of the title compound as a colourless oil (99 %) m/z 180.
  • Method 119 The following compounds were prepared by the procedure of Method 118, using the appropriate starting material.
  • 5-Amino-N-methylnicotinamide A solution of 5-aminonicotinic acid (414 mg, 3 mmol), DlEA (1.57 ml, 9 mmol) and methyl amine (2.0 M in THF, 4.5 ml, 9 mmol) in DMF (l ⁇ ml) was treated with HATU (1.71 g, 4.5 mmol). The reaction was stirred for 5 h and then quenched with H 2 O (30 ml). The reaction mixture was extracted with EtOAc (50 ml), washed with ⁇ aCl (sat) (20 ml) and dried with MgS ⁇ 4. The organics were removed under reduced pressure; m/z 151.
  • EtOAc/hexanes (3:1) as the eluent produced 372 mg of the sulfonyl chloride intermediate.
  • the intermediate was then diluted in a solution of I 1 C 2 CO 3 , MNMe 2 and t)CM. After allowing the reaction mixture to stir for lO minutes, the mixture was concentrated in vacuo to yield the crude product that was purified on an ISCO using EtOAc/hexanes (1 :4) which yielded 165 mg (5 %) of the title compound as a yellow solid.
  • Method 161 The following compounds were prepared by the procedure of Method 160, using the appropriate starting material.
  • DeoxoFluor 1 M was stirred overnight at 85 °C. The reaction was allowed to cool to room temperature and quenched with brine. The mixture was poured into a separator funnel and extracted with EtOAc. The organic extract was dried over Na 2 SO 4 1 , filtered, and concentrated in vacuo to yield the crude product. The crude oil was then subjected to ISCO purification Using EtOAc/hexanes (1 :4) as eluent to yield 396 mg (50%) of the title compound as a colourless oil.
  • the orgaiiics were dried with NaCl (sat ) and then Na 2 SO 4 ⁇ 5 ) and removed under reduced pressure.
  • the resulting solid was purified by column chromatography utilizing an ISCO system (hexanes-EtOAc) to give 234 mg (99%); m/z 366.
  • 2-amino-3-chloro-5- nitropyridine was obtained (10.8 g, 62%) and it was Used in the next step without further purification. M/z 175.
  • 2-amino-3-chloro-5-nitropyridine (8.72g, 50mniol) was dissolved in MeOH (125 ml).
  • a solution of ammonium chloride (13.5 g, 250mmol) in H 2 O (125 ml) were added, followed by 14g of iron powder.
  • the solution was stirred with mechanic stirring at 78 °C for 2 hours.
  • the solution was filtered at 50 °C and the isolated solid was washed by hot MeOH.
  • Method 187 The following compound was prepared by the procedure of Method 186, Using the appropriate starting material.
  • N-(2- ⁇ ttert-butyl(dimethyl)silyl]oxy ⁇ ethyl)-5-nitropyridin-2-amine (Method 156; 1.29 g, 4.34 mmol) was dissolved in 20 ml of MeOH and 260 mg of palladium (l ⁇ wt. % on activated carbon-Degussa®) was added. The reaction was subjected to 1 atmosphere of hydrogen overnight. LC/MS confirmed the formation of the product. The reaction mixture was filtered through diatomaceoUs earth and washed with MeOH and EtOAc. The title compound (970 mg) was collected by evaporation as a thick red oil. M/z 268.
  • Methyl 1 ,3.3-trimethyl-2-oxoindoline-5-carboxylate To a solution of methyl 2-oxoindoline-5-carboxylate (400 mg, 2.09 himol) in THF (10 ml) at -78 0 C was added LiHMDS (1.0 M, 16.7 ml, 16.75 mmol) and Mel (1.3 ml, 20.9 mmol). The reaction was allowed to stir overnight to room temperature. The reaction was then quenched with -25 ml aqueous NH 4 Cl.
  • Methyl 5- ⁇ [3-(l-cyatto-l-methylethyl)benzoyl]amino) -2- chlorobenzoate was collected by evaporation as a reddish-brown oil.
  • Methyl S-ltS-Cl-cyano-l -methylethy ⁇ beiizoylJaniinoJ-Z-chlofobenzoate 120 mg was dissolved in a 3:1 :1 (v/v/v) solution of THF/Me ⁇ H/H 2 O and lithium hydroxide (50 mg) was added slowly. The reaction was then stilted overnight at 25°C. LC/MS confirmed the formation of the product.
  • 3-Cyclopropyl-5-fluorobenzoic acid To a 50 ml round bottom flask charged with a magnetic stir bar was added 3-brottio-5- flUorobenzoic acid (0.500 g, 4.56 mmol) and cyclopropylboroiiic acid (0.590 g, 6.84 mmol). Toluene (15 ml) and H 2 O (0.75 ml) were added followed by K 3 PO4 (3.86 g, 18.24 mmol) and Pd(PPh 3 ⁇ (1.05 g, 0.912 mmol).
  • the resulting reaction mixture was heated to 100 °C for 12 h, was cooled to room temperature, and quenched with 10% aqueous MaOH (-100 ml). The reaction mixture was poured into a separator funnel and extracted with EtOAc (-100 ml). The resulting aqueous phase was isolated and brought to a pH of ⁇ 2 by the careful addition of 3M HCl at which time the desired product precipitated. The precipitate was collected via vacuum filtration, washed with ah additional portion of H 2 O (—100 ml), collected, and dried under vacuum for 24 h which yielded 0.310 g of the title compound (37%) as an off white solid. M/z 181.
  • Methyl 3-[(2-cyano-lH-pyrrol-l-yl)methyl]bertzoate (300 mg) was dissolved in MeOHVH 2 O (10 ml, 3 : 1 v/v) and LiOH (60 mg) was added. The resulting mixture was stirred at room temperature for 10 hours. The aqueous phase was filtered and washed with EtOAc. The basic aqueous layer was acidified by the addition of IN HCl until pH 3. The aqueous layer was extf acted with EtOAc (3x) and then dried with Na 2 SO 4(S) . Evaporation of the solvent afforded the title compound as a white solid (210 mg); m/z 226.
  • the filtrate was concentrated in vacuo to a volume of- 25 ml and diluted with -250 ml OfEt 2 O. A precipitate formed (DlPEA/HCl salt) which was filtered off using a Buchner funnel. The filtrate was concentrated in vacua to yield 3.2 g (98%) the title compound as a yellow oil which was used without further purification; m/ ⁇ ⁇ 4 ⁇ .
  • the reaction was heated to 80 °C with stirring for 5 h before being cooled to room temperature and quenched with -200 ml saturated aqueous NaHCO 3 .
  • the mixture was poured into a separator funnel and extracted with -200 ml of EtOAc.
  • the combined organic extract was dried with MgSO 4 , filtered, and concentrated in vacuo to yield the crude product, which was purified on a 120 g SiO 2 column using hexanes/EtOAc (9:1) as eluent giving 5.26 g (82%) of the title compound as a white solid m/z 527.

Abstract

The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula (I): (A chemical formula should be inserted here - please see paper copy enclosed herewith) (I) which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

Description

PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS
The invention relates to chemical compounds, of pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their Use in the manufacture of medicaments of Use in the production of an anti-cancer effect in a warm-blooded animal such as man. The classical Ras, Raf, MAP protein kinase/extracellular signal -regulated kinase kinase (MElC), extracellular signal -regulated kinase (ERK) pathway plays a central role in the regulation of a variety of cellular functions dependent upon cellular context, including cellular proliferation, differentiation, survival, immortalization and angiogenesis (reviewed in PeyssonnaUx and Eychene, Biology of the Cell, 2001, 93, 3-62). In this pathway, Raf family members are recruited to the plasma membrane upon-binding to guanosine triphosphate (QtP) loaded Ras resulting in the phosphorylation and activation of Raf proteins. Activated Rafs then phosphorylate and activate MEKs, which in turn phosphorylate and activate ERKs. Upon activation, ERKs translocate from the cytoplasm to the nucleus resulting in the phosphorylation and regulation of activity of transcription factors such as EIk-I and Myc. The Ras/Raf/MEK/ERK pathway has been reported to contribute to the tumorigenic phenotype by inducing immortalisation, growth factor-independent growth, insehsitivity to growth-inhibitory signals, ability to invade and metastasis, stimulating angiogenesis and inhibition of apoptosis (reviewed in Kolch et al., Exp.Rev. MoI. Med., 2002, 25 April, http://www.expertreviews.org/02004386h.htm). In fact, ERK phosphorylation is enhanced in approximately 30% of all human tumours (Hoshino et al., Oncogene, 1999, 18, 813-822). This friay be a result of overexpression and/or mutation of key members of the pathway.
Three Raf serine/threonine protein kinase isoforrtts have been reported Raf-1 /c-Raf, B-Raf and A-Raf (reviewed in Mercer and Pritchard, Biochim. Biophys. Acta, 2003, 1653, 25-40), the genes for which are thought to have arisen from gene duplication. All three Raf genes are expressed in most tissues with high-level expression of B-Raf in neuronal tissue and A-Raf in urogenital tissue. The highly homologous Raf family members have overlapping but distinct biochemical activities and biological functions (Hagemann and Rapp, Expt. Cell Res. 1999, 253, 34-46). Expression of all three Raf genes is required for normal murine development however both c-Raf and B-Raf are required to complete gestation. B-Raf -/- mice die at E12.5 due to vascular haemorrhaging caused by increased apoptosis of endothelial cells (Wojnowski et al., Nature Genet., 1997, 16, 293-297). B-Raf is reportedly the major isoform involved in cell proliferation and the primary target of oncogenic Ras. Activating 5 somatic missense mutations have been identified exclusively for B-Raf, occurring with a frequency of 66% in malignant cutaneous melanomas φavies et al., Nature, 2002, 417, 949- 954) and also present in a wide range of human cancers, including but not limited to papillary thyroid tumours (Cohen et al., J. Natl. Cancer Inst., 2003, 95, 625-627), cholangiocarcinomas (Tannapfel et al., Gut, 2003, 52, 706-712), colon and ovarian cancers (Davies et al., Nature,
10 2002, 417, 949-954). The most frequent mutation in B-Raf (80%) is a glutamic acid for valine substitution at position 600. These mutations increase the basal kinase activity of B-Raf and are thought to uncouple Raf/MEK/ERK signalling from Upstream proliferation drives including Ras and growth factor receptor activation resulting in constitutive activation of ERΪC. Mutated B-Raf proteins are transforming in N1H3T3 cells (Davies et al., Nature, 2002,
15 417, 949-954) and melanocytes (Wellbrock et al., Cancer Res., 2004, 64, 2338-2342) and have also been shown to be essential for melanoma cell viability and transformation (Hingorani et al., Cancer Res., 2003, 63, 5198-5202). As a key driver of the Raf/MEK/ERK signalling cascade, B-Raf represents a likely point of intervention in tumours dependent on this pathway. 0 AstraZeneca application WO 00/55120 discloses certain amide derivatives which are inhibitors of the production of cytokines such as TNt1, in particular of TNFα, and various interleukins, in particular IL-I . The present inventors have surprisingly found that certain other, novel, amide derivatives are potent B-Raf inhibitors and are accordingly expected to be Useful in the treatment of neoplastic disease. 5 Accordingly, the present invention provides a compound of formula (I):
Figure imgf000004_0001
(D wherein: Ring A is phenyl of a monocyclic 5 of 6 ftiembefed fully-unsatufated heterocyclic ring; wherein said phenyl or heterocyclic ring may be optionally fused to a five or six membered carbocyclyl or heterocyclyl forming a bicyclic ring; and wherein if said heterocyclyl or heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R5;
R1 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci-βalkyl, C2-ealkenyl, C2-6alkynyl, C|-6alkoxy, C|-6alkanoyi, Ci-ealkanoyloxy, N-(Ci-6alkyl)amino, N,N-(Ci.6alkyl)2amino, Cualkanoylamino, N-(C|.6alkyl)carbamoyl, N,N-(Cj-6alkyl)2carbamoyl, Ci-6alkylS(O)a wherein a is 0 to 2, Cι-6alkoxycarbonyl, Ci-6alkoxycarbonylamino, jV-(Ci-6alkyl)sulphamoyl, 7V,N-(C|-6alkyl)2sulphamoyl, N-(Cj-6alkyl)-N-(C|.6alkoxy)sulphamoyl, iV,N'-(Ci-6alkyl)2Ureido, 7V')N'-(C!-6alkyl)2ureido, N-(Ci-6alkyl)-N'N-(Ci-6alkyl)2Ureido, C|-6alkylsulphottylamino, carbocyclyl-R6- or heterocyclyl-R7-; wherein R may be optionally substituted on carbon by one or more R8; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R9; ft is selected from 0-4; wherein the values of R may be the same or different;
R2 is selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C|-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci^alkoxy, Ci-6alkanoyl, Cι-6alkanoyloxy, N-(C|-6alkyl)amino, 7V,jV-(Ci-6alkyl)2amino,
Cualkanoylamino, N-(Ct-6alkyl)carbamoyl, N,N-(C|.6alkyl)2carbamoyl, C!.6alkylS(O)a wherein a is 0 to 2, C].6alkoxycarbonyl, N-(Cj-6alkyl)sulphanioyl,
MTV-(C |.6alkyl)2sulphamoyl, Cι-6alkylsulphonylamilio, carbocyclyl-Rl0- or heterocyclyl-R1 1-; wherein R2 may be optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13;
R3 is selected from halo, hydroxy, cyano, methyl, methoxy or hydroxymethyl;
R4 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, C|-6alkyl, C2-6alkenyl, C2-6alkynyl, C|-6alkoxy, C|.6alkanoyl, C|-6alkanoyloxy, N-(C|-6alkyl)amiiio, N,N-(Cι-6alkyl)2amirtσ,
Cualkanoylamino, N-(Ci-6alkyl)carbamoyl, N,N-(Cι-6alkyl)2carbamoyl, C|-6alkylS(O)d wherein a is 0 to 2, C|-6alkoxycarbonyl, N-(Ci -6alkyl)sulphamoyl, N,N-(Ci-6alkyl)2sulphamoyl, Cι-6alkylsulphonylamino, carbocyclyl-R14- or heterocyclyl-R15-; wherein R may be optionally substituted on carbon by otie of more R ; and wherein if said heterocyclyl contains an -NtI- moiety that nitrogen may be optionally substituted by a group selected from R17; tti is selected from 0-4; wherein the values of R4 may be the same or differeht; R8 and R12 are independently selected from halo, ftitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C|-6alkyl, C2-6alkenyl, C2-6alkynyl, Cι-6alkoxy, Ci-6alkanoyl, Cualkanoyloxy, /V-(Ci-6alkyl)amino, jV,N-(C|-6alkyl)2amino, jV-(Ci-6alkyl)-7V-(C|-6alkoxy)aniino, C|-6alkanoylamino, N-(Ci-6alkyl)carbamoyl, jV,N-(C|.6alkyl)2carbamoyl, Ci-6alkylS(O)a wherein a is 0 to 2, Ci-6alkoxycarbonyl, jV-(C]-6alkyl)sulphamoyl, N,7V-(Ci.6alkyl)2sulphamoyl,
Ci-6alkylsulphonylamino, carbocyclyl-R18- or heterocyclyl-Rl9-; wherein R8 and R12 independently of each other may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R2'; R|G is selected from halo, ttitfo, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, C|-6alkoxy, Cι-6alkanoyl, Cualkanoyloxy, iV-(Cι-6alkyl)amino, /V,/V-(Cι-6alkyl)2amino, C|.6alkanoylamino, TV-(C ι-6alkyl)cafbamoyl, 7V;N-(Ci-6alkyl)2carbamoyl, C|-6alkylS(O)a wherein a is 0 to 2, Ci-6alkoxycarbonyl, /V-(Ci-6alkyl)sulphamoyl, 7V,N-(C|-6alkyl)2SUlphamoyl, C]-6alkylsulphonylamino, carbocyclyl-R22- or heterocyclyl-R23-; wherein R16 may be optionally substituted on carbon by one or more R24; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R25;
R6, R7, R10, R", R14, R15, R18, R19, R22 and R23 are independently selected from a direct bond, -O-, -N(R26)-, -C(O)-, -N(R27)C(O)-, -C(O)N(R28)-, -S(O)5-, -SO2N(R29)- or -N(R30)SO2-; wherein R26, R27, R28, R29 and R30 are independently selected from hydrogen or Cualkyl and s is 0-2;
R5, R9, R13, R17, R21 and R25 are independently selected from Cualkyl, Cualkanoyl, Cualkylsulphonyl, Cualkoxycarbonyl, carbamoyl, /V-(C i-6alkyl)carbamoyl, N,N-(Ci-6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
R20 and R24 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, tfifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-niethyl-N-ethylamino, acetylaminσ, iV-methylcarbamoyl, jV-ethylcarbamoyl,
N, N-dimethylcarbamoyl, N, N-diethylcarbamoyl, jV-methyl-jV-ethylcarbamoyl, phenyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphohyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphanioyl, iV-ethylsυlphanioyl, ΛζN-dimethylsulphamoyl, ΛζjV-diethylsulphanioyl of 7V-methyl-7V-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is hot:
N-[4-chloro-3-({t6-(4-methylpiperazin-l-yl)pyridin-3-yl]amino}carbonyl)phenyl]-2- morpholin-4-ylisotticotinamide; jV-t4-chloro-3-({t6-(4-ethylpiperaziti-l-yl)pyridin-3-yl]amino]carboriyl)phenyl]-2-morpholih-
4-y 1 i soni cotinamide ;
N-{4-chloro-3-t({6-tt3-(dimethylamino)propyl](methyi)amino]pyridin-3-yl}amino)carbonyl]
"phenyl } -2-morpholiti-4-ylisotiicotinamide;
N-{4-chloro-3-t({6-[t2-(dimethylamino)ethyl](methyl)amiho]pyridin-3-yl}amiiio)carbollyl] phenyl ) -2-morpholin-4-ylisonicotinamide; or
N-t4-chloro-3-({t6-(4-methyl-l,4-diazepan-l-yl)pyridin-3-yl]amino}carboiiyl)pheiiyl]-2- morpholih-4-ylisonicotinamide.
According to a further feature of the present invention there is provided a compound of formula (1) wherein: Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from k5;
R is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci-6alkyl, C2-6alkenyl,
C2-6alkynyl, Ci-6alkoxy, C|-6alkanoyl, Cι-6alkanoyloxy, jV-(C|-6alkyl)amino, 7V,N-(Ci-6alkyl)2amino, C|-6alkanoylamino, N-(C|-6alkyl)carbamoyl, jV,N-(Ci-6alkyl)2carbamoyl, C|-6alkylS(O)a wherein a is 0 to 2, C|-6alkoxycarbonyl, jV-(C|.6alkyl)sUlphamoyl, jV,N-(C|.6alkyl)2sulphamoyl, Cualkylsulphonylamino, carbocyclyl-R6- or heterocyclyl-R7-; wherein R1 may be optionally substituted on carbon by one or more R8; and wherein if said heterocyclyl contains an -MH- moiety that nitrogen may be optionally substituted by a group selected from R9;
H is selected from 0-4; wherein the values of R1 may be the same or different;
R2 is selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci^alkyl, C2-6alkenyl, C2-6alkyiiyl, Cualkoxy, Ci-r,alkanoyl, C|.6alkanoyloxy, iV-(C|-6alkyl)amino, TV,TV-(C|-6alkyl)2amino,
C|.6alkaiioylamino, TV-(C i-6alkyl)carbamoyl, TV,/V-(C|-6alkyl)2carbanioyl, C|-6alkylS(O)a wherein a is 0 to 2, C|.6alkoxycarbonyl, TV-(C i-6alkyl)sulphattioyl,
N,TV-(C|-6alkyl)2sulptiattioyl, Ci-6alkylsulphonylamino, carbocyclyl-R10- of heterocyclyl-R1 '-; wherein R2 may be optionally substituted on carbon by one or more R 2; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R13;
R is selected from halo, hydroxy, cyatto, methyl, methoxy or hydroxyniethyl; R is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C|-6alkyi, C2-6alkenyl, C2-6alkynyl, Ci^alkoxy,
C|.6alkanoyl, Cualkanoyloxy, TV-(C ι-6alkyl)amino, TV,TV-(Ci-6alkyl)2amino,
Ci-6alkanoylamino, TV-(C ι-6alkyl)carbattioyl, TV,TV-(C|-6alkyl)2carbamoyl, Cι-6alkylS(O)a wherein a is 0 to 2, Cualkoxycarbonyl, TV-(Ct-6alkyi)sulphamσyl,
TV, TV-(C |.6alkyl)2sulphamoyl, C|-6alkylsUlphonylamino, carbocyclyl-R - or heterocyclyl-R15-; wherein R4 may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17; m is selected from 0-4; wherein the values of R may be the same or different; R8 and R12 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C|-6alkyl, C2-6alkenyl,
C2-6alkynyl, Cι-6alkoxy, C]-6alkanoyl, Ci^alkanoyloxy, TV-(C ι-6alkyl)amino,
N,N-(C|-6alkyl)2amino, C|-6alkanoylamino, jV-(C|.6alkyl)carbamoyl,
N,N-(C\ -6alkyl)2carbamoyl, Ci.6alkylS(O)a wherein a is 0 to 2, C|-6alkoxycarbonyl,
TV-(C I -6alky l)sulρhamoy 1, N, N-(C i -6alky l)2sulphamσy 1, C i -6alky lsulphony lamino, carbocyclyl-R18- or heterocyclyl-R19-; wherein R8 and R12 independently of each other may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R2'; R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Cualkyl, C2-6alkenyl, C2-6alkynyl, C|-6alkoxy, C|-6alkanoyl, C|-6alkaiioyloxy, jV-(Cι-6alkyl)aminσ, N, TV-(C ι-6alkyl)2amino,
Cualkanoylamino, TV-(C ι-6alkyl)carbamoyi, TV,TV-(C|.6alkyl)2carbamoyl, Ci-6alkylS(O)d wherein a is 0 to 2, C|-6alkoxycarbonyl, TV-(C|.6alkyl)sulphamoyl,
TV,TV-(C|.6alkyl)2sulphanioyl, Cualkylsulphonylamino, carbocyclyl-R22- or heterocyclyl-R23-; wherein R 6 may be optionally substituted on carbon by one of more R2 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R25;
R6, R7, R10, Rn, R14, R1S, R18, R19, R22 and R23 are independently selected from a direct bond, -O-, -N(R26)-, -C(O)-, -N(R27)C(O)-, -C(O)N(R28)-, -S(O)8-, -SO2N(R29)- or
-N(R30)SO2-; wherein R26, R27, R28, R29 and R30 are independently selected from hydrogen or
Ci-Galkyl and s is 0-2;
R5, R9, R13, R17, R2t and R25 are independently selected from Cualkyl, Ci-6alkanoyl,
Ci-ealkylsulphonyl, Cι-6alkoxycarbonyl, carbamoyl, TV-(C i-βalkyrjcarbamoyl, N,7V-(Cι-6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; R20 and R24 are independently selected from halo, nitro, cyano, hydroxy, trifiuoromethoxy, trifiuoroirtethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamiiio, ethylamino, diniethylamino, diethylamino, jV-methyl-jV-ethylamino, acetylamino, TV-rnethylcarbamoyl, jV-ethylcarbarnoyl, N, jV-dimethylcarbamoyl, 7V,7V-diethylcarbamoyl, N-methyl-jV-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, ttiethoxycarbonyl, ethoxycarbonyl, 7V-methylsulphattloyl, jV-ethylsUlphamoyl, N, N-dimethylsUlphattiσyl,
N,N-diethylsulphdmoyl or jV-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not:
7V-t4-chloro-3-({[6-(4-methylpiperazin-l-yl)pyridin-3-yl]amino}carbonyl)phenylj-2- niorpholin-4-ylisonicotinamide; jV-t4-chloro-3-({[6-(4-ethylpiperazin-l-yl)pyridin-3-yl]amino}carbonyl)phenyl]-2-morpholin-
4-ylisonicotinamide; yV-{4-chloro-3-[({6-tt3-(dimethylamino)propyl](methyl)amino]pyridin-3-yljamino)carbonyl] phenyl ) -2-morpholin-4-y lisonicotinamide;
7V-{4-chloro-3-t({6-[t2-(dimethylamino)ethyl](methyl)amino]pyridin-3-yl] amino)carbonyl] phenyl}-2-ttiorpholitt-4-ylisonicotinamide; or
N-t4-chloro-3-({t6-(4-methyl-l,4-diazepan-l-yl)pyridin-3-yl]amino) carbonyl)phenyl]-2- morρholin-4-ylisonicotinamide.
In this specification the term "alkyl" includes both straight and branched chain alkyl groups. References to individual alkyl groups such as "propyl" are specific for the straight chain version only and references to individual branched chain alkyl groups sUch as 'isopropyl' are specific for the branched chain version only, for example, "C|-6alkyl" includes Cualkyl, C|-3alkyl, propyl, isopropyi and /-butyl. A similar convention applies to other radicals, for example "phenylC|-6alkyl" includes pheliylCualkyl, benzyl, 1 -phenylethyl and 2-phenylethyl. The term "halo" refers to fluoro, chloro, bromo and iodo. Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from olie of the specified groups or the substituents being chosen from two or more of the specified groups.
Ring A may be a "monocyclic 5 or 6 membered fully unsaturated heterocyclic ring". A "monocyclic 5 or 6 membered fully unsaturated heterocyclic ring" is fully unsaturated, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2- group can optionally be replaced by a -C(O)- and a ring sulphur atom may be optionally oxidised to form the S-oxides. Examples of a "monocyclic 5 or 6 membered fully unsaturated heterocyclic ring" are pyridyl, pyrazolyl, thienyl, isoxazolyl, furanyl, 1 ,3-thiazolyl, pyrimidinyl and pyrrolyl.
Ring A may also be phenyl or a monocyclic 5 or 6 membered fully unsaturated heterocyclic ring; "wherein said phenyl or heterocyclic ring may be optionally fused to a five or six membered carbocyclyl or heterocyclyl forming a bicyclic ring". Here said bicyclic ring is a bicyclic ring containing 8, 9 or 10 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2- group can optionally be replaced by a -C(O)- and a ring sulphur atom may be optionally oxidised to form the S-oxides. Examples of such a bicyclic ring include indolyl, 2,3-dihydrobenzofuranyl, imidazo[l ,2-a]pyridinyl, benzimidazolyl and 2- oxoindolinyl. A "heterocyclyl" is a saturated, partially saturated of unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may," unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2- group can optionally be replaced by a -C(O)- and a ring sulphur atom may be optionally oxidised to form the S-oxides. Examples and suitable values of the term "heterocyclyl" are niorpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, pyrazolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1 ,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, N-methylpyitolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, pyridine-N-oxide and quinoline-7V-oxide. A particular example of the term "heterocyciyl" is pyrazolyl. Ih one aspect of the invention ύ "heterocyclyl" is a saturated, partially saturated or unsaturated, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a -CH2- group can optionally be replaced by a -C(O)-and a ring sulphur atom may be optionally oxidised to form the S-oxides.
A "carbocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CM2- group can optionally be replaced by a -C(O)-. Particularly "carbocyclyl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "carbocyclyl" include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl. A particular example of "carbocyclyl" is phenyl.
An example of "Cualkanoyloxy" is acetoxy. Examples of "Cι-6alkoxycarbonyl" include methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbortyl. Examples of "Ci-6alkoxy" include methoxy, ethoxy and propoxy. Examples of "C].6alkanoylamino" include formamido, acetamido and propionylamino. Examples of "C|-6alkylS(O)a wherein a is 0 to 2" include methylthio, ethylthio, rnethylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of "C|-6alkanoyl" include propionyl and acetyl. Examples of 'W-(Ci -6alkyl)amino" include methylamino and ethylamino. Examples of "7V,7V-(C|-6alkyl)2amino" include di-W-methylamino, di-(N-ethyl)amino and
N-ethyl-N-methylamiho. Examples of "C2-6alkenyl" are vinyl, allyl and 1 -propenyl. Examples of "C2-6alkynyl" are ethynyl, 1-propynyl and 2-propynyl. Examples of 'W-(C|.6alkyl)sulphamoyl" are N-(methyl)sulphanioyl and N-(ethyl)sulphamoyl. Examples of ςW-(Cj-6alkyl)2sulphanioyl" are jV,N-(dimethyl)sulphamoyl and N-(methyl)-N-(ethyl)sulρhamoyl. Examples of 'W-(Ci -6alkyl)carbamoyl" are jV-(Cualkyl)carbamoyl, methylaminocarbonyl and ethylaminocarbonyl. Examples of 'W,jV-(C|.6alkyl)2carbamoyl" are N,W-(Cualkyl)2carbamoyl, diitiethylaminocarbonyl and methylethylaminocarbonyl. Examples of "C|.6alkylsulphonyl" are mesyl, ethylsulphonyl and isopropylsulphonyl. Examples of "Cι-6alkylsulphonylamino" are mesylamino, ethylsulphonylamino and isopropylsulphonylamino. Examples of "C|-6alkoxycarbohylamino" are methoxycarbonylamino and f-butoxycarbohylamino. Examples of 'W-(C|-6alkyl)-jV-(C|.6alkoxy)sulphamoyl" are N-(methyl)-N-(methoxy)sulphanioyl and N-(ethyl)-jV-(propoxy)sulphamoyl. Example of ςW,N-(Cι-6alkyl)2ureido" are N,N'-dimethylureido and N-methyl-N'-propylureido. Examples of "N',N-(C|.6alkyl)2ureido" are N'N'-diethylureido and N'-methyl-N'-propylureido. Example of 'W-(C|-6alkyl)-N',N'-(Ci-6alkyl)2ureido" are N-(methyl)-N'-ethyl-N'-isopropylureido and N-ethyl-N'N'-diethylureido. Examples of W-(Ci -6alky I)-N-(C ι-6alkoxy)amino" are N-(methyl)-N-(propoxy)amino and N-methyl-N-methoxyamino.
A suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
Some compounds of the formula (I) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess B-Raf inhibitory activity. The invention further relates to any and all tautomeric forms of the compounds of the formula (I) that possess B-Raf inhibitory activity.
It is also to be understood that certain compounds of the formula ,(1) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess B-Raf inhibitory activity. Particular values of variable groups are as follows. Such values may be Used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.
Ring A is a monocyclic 5 or 6 membered fully-unsaturated heterocyclic ring; wherein if heterocyclic ring contains an -Νtt- moiety that nitrogen may be optionally substituted by a group selected from R5.
Ring A is phenyl fused to a five or six membered carbocyclyl or heterocyclyl forming a bicyclic ring; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R5. Ring A is a heterocyclic ring fused to a five or six membered carbocyclyl or heterocyclyl forming a bicyclic ring; wherein if said heterocyclyl or heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R5.
Ring A is carbocyclyl. Ring A is phenyl.
Ring A is heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R5.
Ring A is pyridyl.
Ring A is pyrazolyl; wherein said pyrazolyl may be optionally substituted on nitrogen by a group selected from R5.
Ring A is thienyl.
Ring A is imidazo[l,2-a]pyridinyl.
Ring A is indolyl.
Ring A is 2,3-dihydrobenzofuranyl. Ring A is isoxazoiyl.
Ring A is benzimidazolyl.
Ring A is 2-oxoindolinyl.
Ring A is furanyl.
Ring A is 1,3-thiazolyl. Ring A is pyrimidinyl.
Ring A is pyttolyl.
Ring A is phenyl, pyridyl, pyrazolyl, thienyl, indolyl, 2,3-dihydrobenzofuranyl, ittiidazo[l,2-a]pyridinyl, isoxazoiyl, benzimidazolyl, 2-oxoindolinyl, furanyl, 1,3-thiazolyl, pyrimidinyl and pyitolyl; wherein said pyrazolyl, indolyl, pyrrolyl may be optionally substituted on nitrogen by a group selected from R5; wherein
R5 is selected frotti Ci-ealkyl.
Ring A is phenyl, pyridyl, pyrazolyl, thienyl, indolyl, 2,3-dihydrobenzofuranyl and imidazo[l,2-a]pyridinyl; wherein said pyrazolyl may be optionally substituted on nitrogen by a group selected from R5; wherein R5 is Cι-6alkyl.
Ring A is phenyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, l-methylpyrazol-5-yl, \-ι- butylpyrazol-5-yl, thien-2-yl, thiert-3-yl, ilidol-2-yl, 1 -methylindol-2-yl, indol-4-yl, indol-5-yl, indol-6-yl, indol-7-yl, 2,3-dihydrobeiizofuran-7-yl, imidazo[l ,2-a]pyridin-2-yl, isoxazol-3-yl, pyrrol-2-yl, benzimidazol-6-yl, l-methyl-2-oxoindolih-5-yl, furan-2-yl, l,3-thiazol-5-yl, pyrimidili-4-yl and l-methylpytτol-2-yl.
Ring A is phenyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, l -methylpyrazol-5-yl, thien-2-yl, thien-3-yl, indol-5-yl, indol-6-yl, 2,3-dihydrobenzofurati-7-yl or imidazo[l,2-a]pyridinyl. Ring A is not pyridyl.
Ring A is not pyrid-4-yl.
R is a substituent on carbon and is selected from halo, cyano, hydroxy, stilphanioyl, C|-6alkyl, C2-6alkynyl, C|-6alkoxy, N,N-(C|.6alkyl)2amino, C ι-6alky IS(O)8 wherein a is 0 to 2, Ci-6alkoxycarbonylamino,
Figure imgf000014_0001
N,iV-(C|-6alkyl)2sulphamoyl, N-(C I -6alky I)-N-(C i -6alkoxy )sulphamoyl, N', N-(C i -6alky l)2ureido, C i -6alky lsulphony lamino, carbocyclyl-R6- or heterocyclyl-R7-; wherein R1 may be optionally substituted on carbon by one or more R8;
R8 is selected from halo, cyano, hydroxy, C|-6alkyl, C|-6alkoxy, N,N-(Ci.6alkyl)2amino, N,N-(C|-6alkyl)2carbamoyl, C]-6aikyiS(O)a wherein a is 0 to 2, N,N-(Cι-6alkyl)2sulphamoyl, N-(Cι-6alkyi)-N-(Cι-6alkoxy)amino, carbocyclyl-R18- or heterocyclyl-R19-; wherein R8 may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R ;
R6, R7, R18 and R19 are independently selected from a direct bond, -O-, -S(O)8- or -N(R30)SO2-; wherein R30 is selected from hydrogen and s is 2;
R2' is selected from Cι-6alkyl;
R20 is selected from cyano or hydroxy.
R1 is a substituent on carbon and is selected from halo, cyano, Ci^alkyl, C2-6alkynyl, C|-6alkoxy, N,N-(C|-6alkyl)2amino, C|.6alkylS(0)a wherein a is 0 to 2, N,N-(Ci_6alkyl)2sulphamoyl, C ualkylsulphony lamino, carbocyclyl-R6- or heterocyclyl-R7-; wherein R1 may be optionally substituted on carbon by one or more R8;
R8 is selected from halo, cyano, hydroxy, N,N-(C|-6alkyl)2amino or heterocyclyl-R19-; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R2'; R6, R7 and R19 are independently selected from a direct bond, -S(O)5- or -N(R30)SO2-; wherein R30 is hydrogen and s is 0-2;
R2 l is C1-6alkyl. R1 is a substituent on carbon and is selected from fluoro, chloro, bromo, iodo, cyano, hydroxy, sulphamoyl, methyl, ethyl, isopropyl, sec-butyl, /-butyl, 2-ttiethylbut-2-yl, 3- methylbut-2-yl, l,l-dimethylprop-2-yn-l-yl, l,l-dimethylbut-2-yn-l-yl, 3,3-dimethylbut-l- yn-l-yl, 3-methylbut-l-yn-l-yl, methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, 7V,N-dimethylamiho, ΛζN-diethylamino, methylthio, mesyl, f-butoxycarbonylamino, N-methylsulphamoyl, N-methyl-N-propylsulphamoyl, N,N-dimethylsulphamoyl, N-(methyl)-N-(methoxy)sulphamoyl, N'N'-dimethylureido, mesylamino, cyclopropyl-R6-, phenyl-R5-, morpholino-R7-, imidazolyl-R7-, 1,3-thiazolyl-R7-, pyHdyl-R7-, piperidinyl-R7- or azetidinyl-R7-; wherein R1 may be optionally substituted on carbon by one or more R8; R8 is selected from fluoro, cyano, hydroxy, methyl, methoxy, iV,iV-dimethylamino, jV,jV-dimethylcarbamoyl, methylthio, mesyl, 7V,N-dimethylsulphamoyl, N-(methyl)-N-(methoxy)sulphamoyl, cyclopropyl-R18-, piperazinyl-Rl9-, pyrrolyl-Rl9- or tetrahydrofuryl-R -; wherein R8 may be optionally substituted oh carbon by one or more R20; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R21;
R6, R7, R18 and R19 are independently selected from a direct bond, -O-, -S(O)5- or -Ν(R30)SO2-; wherein R30 is selected from hydrogen and s is 2; R21 is selected from methyl or ethyl; R20 is selected from cyano or hydroxy. R1 is a substituent on carbon and is selected from fluoro, chloro, bromo, iodo, cyano, methyl, isopropyl, t-butyl, 3-methylbut-l-yn-l-yl, 3,3-dimethylbut-l -yii-l-yl, methoxy, propoxy, isopropoxy, isobutoxy, dittiethylamino, methylthio, mesyl, jV.N-dimethylsulphamoyl, mesylamino, cyclopropyl-R6- or azetidin-1-yl-R7-; wherein R1 may be optionally substituted on carbon by one or more R8; R8 is selected from fiuoro, cyano, hydroxy, dimethylamino or piperazin-1-yl-R19-; wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from
R6, R7 and R19 are independently selected from a direct bond, -S(O)5- or -K(R30)SO2-; wherein R30 is hydrogen and s is 2; R2' is methyl or ethyl.
R1 is a substituent on carbon and is selected from fluoro, chloro, bromo, iodo, cyano, hydroxy, sulphamoyl, methyl, trifluoromethyl, 1 -cyano- 1-metliylethyl, methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, TV.N-dimethylaminσ, difluoromethylthio, jV.jV-dimethylsulphanioyl, f-butyl, mesyl, cyclopropylaminosulphonyl, azetidin-1-ylsulphonyl, teti-ahydrofumn-2-ylmethylaiτiinosulphottyl, τV-niethyl-jV-(2,3-dihydi-oxypropyl)sulphaiiioyl, mesylamino, morpholinosulphonyl, 1 -methylpiperazin-4-ylmethyl, l-ethylpiperazih-4- ylmethyl, 3,3-diniethylbut-l-yn-l-yl, morpholino, TV.N-dimethylaminoniethyl, 3-methyl-3- hydroxybut- 1 -yn- 1 -y 1, methylthiomethy 1, mesylmethyl, N-(methyl)-jV-(methoxy)sulphamoyl, 2-hydroxymethylpiperidin-l-ylsulphonyl, 3-hydroxymethylpiperidiii-l -ylsulphonyl, A- hydroxyniethylpiperidin-1 -ylsulphonyl, 1 , 1 -diflϋoroethyl, piperidin-1-yl, 7V,7V-diethylamino, N', iV'-dimethylureido, cyclopropyl, /-butoxycarbonylamino, pyfid-2-yl, phenoxy, 2-methoxy- 1,1-dimethylethyl, mesylmethyl, l,3-thiazol-2-yl, 2-methyl-l,3-thiazol-5-yl, 1- methy lcyclopropyl, 1 , 1 -dimethylprop-2-yn- 1 -yl, 1 -(N, jV-ditnethylsulphamoyl)- 1 -methylethyl, 1 , 1 -dimethylbut-2-yn- 1 -yl, N-(methyl)-7V-(methoxy)amihomethyl, 1 - (W,jty-dimethylcarbamoyl)-l -methylethyl, 4-methylimidazol-l-yl, 1 -(cyclopropyl)- 1 - methylethyl, 2-methyl-3,4-dihydl-oxybut-2-yl, 2-methylbut-2-yl, 1-hydfoxy-l- cyclopropylethyl, 1-cyanoethyl, 2-cyano-3-methylbut-2-yl, 2-cyanobut-2-yl, l-hydroxy-2- cyanoprop-2-yl and 2-cyanopyttol-l-ylmethyl.
R is a substitueπt oh carbon and is selected from flυoro, chloro, bromo, iodo, cyano, methyl, t-butyl, trifluoromethyl, dimethylaminomethyl, 1 -methyl- 1-cyattoethyl, A- methylpiperazin-1-ylmethyl, 4-ethylpiperazin-l-ylmethyl, 3-hydroxy-3-methylbut-l-yn-l -yl, 3,3-dimethylbut-l-yn-l -yl, methoxy, propoxy, isopropoxy, isobutoxy, dimethylamino, difluoromethylthio, jV,N-dimethylsulphamoyl, mesyl, cyclopropylaminosulphonyl, azetidin-1- ylsulphonyl or mesylamirio.
R1 is a substituent on carbon aiid is selected from 1 -methyl- 1-cyahoethyl.
R1 is a substituent on carbon and is selected from trifluoromethyl. ri Is selected from 0-2; wherein the values of R may be the same or different. n is 0. tt Is 1. n is 2; wherein the values of R1 may be the same or different.
R2 is hydrogen.
R3 is selected from halo, methyl or methoxy. R3 is selected from halo or methyl.
R3 is selected from fluoro, chloro, methyl or methoxy.
R3 is selected from fluoro, chloro or methyl.
R3 is fluoro. R3 is chloro.
R3 is methyl.
R3 is methoxy.
R3 is not chloro. R is selected from halo, cyano, hydroxy, amino, carbamoyl, ureido, Ci-ealkyl,
C2-6alkynyl, C|-6alkoxy, Cι-6alkanoyl, τV-(C|.6alkyl)amino, 7V,N-(C|-6alkyl)2amino, Cι-6alkanoylamirio, N-(C|.6alkyl)carbamoyl, Ci-ealkoxycarbonyl, Λζ N-(Ci.6alkyl)2sulphamoyl, C|-6alkylsulphonylamino, carbocyclyl-Rt4- or heterocyclyl-Rl 5-; wherein R4 may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R17;
R16 is selected from halo, hydroxy, amino, C|-6alkoxy, W-(Ci -6alkyl)amino, N,N-(Ci-6alkyl)2amino, carbocyclyl-R22- or heterocyclyl-R23-; wherein R may be optionally substituted oh carbon by one or more R ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R25; R14, R15, R22 and R23 are independently selected from a direct bond, -N(R26)- or
-C(O)N(R28)-; wherein R26 and R28 are hydrogen;
Rl ? and R25 are independently selected from Ci-6alkyl and Cualkoxycarbonyl;
R24 is methyl or phenyl.
R4 is selected from halo, cyano, amino, Cj-6alkyl, Ci-6alkoxy, N-(C|-6alkyl)amino, Ci-6alkanoylamino, N-(C|-6alkyl)carbainoyl or heterocyclyl-R -; wherein
R15 is a direct bond.
R is selected from fluoro, chloro, bromo, cyano, hydroxy, amino, carbamoyl, ureido, methyl, ethyl, propyl, prop-1-ynyl, methoxy, ethoxy, propoxy, isopropoxy, acetyl, hiethylamino, ethylamino, propylamino, isopropylamino, butylamino, dimethylamitto, N- methyl-7V-ethylamino, jV-methyl-N-propylamino, formylamino, acetylamino, propanoylamino, 2,2-dimethylpropanoylamino, 7V-methylcarbamoyl, methoxycarbonyl, N,jV-dimethylsUlphamoyl, mesylamino, cyclopropyl-R14-, cyclobutyl-R14-, piperazinyl-R15-, pyrrolyl-Rl 5-, pyrrolidinyl-R15-, pyrazolyl-Rl 5 : or morpholino-R15-; wherein R4 may be optionally substituted on carbon by one or more R16; and wherein said piperazinyl or pyrrolidinyl may be optionally substituted on nitrogen by a group selected from Rl ?;
R16 is selected from fluoro, hydroxy, amino, methoxy, niethylamino, jV.N-dimethylamirto, cyclopropyl-R22-, 1,3-dioxolanyl-R23-, imidazolyl-R23-, morpholino-R23-, piperazinyl-R23-, piperidihyl-R23- or pyrrolidinyl-R23-; wherein Rl 6 may be optionally substituted on carbon by one or more R2 ; and wherein said piperazinyl or pyrrolidinyl may be optionally substituted on nitrogen by a group selected from R25;
R14, R15, R22 and R23 are independently selected from a direct bond, -N(R26)- or -C(O)N(R28)-; wherein R26 and R28 are hydrogen; R17 and R25 are independently selected from methyl and f-butoxycarbonyl;
R24 is methyl or phenyl.
R is selected from fluoro, chloro, bromo, cyano, amino, methyl, methoxy, niethylamino, acetylamino, iV-inethylcarbamoyl or morpholino.
R is selected from fluoro, chloro, bromo, cyano, hydroxy, amino, carbamoyl, ureido, methyl, ethyl, methoxy, methylamino, isopropylamino, morpholino, 2-
(dimethylamiho)ethylamino, 2-(hydroxy)ethylamino, 2-(amiiio)ethylamino, 3-(pyrrolidin-l- yl)propylamiiio, jV-ttiethylcarbamoyl, acetylamino, 2-hydroxyacetylamino, trifluoromethyl, mesylamitto, 2,2-dimethylpropanoylamino, 3-methoxypropanoylamino, cyclobutylcarboilylamino, cyclopropylamino, 2,3-dihydroxypropylamino, 1,3-dihydroxyprop- 2-ylamino, 1 -rhethylpiperazin-4-yl, l-methylpiperazin-4-ylmethyl, acetyl, N-methyl-jV-(3- diniethylaminopropyl)amino, N-methyl-N-(2-methoxyethyl)amino, dimethylamino, hydroxymethyl, 1,2-dihydroxyethyl, pyrazol-5-ylamino, 3-aminoprop-l-yii-l-yl, 3- hydroxyprop-1-yn-l-yl, 3-methylaminoprop-l-yn-l -yl, 3-dimethylamittoprop-l-yn-l-yl, A- aminobutylamino, pyrrolidin-2-ylamino, 3-methylaminopropyl, 3-dimethylaminopropyl, 3- hydroxypropyl, 3-dimethylamitiopropylamino, aminomethyl, piperazin-1-yl, 1- methylpiperaziti-4-yl, 2,2-dimethyl-l ,3-dioxolan-4-ylmethylamino, pyrrolidin-3- ylmethylamitto, piperidin-4-ylmethylamino, imidazoi-2-ylmethylamino, methoxymethyl, ΛζN-dimethylsulphamoyl, formylamino, morpholinomethyl, aminomethyl, 2- (dimethylamino)ethylamino, pyrrol- 1-yl, pyrrol-2-yl, pyrrolidin-2-yl, imidazol-4-yl, cyclobutylamino, jV-methyl-jV-(2-diniethylaminoethyl)amirio, 2-dimethylaminoethoxy, dimethylaminomethyl, cyclopropylaminomethyl, pipeHdin-1 -ylmethyl, methylamiliomethyl, pyrrolidin-2-ylmethoxy, 3-dimethylaminopropoxy, methoxycarbonyl, l -(/- butoxycarboriyl)pyrrolidiri-2-ylmethylamino, 1 -(r-butoxycarbonyl)pyrrolidin-2-ylmethoxy, 2- phenoxy acetyl ami no and 1 -(/-butoxycarbonyl)pyrrolidin-2-yl. m Is selected from 0-2; wherein the values of R4 may be the same or different. m is O. m is 1. m is 2; wherein the values of R4 may be the same or different. Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein:
Ring A is phenyl, pyridyl, pyrazolyl, thienyl, indolyl, 2,3-dihydrobeiizofuranyl, imidazotl,2-a]pyridinyl, isoxazolyl, benzimidazolyl, 2-oxoindolinyl, furanyl, 1,3-thiazolyl, pyrimidinyl and pyrrolyl; wherein said pyrazolyl, indolyl, pyitolyl may be optionally substituted on nitrogen by a group selected from R5;
R is a substituent oh carbon and is selected from halo, cyano, hydroxy, sulphamoyl, C|-6alkyl, C2-6alkynyl, Cι-6alkoxy, TV, TV-(C i-6alkyl)2amino, Ci-6alkylS(O)a wherein a is 0 to 2, Cj-ealkoxycarbonylamino, jV-(Ci-6alkyl)sulphamoyl, 7V,7V-(C|-6alkyl)2Sulphamoyl, 7V-(Ci-6alkyl)-N-(Ct-6alkoxy)sulphamoyl, N' N'-(Ci-6alkyl)2ureido, Ci-6alkylsulphonylamino, carbocyclyl-R6- or heterocyclyl-R7-; wherein R may be optionally substituted on carbon by one or more R8; n is selected from 0-2; wherein the values of R may be the same or different;
R2 is hydrogen; R3 is selected from halo, methyl or methoxy;
R is selected from halo, cyano, hydroxy, amino, carbamoyl, ureido, C|-6alkyl, C2-6alkyriyl, C|-6alkoxy, Cualkanoyl, /V-(Ci-6alkyl)amiho, N,N-(C|-6alkyl)2amino, Ci-6alkanoylamino, 7V-(C|.6alkyl)carbamoyl, Ci^alkoxycarbonyl, N, N-(C ι-6alkyl)2sulphamoyl, Ct-βalkylsulphonylamino, carbocyclyl-R14- or heterocyclyl-R15-; wherein R4 may be optionally substituted on carbon by one or more R ; and wherein if said heterocyclyl contains art -NH- moiety that nitrogen may be optionally substituted by a group selected from R ;
R5 is selected from Ci-6alkyl; m is selected from 0-2; wherein the values of R may be the same or different;
R6, R7, R18 and R19 are independently selected from a direct bond, -O-, -S(O)5- or -N(R30)SO2-; wherein R30 is selected from hydrogen and s is 2;
R8 is selected from halo, cyano, hydroxy, C|-6alkyl, Ci^alkoxy,
Figure imgf000019_0001
N,N-(Cι-6alkyl)2carbamσyl, Cι-6alkylS(O)a wherein a is 0 to 2, N,N-(Ci-6alkyl)2sulphamoyl, N-(C ι-6alky I)-N-(C ι-6alkoxy)amino, carbocyclyl-R18- or heterocyclyl-R -; wherein R8 may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R2';
R14, R15, R22 and R23 are independently selected from a direct bond, -N(R26)- or -C(O)N(R28)-; wherein R26 and R28 are hydrogen; R16 is selected from halo, hydroxy, amino, C|.6alkoxy, N-(Ci-6alkyl)amiho, N,N-(Ci-6alkyl)2ainino, carbocyclyl-R22- or heterocyclyl-R23-; whereih R16 may be optionally substituted on carbon by one or more R24; and wherein if said heterocyclyl contains an -NH- ttioiety that nitrogen may be optionally substituted by a group selected from R25; R17 and R25 are independently selected from C1-6alkyl and Ci-6alkoxycarbonyl;
R2 is selected from Chalky!;
R20 is selected from cyano or hydroxy;
R24 is methyl or phenyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not:
N-t4-chloro-3-({t6-(4-methylpiperazin-l-yl)pyridin-3-yl]amino}carbonyl)phenyl]-2- ttiorpholin-4-ylisonicotinamide;
N-t4-chloro-3-({t6-(4-ethylpiperazin-l-yl)pyridih-3-yl]amino}carbonyl)phenyl]-2-morpholin- 4-ylisonicotinamide; ΛL{4-chloro-3-t({6-tt3-(dimethylamino)propyl](methyl)amino]pyridin-3-ylj amino)carbonyl] phenyl }-2-morpholin-4-ylisonicotinamide;
7V-{4-chloro-3-t({6-[t2-(dimethylamino)ethyl](methyl)amino]ρyridin-3-yl] amino)carbonyl] phenyl}-2-morpholin-4-ylisohicotinamide; or
N-t4-chloro-3-({t6-(4-methyl-l,4-diazepan-l-yl)pyridin-3-yl]amino] carbonyl)ρhenylJ-2- morpholin-4-ylisonicotinamide.
Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein:
Ring A is phenyl, pyridyl, pyrazolyl, thienyl, indolyl, 2,3-dihydrobenzofuranyl and imidazotl,2-a]pyridinyl; wherein said pyrazolyl may be optionally substituted on nitrogen by a group selected from R5;
R is a substituent on carbon and is selected from halo, cyano, Ci-ealkyl, C2-6alkynyl, C|-6alkoxy, N,N-(Ci-6alkyl)2amino, Ci-6alkylS(O)a wherein a is 0 to 2, N,N-(C|-6alkyl)2sulphamoyl, Ci-6alkylsuiphonylamino, carbocyclyl-R6- or heterocyclyl-R7-; wherein R1 may be optionally substituted on carbon by one or more R8; n is selected from 0-2; wherein the values of R1 may be the same or different;
R2 is hydrogen;
R3 is selected from halo or methyl; R is selected from halo, cyano, amino, C|-6alkyl, C|.6alkoxy, TV-(C ι-6alkyl)amino, Cualkanoylamino, /V-(C|-6alkyl)carbamoyl or heterocyclyl-R15-; m is selected from 0-2; wherein the values of R4 may be the same or different;
R5 is Ci-6alkyl; R6, R7 and R19 are independently selected from a direct bond, -S(O),- or -N(R30)SO2-; wherein R30 is hydrogen and s is 0-2;
R8 is selected from halo, cyano, hydroxy, /V,/V-(C!-6alkyl)2amino or heterocyclyl-R19-; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R ; R15 is a direct bond;
R21 is Cualkyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not:
7V-{4-chloro-3-t({6-[t3-(dimethylamino)propyl](methyl)amino]pyridin-3-yl}amino)carbonyl] phenyl } -2-morpholin-4-ylisonicotinamide; or
7V-{4-chloro-3-t({6-tt2-(dimethylamino)ethyl](methyl)amino]pyridin-3-ylj amiho)carbonyl] phenyl } -2-morpholin-4-ylisonicotinamide.
Therefore in a further aspect of the invention there is provided a compound of formula (1) (as depicted above) wherein: Ring A is phenyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, l-methylpyrazol-5-yl, 1-/- butylpyrazol-5-yl, thien-2-yl, thien-3-yl, indol-2-yl, l-methylindol-2-yl, indol-4-yl, indol-5-yl, indol-6-yl, indol-7-yl, 2,3-dihydrobenzofuran-7-yl, imidazo[l,2-a]pyridin-2-yl, isoxazol-3-yl, pyrrol-2-yl, benzimidazol-6-yl, l-methyl-2-oxoindolin-5-yl, furan-2-yl, l ,3-thiazol-5-yl, pyrimidin-4-yl and l-niethylpyrrol-2-yl; R is a substituent on carbon and is selected from fluoro, chloro, bromo, iodo, cyano, hydroxy, sulphamoyl, methyl, trifluoromethyl, 1 -cyano- 1-methylethyl, methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, 7V,/V-dimethylamino, difluoromethylthio, 7V,N-dittiethylsulphamoyl, /-butyl, mesyl, cyclopropylaminosulphonyl, azetidin-1-ylsulphonyl, tetrahydrofuran-2-ylmethylaminosulphonyl, N-methyl-7V-(2,3-dihydroxypropyl)sulphamoyl, mesylamino, morpholinosulphonyl, 1 -methylpiperazin-4-ylmethyl, 1 -ethylpiperazin-4- ylmethyl, 3,3-dimethylbut-l-yn-l-yl, morpholino, /V,N-dimethylaminottiethyl, 3-methyl-3- hydroxybut-1 -yn-l-yl, methylthiomethyl, mesylmethyl, /V-(methyl)-/V-(methoxy)sulphamoyl, 2-hydroxymethylpiperidin-l -ylsulphonyl, 3-hydroxymethylpiperidin-l-ylsulphonyl, 4- hydroxymethylpiperidin-1-ylsulphonyl, 1 ,1-difluoroethyl, piperidin-1-yl, /V,/V-diethylamiiio, N'N'-dimethylureido, cyclopropyl, f-butoxycarbonyl amino, pyrid-2-yl, phenoxy, 2-methoxy- 1 ,1-dimethylethyl, lnesylmethyl, l,3-thiazol-2-yl, 2-methyl-l,3-thiazol-5-yl, 1- methy lcyclopropyl, 1 , 1 -dimethylprop-2-yn- 1 -y 1, 1 -(N, /V-dimethy lsulphamoy I)- 1 -methy lethyl, 1,1 -dimethy lbut-2-yti- 1 -y 1, /V-(methyl)-N-(methoxy)aminomethy 1, 1 -
(jV,N-dimethylcarbamoyl)-l-methylethyl, 4-methylimidazol-l-yl, 1 -(cyclopropyl)- 1 - methylethyl, 2-methyl-3,4-diliydroxybut-2-yl, 2-methylbut-2-yl, 1 -hydroxy-l - cyclopfopylethyl, 1-cyattoethyl, 2-cyano-3-methylbut-2-yl, 2-cyanobut-2-yl, l-hydroxy-2- cyanoprop-2-yl and 2-cyanopyitol-l-ylmethyl; n is selected from 0-2; wherein the values of R1 may be the same or different;
R2 is hydrogen;
R3 is selected from fiuoro, chloro, methyl or methoxy;
R is selected from fiuoro, chloro, bromo, cyano, hydroxy, amino, carbamoyl, ureido, methyl, ethyl, methoxy, methylamilio, isopropylamino, morpholiiio, 2- (dimethylamino)ethylamino, 2-(hydroxy)ethylamino, 2-(amino)ethylamino, 3-(pyrrolidin-1 - yl)propylamino, jV-methylcarbamoyl, acetylamino, 2-hydroxyacetylamino, trifluoromethyl, mesylamino, 2,2-dimethylpropanoylamino, 3-methoxypropanoylamino, cyclobutylcarbonylamino, cyclopropylamino, 2,3-dihydroxypropylamino, 1,3-dihydroxyprop- 2-ylamino, 1 -methylpiperazin-4-yl, l-methylpiperazin-4-ylmethyl, acetyl, N-methyl-N-(3- dimethylaminopropyl)amino, N-niethyl-jV-(2-methoxyethyl)amino, diniethylamino, hydroxymethyl, 1 ,2-dihydroxyethyl, pyrazol-5-ylamino, 3-aminoprop-l -yn-l-yl, 3- hydroxyprop-1-yn-l-yl, 3-methylaminoprop-1-yn-l -yl, 3-dimethylaminoprop-l-yn-l -yl, A- aminobutylamino, pyrrolidin-2-ylaniino, 3-methylaminopropyl, 3-dimethylamiiiopropyl, 3- hydroxypropyl, 3-dimethylaminopropylamino, aminomethyl, piperazin-1-yl, 1- methylpiperazin-4-yl, 2,2-dimethyl-l,3-dioxolan-4-ylmethylamino, pyrrolidin-3- ylmethylamino, piperidin-4-ylmethylamino, imidazol-2-ylmethylamino, methoxymethyl, TV, N-diniethy lsulphamoy I, formylamino, morpholinomethyl, aminomethyl, 2- (dimethylamino)ethylamiiio, pyrrol-l -yl, pyttol-2-yl, pyrrolidin-2-yl, imidazol-4-yl, cyclobutylamino, jV-methyl-jV-(2-dimethylaminoethyl)amino, 2-dimethylaminoethoxy, diinethylarninomethyl, cyclopropylarninomethyl, piperidin-l -ylmethyl, methylaminomethyl, pyrrolidin-2-ylmethoxy, 3-dimethylaminopropoxy, methoxycarbonyl, l-(/- butoxycarbonyl)pyrrolidirt-2-ylmethylamino, I -(/-butoxycarbony))pyrrolidin-2-ylmethoxy, 2- pheiioxy acetylamino and 1 -(f-butoxycarbonyl)pyrrolidin-2-yl; in is selected from 0-2; wherein the values of R4 may be the same or different; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not:
N-t4-chloro-3-({t6-(4-methylpiperazin-l-yl)pyridin-3-yl]amino] carbonyl)phenyl]-2- morpholin-4-ylisonicotinamide; jV-{4-chloro-3-t({6-[t3-(dimethylamino)propyl](niethyl)amino]pyridin-3-yl] amino)carbonyl] phenyl) -2-niorpholin-4-ylisonicotinamide; or jV-{4-chloro-3-t({6-tt2-(dimethylamino)ethyl](niethyl)amino]pyridin-3-yl}amino)carbonyl] pheiiyl}-2-niorpholin-4-ylisoiiicotinamide. Therefore in a further aspect of the invention there is provided a compound of formula
(I) (as depicted above) wherein:
Ring A is phenyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, l-methylpyrazol-5-yl, thien-2-yl, thien-3-yl, indol-5-yl, indol-6-yl, 2,3-dihydrobenzofUran-7-yl or imidazo[l,2-a]pyridinyl;
R is a substittient on carbon and is selected from fluoro, chloro, bromo, iodo, cyano, methyl, t-butyl, trifluoromethyl, dimethylaminoniethyl, 1 -methyl- 1 -cyattoethyl, 4- methylpiperazin- 1 -ylmethyl, 4-ethylpiperazin- 1 -ylniethyl, 3-hydroxy-3-methylbut- 1 -yn- 1 -yl, 3,3-diniethylbut-l-yn-l -yl, methoxy, propoxy, isopropoxy, isobutoxy, dimethylamino, difluoroniethylthio, ΛζjV-dimethylsulphamoyl, mesyl, cyclopropylaminosulphonyl, azetidin-1- ylsulphoiiyl or mesylamino; n is selected from 0-2; wherein the values of R1 may be the same or different;
R2 is hydrogen;
R3 is selected from fluoro, chloro or methyl;
R is selected from fluoro, chloro, bromo, cyano, amino, methyl, methoxy, niethylaniino, acetylaniinσ, jV-methylcarbamoyl or morpholino; m Is selected from 0-2; wherein the values of R4 may be the same or different, or a pharmaceutically acceptable salt thereof.
In another aspect of the invention, preferred compounds of the invention are any one of the Examples or a pharmaceutically acceptable salt thereof.
In another aspect of the invention, preferred compounds of the invention are any one of:
N-(6-amino-5-chloropyridin-3-yl)-5-{t3-(l-cyano-l-methylethyl)benzoyl]amino) -2- methylbenzamide; 7V-(6-amino-5-chloropyHditt-3-yl)-5-{[3-(l-cyaiio-l-methylethyl)-5-fluofobenzoyl]amino}-2- methylbenzaniide;
5-{t3-(l -cyano-l-hiethylethyl)benzoyl]amitio}-N-(5-methoxypyridin-3-yl)-2-methyl beilzamide; 5 N-(6-amino-5-chlofopyridin-3-yl)-2-methyl-5-{[3-(tfifltiorometliyl)benzoyl]attiino} benzatnide;
S-ltS-Cl-cyano-l-methylethyObeiizoy^amiiioj -N-CS^-diniethylpyridin-S-yl)^- ttiethylbenzamide; iV-(3-{[(6-aniino-5-chlotOpyridin-3-yl)amino]cai-bonyl}-4-niethylpheiiyl)-2-(l-cyaiio-l- 1.0 methylethyl)isonicotinamide;
7V-(6-amino-5-chlo)-opyridin-3-yl)-2-chloi-o-5-{t3-(tHflυol:omethyl)benzoyl]amino} benzamide;
N-(6-acetylainiiio-pyridili-3-yl)-5-t3-(cyano-diltiethyl-niethyl)-benzoylaniino]-2-niethyl- benzamide; 15 jV-t6-(acetylamino)pyridin-3-yl]-2-chloi-o-5-{t3-(trifluoiOmethyl)benzoyljamino) benzamide; and
7V-(6-amino-5-metliylpyHdin-3-yl)-2-chlofo-5-{t3-(l-cyano-l-methylethyl)bettzoyl]amino3 benzamide; or a pharmaceutically acceptable salt thereof. 0 Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprises of:
Process a) reacting an amine of the formula (II)
Figure imgf000024_0001
with an acid of formula (tit):
Figure imgf000025_0001
(III) of an activated acid derivative thereof; Process b) reacting an acid of formula (IV):
Figure imgf000025_0002
(IV) with an amine of formula (V):
Figure imgf000025_0003
or an activated acid derivative thereof; and thereafter if necessary: i) converting a compound of the formula (I) into another compound of the formula (I); ii) removing ally protecting groups; iii) forming a pharmaceutically acceptable salt. Specific reaction conditions for the above reactions are as follows.
Process a) and Process b) Amines and acids may be coupled together in the presence of a suitable coupling reagent. Standard peptide coupling reagents known in the art can be employed as suitable coupling reagents, or for Example carbonyldiimidazole and dicyclohexyl-carbodiimide, optionally in the presence of a catalyst such as dittiethylaminopyrldine or 4-pyrrolidinopyridine, optionally in the presence of a base for Example triethylamine, pyridine, or 2,6-di-o%/-pyridines such as 2,6-lutidine or 2,6-di-fe/V-butylpyridine. Suitable solvents include diniethylacetamide, dichloromethane, benzene, tetrahydrofuran and dihiethylformaniide. The coupling reaction may conveniently be performed at a temperature in the range of -40 to 40 °C. Suitable activated acid derivatives include acid halides, for Example acid chlorides, and active esters, for Example pentafluorophenyl esters. The reaction of these types of compounds with amines is well known in the art, for Example they may be reacted in the presence of a base, such as those described above, and in a suitable solvent, such as those described above. The reaction may conveniently be performed at a temperature in the range of -40 to 40 0C.
Amines of formula (II) may be prepared according to Scheme 1:
Figure imgf000026_0001
UD
Scheme 1 Acids of formula (IV) may be prepared according to Scheme2:
Conditions as
Process a) or b)
Figure imgf000026_0002
Figure imgf000026_0003
(IV)
Scheme 2
Wherein Pg is an acid protecting group, for example such as those described herein below.
Compounds of formula (til), (V), (ila) and (IVd) are commercially available compounds, or they are known in the literature or they may be prepared by standard processes known in the art.
It will be appreciated that certain of the various ring substitUents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenatioii with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heatihg; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be Used in accordance with standard practice (for illustration see T. W. Green, Protective OroUps in Organic Synthesis, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein. A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a rnethoxycarbohyl, ethoxycarbonyl or /-butoxycarbonyl group, an arylmethoxycarbohyl group, for example benzyloxycarbottyi, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a /-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrσgenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamiiie, or with hydrazine.
A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkaiioyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vaty with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a f-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
As stated hereinbefore the compounds defined in the present invention possess anti-cancer activity which is believed to arise from the B-Raf inhibitory activity of the compounds. These properties may be assessed, for example, Using the procedure set out below. B-Raf in vitro ELlSA assay
Activity of human recombinant, purified wild type His-B-Raf protein kinase was determined in vitro Using ah enzyme-linked immunosorbent assay (ELlSA) assay format, which measures phosphorylation of the B-Raf substrate, human recombinant, purified His-derived (detagged) MEtCl . The reaction Utilized 2.5 nJVl B-Raf, 0.15 μM MEKl and 10 μM adenosine triphosphate (ATP) in 40 niM 7V-(2-hydroxyethyl)piperaziiie-N'-(2- ethanesulfonic acid hemisodium salt (HEPES), 5 hiM 1 ,4-dithio-t)L-threitol (DTT), 10 mM MgCl2, 1 mM ethyleliediamihetetraacetic acid (Et)TA) and 0.2 M NaCl (Ix HEPES buffer), with or without compound at various concentrations, in a total reaction volume of 25μl in 384 well plates. B-Raf and compound were preincubated in Ix HEPES buffer for 1 hour at 25 °C. Reactions were initiated with addition of MElCl and ATP ill Ix HEPES buffer and incubated at 25 °C for 50 minutes and reactions stopped by addition of 10 μl 175 mM EDTA (Final concentration 50 mM) in Ix HEfES buffer. 5 μl of the assay mix was then diluted 1 :20 into 50 mM EDTA ill Ix HEPES buffer, transferred to 384 well black high protein binding plates and incubated overnight at 4 °C. Plates were washed in tris buffered saline containing 0.1% Tween20 (TBST), blocked with 50 μl Superblock (Pierce) for 1 hour at 25 °C , washed in TBST, incubated with 50 μl rabbit polyclonal anti-phospho-MEK antibody (Cell Signaling) diluted 1 :1000 in TBS for 2 hours at 25 °C , washed with TBST, incubated with 50 μl goat anti-rabbit horseradish peroxidase -linked antibody (Cell Signaling) diluted 1 :2000 in TBS for 1 hour at 25 0C and washed with TBST. 50 μl of fluorogenic peroxidase substrate (Quantablu - Pierce) was added and following incubation for 45-60 minutes, 50 μl QuantabluSTOP
(Pierce) was added. Blue fluorescent product was detected at excitation 325 and emission 420 using a TECAN Ultra plate reader. Data was graphed and IC^s calculated using Excel fit (Microsoft).
When tested in the above in vitro assay, the compounds of the present invention exhibited activity less than 30 μM. for example the following results were obtained:
Figure imgf000029_0001
According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore, in association with a pharmaceutically-acceptable diluent or carrier. The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
In general the above compositions may be prepared in a conventional manner using conventional excipients.
The compound of formula (I) will normally be administered to a warm-blooded animal at a unit dose within the range 1 -1000 mg/kg, and this normally provides a therapeutically-effective dose. Preferably a daily dose in the range of 10-100 mg/kg is employed. However the daily dose will necessarily be varied depending Upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
According to a further aspect of the present invention there is provided a compound of the formula (1), or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use in a method of treatment of the human or animal body by therapy.
We have found that the compounds defined in the present invention, or a pharmaceutically acceptable salt thereof, are effective anti-cancer agents which property is believed to arise from their B-Raf inhibitory properties. Accordingly the compounds of the present invention are expected to be useful in the treatment of diseases or medical conditions mediated alone or in part by B-Raf , i.e. the compounds may be used to produce a B-Raf inhibitory effect in a warm-blooded animal in need of such treatment.
Thus the compounds of the present invention provide a method for treating cancer characterised by inhibition of B-Raf, i.e. the compounds may be Used to produce an anti- cancer effect mediated alone or in part by the inhibition of B-Raf.
Such a compound of the invention is expected to possess a wide range of anti-cancer properties as activating mutations in B-Raf have been observed in many human cancers, including but not limited to, melanoma, papillary thyroid tumors, cholangiocarcinomas, colon, ovarian and lung cancers. Thus it is expected that a compound of the invention will possess anti-cancer activity against these cancers. It is in addition expected that a compound of the present invention will possess activity against a range of leukaemias, lymphoid malignancies and solid tumours such as carcinomas and sarcomas in tissues such as the liver, kidney, bladder, prostate, breast and pancreas. In particular such compounds of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the skin, colon, thyroid, lungs and ovaries. More particularly such compounds of the invention, or a pharmaceutically acceptable salt thereof, are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with B-Raf, especially those tumours which are significantly dependent on B-Raf for their growth and spread, including for example, certain tumours of the skin, colon, thyroid, lungs and ovaries. Particularly the compounds of the present invention are useful in the treatment of melanomas.
Thus according to this aspect of the invention there is provided a compound of the formula (t), or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use as a medicament. According to a further aspect of the Invention there is provided the Use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of a B-Raf inhibitory effect in a warm-blooded animal such as man. According to this aspect of the invention there is provided the Use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for Use in the production of an anti-cancer effect in a warm-blooded animal such as man.
According to a further feature of the invention, there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined herein before in the manufacture of a medicament for use in the treatment of melanoma, papillary thyroid tumours, cholahgiocarcittottias, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries.
According to a further feature of this aspect of the invention there is provided a method for producing a B-Raf inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined above. According to a further feature of this aspect of the invention there is provided a method for producing an anti-cancer effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined above. According to an additional feature of this aspect of the invention there is provided a method of treating melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries, in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined herein before. According to a further aspect of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore for Use in the production of a B-Raf inhibitory effect in a wdrm-blooded animal such as man.
According to this aspect of the ittvelitioh there is provided the Use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use in the production of an anti-cancer effect in a warm-blooded animal such as man.
According to a further feature of the invention, there is provided the Use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined herein before for Use in the treatment of melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries.
In a further aspect of the invention there is provided a pharmaceutical composition which comprises ύ compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined herein before in association with a pharmaceUtically-acceptable diluent or carrier for use in the production of a B-Raf inhibitory effect in a warm-blooded animal such as man.
In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (J), or a pharmaceutically acceptable salt thereof, as defined herein before in association with a pharmaceutically-acceptable diluent or carrier for Use in the production of an anti-cancer effect in a warm-blooded animal such as man.
In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined herein before in association with a pharmaceutically-acceptable diluent or carrier for use in the treatment of melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries in a warm-blooded animal such as man.
The B-Raf inhibitory treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti-tumour agents :- (i) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, lnelphalan, chlorambucil, busulphaii and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside and hydroxyurea; antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacHne, topotecan and camptothecin);
(ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene), oestrogen receptor down regulators (for example fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LMRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example ttiegestrol acetate), aromatase inliibitors (for example as anastrozole, letrozole, vorazole and exelnestane) and inhibitors of 5α-reductase such as finasteride;
(iii) Agents which inhibit cancer cell invasion (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function); (iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example the anti-erbb2 antibody trastuzumab [Herceptin+M] and the anti-erbbl antibody cetuximab [C225J) , farnesyl transferase inhibitors, MEK inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inliibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as N-(3-chloro-4-fluoropliertyl)-7-methoxy-6-(3- ttiorpholinopropoxy)quinazolin-4-amine (gefitinib, AZD 1839), 7V-(3-ethyiiylphenyl)-6,7- bis(2-methoxyetlioxy)α.uinazolin-4-amine (erlotinib, OS1-774) and 6-acrylamido-7V-(3-chloro- 4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (Cl 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors of the hepatocyte growth factor family;
(v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, (for example the anti-vascular endothelial cell growth factor antibody bevacizumab [AvastintM], compounds such as those disclosed in International Patent AppHcations WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compounds that work by other mechanisms (for example linomide, inhibitors of integrin αvβ3 function and atigiostatin);
(vi) vascular damaging agents sUch as Combretastatiii A4 and compounds disclosed in International Patent Applications WO 99/02166, WO00/40529, WO 00/41669, WOOl/92224,
WO02/04434 and WO02/08213;
(vii) antisettse therapies, for example those which are directed to the targets listed above, such as IStS 2503, an anti-ras antisense;
(viii) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCAl or BRCA2, Gt)]EPT (gene-directed enzyme pro-drug therapy) approaches such as those Using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy;
(ix) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the ininiuttogenicity of patient tumour cells, such as transfectioli with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches Using transfected immune cells such as cytokine-transfected dendritic cells, approaches Using cytokine-traiisfected tumour cell lines and approaches using anti-idiotypic antibodies; (x) Cell cycle inhibitors including for example CDlC inhibitiors (eg flavopiridol) and other inhibitors of cell cycle checkpoints (eg checkpoint kinase); inhibitors of aurora kinase and other kinases involved in mitosis and cytokinesis regulation (eg mitotic kinesins); and histone deacetylase inhibitors; and
(xi) endothelin antagonists, including endothelin A antagonists, endothelin B antagonists and endothelin A and B antagonists; for example ZD4054 and Zt)161 1 (WO 96 40681 ), atrasentan and YM 598.
Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention within the dosage range described hereinbefore and the other pharmaceUtically-active agent within its approved dosage range.
In addition to their use in therapeutic medicine, the compounds of formula (1) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of In vitro and in vivo test systems for the evaluation of the effects of inhibitors of B-Raf in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
In the above other pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply.
Examples
The invention will now be illustrated by the following nott limiting examples in which, unless stated otherwise:
(i) temperatures are given in degrees Celsius (0C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25°C;
(ii) organic solutions were dried over anhydrous sodium sulphate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals; 4.5-30 mmHg) with a bath temperature of up to 60 0C;
(iii) in general, the course of reactions was followed by TLC and reaction times are given for illustration only;
(iv) final products had satisfactory proton nuclear magnetic resonance (NMR) spectra and/or mass spectral data;
(v) yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required; (vii) when given, NMR data is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 400 MMz Using perdeuterio dimethyl sulphoxide (DMSOd6) as solvent Unless otherwise indicated;
(vii) chemical symbols have their usual meanings; Sl units and symbols are used; (vϋi) solvent ratios are given in volume:voluttie (v/v) terms; and
(ix) mass spectra were run with an electron energy of 70 electron volts in the chemical ionization (Cl) mode Using a direct exposure probe; where indicated ionization was effected by electron impact (El), fast atom bombardment (F1AB) or electrospray (ESP); values for m/z are given; generally, only ions which indicate the parent mass are reported; and unless otherwise stated, the mass ion quoted is (MH)+;
(x) where a synthesis is described as being analogous to that described in a previous example the amounts used are the millimolar ratio equivalents to those Used in the previous example;
(xi) the following abbreviations have been used: HATU O-(7-AzabeftzotHazol-l-yl)-N)7V,N',7V'-tetramethylutoiiiuni hexaflUorophosphate; THF tetrahydrofuran;
DMF ΛζN-dimethylformamide; £tOAc ethyl acetate;
DItA N, N-diisopropylethylamine; t)CM dichloromethane;
DMSO dimethylsulphoxide;
MeCΝ acetonitHle; KBS iV-brottiosuccinimide; and
MeOH methanol;
(xii) "ISCO" refers to normal phase flash column chromatography Using 12 g and 40 g prepacked silica gel cartridges used according to the manufacturers instruction obtained from ISCO, Inc, 4700 superior street Lincoln, Ν£, USA.; and (xiϋ) "Gilson HPLC" refers to a YMC-AQC 18 reverse phase HPLC Column with dimension 20 mm/100 and 50 mm/250 in water/MeCΝ with 0.1% TFA as mobile phase, obtained (xiv) Parr Hydrogenator or Parr shaker type hydrogenators are systems for treating chemicals with hydrogen in the presence of a catalyst at pressures up to 5 atmospheres (60 psig) and temperatures to 80 0C.
Example 1 5-r(3-Fluorobenzoyliamino1-2-methyl-N-pyridin-3-ylbenzamide
A solution of 5-amino-2-methyl-iV-pyriditt-3-ylbenzamide (Method 68; 60 mg, 0.264 mmol), 3-fluorobenzoic acid (41 mg, 0.290 mniol) and DlEA (115 μL, 0.66 mmol) in DMF (1.5 ml) was treated with HATU (120 mg, 0.3168 mmol). The reaction mixture was shaken overnight at 25 °C. Water (10 ml) was added slowly to precipitate the product. The resulting precipitate was washed with water (10 ml), isolated and dried overnight in a vacuum oven at 70 °C to give the title compound 61.2 mg, (66%) as a solid. MMR (300 MHz): 10.59 (s, IH), 10.43 (s, IH), 8.87 (s, IH), 8.30 (d, I H), 8.18 (d, IH), 7.92 (s, IH), 7.75-7.84 (m, 3H), 7.55- 7.63 (m, IH), 7.37-7.48 (m, 2H), 7.31 (d, IH), 2.35 (s, 3H); m/z 349. Examples 2-120
The following compounds were prepared by the procedure in Example 1 Using 5- amino-2-methyl-7V-pyridiri-3-ylbenzamide (Method 68) or 5-amino-2-chloro-N-(5- fluoropyridin-3-yl)benzamide for (Method 79) Example 55 and the appropriate SM. In some cases, further purification was required (supercritical fluid, Gilson reverse phase preparatory HPLC or colurnh chromatography utilizing an ISCO system).
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Ex. Compound NMR m/z SM
120 5-[(3-Chloro-4- 10.59 (s, IH), 10.46 (s, IH), 8.88 (d, 384 3-chloro-4- fluotobenzoyl) IH), 8.82 (dd, IH), 8.l7 - 8.24 (m, fluorobenzoic amino] -2-methy 1-7V- 2H), 7.99 - 8.1 34 (m, IH), 7.90 (s, acid pyfidin-3- IH), 7.82 (dd, IH), 7.61 (t, IH), ylbenzamide 7.40 (dd, IH), 7.32 (d, IH), 2.36 (s
3H)
Example 121
2-ChlolO-5 - f (3 -fluorobehzoyl)aniino1-./V-pyridin-3 -ylbeftzamide
A solution of 5-amino-2-chlofo-yV-pyridin-3-ylbenzaniide (Method 76; 65 nig, 0.264 mmol), 3-flUorobenzoic acid (41 nig, 0.290 mmol), and t)l£A (115 μl, 0.66 ttimol) in t)Mf (1.5 ml) was treated with HATU (120 mg, 0.3168 mmol). The reaction mixture was shaken overnight at 25 °C. Water (10 ml) was added slowly to precipitate the product. The resulting precipitate was washed with water (10 ml), isolated and dried overnight in a vacuum oven at 70 °C to give the title compound 46.9 mg, (48%) as a solid. NMR (300 MHz): 10.81 (s, IH), 10.59 (s, IH), 8.85 (s, IH), 8.33 (d, IH), 8.16 (d, IH), 8.03 (s, IH), 7.93 (dd, IH), 7.74-7.84 (ni, 2H), 7.54-7.65 (m, 2H), 7.37-7.51 (m, 2H); m/z 369.
Examples 122-157
The following compounds were prepared by the procedure in Example 121 Using 5- amino-2-chloro-jV-pyridin-3-ylbenzamide (Method 76) and the appropriate SM with the exception of Example 157 which was prepared from 2-chloro-5-{[3-(trifiuoromethyl)benzoyl] amino) benzoic acid (Method 224) and 7V-(5-aminopyridin-2-yl)acetamide. In some cases, further purification was required (supercritical fluid, Oilson reverse phase preparatory HPLC or column chromatography utilizing an ISCO system).
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Example 158 jV-f6-Acetylpyfidin-3-yl)-2-chloto-5-{f3-ftfifluofomethyl)betizoyl1aminolbelizamide
To a solution of N-(6-bromopyridin-3-yl)-2-chloro-5-{[3-(trifluoromethyl) beiizoyl]amino}beiizamide (Example 215; l OO nig) in NMP (3 ml) were added tributyl[(l£> 5 2-methoxypiOp- 1 -en- 1 -yljstannaiie (0.4 ml), Pd(PPh3^ (50 nig) under argon, the resulting mixture was heated to 80°C for 10 hours. The mixture was partitioned between M2O and EtOAc, and the organic layer was washed with brine, saturated aqueous Nat7 solution and dried with MgSθ4. Evaporation of the solvent gave a solid, which was dissolved in 2 N HCl and stirred for 3 hours at room temperature. Extraction of the aqueous layer with EtOAc (3x
10 25 ml) and the organic layer was washed with brine and dried with MgSO4. Evaporation gave a brown solid, which was purified by Reverse phase MPLC (5-95% MeCN/H20, 15 min). The title compound (2 nig) was collected by evaporation. NMR (300 MHz) 11.26 (s, IH), 10.82 (s, I H), 9.03 (d, IH), 8.-6 - 8.63 (m, 3H), 7.-8 - 8.23 (m, 4H), 7.88 (t, IH), 7.69 (d, IH), 2.68 (s, 3H), m/z 46l .
15
Example 159
N-(6-rr2-Hvdroxyethyl)amino1t)yridin-3-vU-2-methyl-5-it3-rtriflUoromethyl) benzoylfomino 1 benzamide
To a solutioh of N-{6-t(2-{ttert-butyl(dimethyl)silyl]oxyj ethyl)amino]pyridine-3-yl}- 0 2-methyi-5-{[3-(trifluoromethyl)benzoyl]amino] benzamide (Method 99; 125 mg) in THF was added tertabutylammoniUm fluoride (3 ml, 1.OM in THF) and the resulting dark red solution was stirred at room temperature for 2 hours. The mixture was partitioned between H2O and EtOAc, and the organic layer was washed with brine and dried with MgSO4. Evaporation of the solvent gave a pale purple oil, which was purified by Reverse phase HPLC 5 (5-95% ACN/ H2O, 20 min). The title compound (43 mg) was collected by evaporation as a pale purple solid. NMR (300 MHz): 10.59 (s, 2H), 8.47 (s, I H), 8.23 - 8.35 (m, 2H), 7.88 - 8.03 (m, 3H), 7.75 - 7.86 (m, 2H), 7.34 (d, IH), 7.06 (s, IH), 3.58 - 3.67 (m, 4H), 2.36 (s, 3H); m/z 459. Example 160
S-iD-d-Cvano-l-methylethy^benzoyliamiiiol-N-fβ-fglvcoloylatiiiiiol-S-niethylpyridin-S- yl"|-2-methylbenzaniide to a solution of N-(6-{t(beHzyloxy)acetyl]amino}-5-methylpyridin-3-yl)-5-{[3-(l- cyano-l-methylethyl)benzoyl]amino}-2-methylbenzamide (Example 316; 30 ttig) in MeOH (3 ml) were added HCO2NH4 and HCO2H (5 ml, 1 : 10 v/v) and the resulting mixture was refluxed for 12 hours. The mixture was partitioned between EtOAc and H2O and the organics were washed with NaCl(Sat) and then dried with Na2SO^5). Evaporation of the solvent gave a solid, which was purified by Reverse phase HPLC (5-95% ACN/H20, 15 min). The title compound (5 mg) was collected by evaporation. NMR (300 MHz): 10.55 (s, IH), 10.43 (s, IH), 9.62 (s, IH), 8.55 (d, IH), 8.03 - 8.10 (m, 2H), 7.96 (d, IH), 7.89 (d, IH), 7.85 (dd, IH), 7.75 (d, I H), 7.61 (t, IH), 7.33 (d, IH), 4.08 - 4.18 (m, 2H), 2.37 (s, 3H), 2.19 (s, 3H), 1.76 (s, 6H); m/z 486.
Example 161
J/V-["6-(Aminomethyl)pyridin-3-yl1-5-(t3-(l-cyano-l-methylethyl)benzoyl1aminol-2- methylbenzamide
To a solution of 5-{t3-(l-cyano-l-methylethyl)benzoyl]amino}-jV-(6-cyanopyridin-3- yl)-2-methylbenzamide (Example 321 ; lOO mg) in THE (3ml) was added slowly LiAlH4 (3 ml, 1.0M in THF) and the resulting mixture was stirred at ambient temperature for 5 minutes. The mixture was cooled with an ice bath and a saturated solution of tartaric acid was added slowly until evolution of gas ceased. The mixture was filtered to remove the aluminium salts and the filtrate was partitioned between EtOAc and H2O. The organics were washed with NaCl(sat) and then dried with Na2Sθ4(s). Evaporation of the solvent gave a solid, which was purified by reverse phase HPLC (5-95% ACN/H2O, 15 mih). The title compound (50 mg) was collected by evaporation. NMR (300 MHz): 10.72 (s, IH), 10.52 (s, IH), 8.96 (s, IH), 8.33 - 8.41 (bs, 2H), 8.22 (d, IH), 8.08 (s, IH), 7.95 - 8.03 (m, 2H), 7.82 (d, IH), 7.77 (d, IH), 7.61 (t, IH), 7.54 (d, IH), 7.28 - 7.41 (m, 2H), 4.1 1 - 4.20 (m, 2H), 2.38 (s, 3H), 1.79 (s, 6H); m/z 429.
Example 162
The following compound was prepared by the procedure of Example 161 , Using the appropriate starting material. Ex Compound NMR M/z SM
162 N- [5 -(Aminomethy 1) 10.99 (s, IH) , 10.60 (s, IH), 8.71 (s, 449 Example pyridin-3-yl]-2-chloro-5- IM), 8.42 (s, IH), 8.17 - 8.28 (m, 313
{ [3-( 1 -cyano- 1 -methyl 2H), 8.01 - 8. 1 1 (m, 2H), 7.Ϊ 58 - 8.01 ethy l)benzoy 1] amino } (m, 2H), 7.78 (d, IH), 7.53 - 7.68 benzamide (m, 2H), 4.l 3 (dd, 2H) 1.74 (s, 6H)
Example 163
5-{f3-(l-Cvano-l-methylethyl)benzoyl1aminol-N-f5-(methoxymethyl)pyridiii-3-yl"|-2- lnethylbeiizaniide To a solution of 5-{f3-(l -cyano-l-methylethyl)benzoyl]aminoj -N-[5-
(hydroxymethyl)pyridin-3-yl]-2-methylbehzamide (Example 299; 24 mg) in THf (2 ml) was added slowly at 0°C NaH (5 mg) and the mixture was stilted at this temperature for 30 minutes. Mel (0.05 ml) was added and the mixture was stirred at room temperature for 4 hours. The mixture was cooled with an ice bath and H2O was added until evolution of gas ceased. The mixture was partitioned between EtOAc and H2O. The organics were washed with NaCl(sat) and then dried with Na2SO4^5). Evaporation of the solvent gave a solid, which was purified by reverse phase HPLC (5-95% MeCNVH2O, 15 mill). The title compound (5.7 mg) was collected by evaporation. NMR (300 MHz): 10.89 (s, IH), 10.41 (s, IH), 8.45 (s, IH), 8.30 (s, IH), 8.20 (d, IH), 8.05 (s, IH), 7.90 - 8.00 (m, 2H), 7.86 (d, IH), 7.76 (d, IH), 7.65(t, IH), 7.32 (d, IH), 4.50 (s, 2H) 3.35(s, 3H) 2.10 (s, 3H), 1.76 (s, 6H); m/z 443.
Example 164
2-Chloro-N-r5-fluorot3yridin-3-yl)-5-{r3-flυoro-5-rtrifluoromethyl)benzoyl1aminol- benzamide A solution of 5-amino-2-chloro-N-(5-fluoropyridin-3-yl)benzamide (Method 79; 124 mg, 0.466 mmol) and DlEA (405 μL, 2.33 mmol, 5.0 equiv) in THF (2.0 ml) was treated with 3-fluoro-5-(trifluorottiethyl)benzoyl chloride (131 mg, 0.582 mmol, 1.25 equiv). The reaction mixture was stirred for 12 h at 25 °C. The reaction was quenched with 10% NaOH and extracted with EtOAc. The organics were dried with ΝaCl(sat) and then Na2SO4^) and removed under reduced pressure. The residue was purified directly by Gilson reverse phase preparatory Hl3LC (5-95% MeCN/H2O) to give 75 mg of product (35%). NMR: 11.11 (s, IH), 10.80 (s, IH), 8.68 (s, I H), 8.37 (s, IH), 8.18-8.12 (m, 3H), 8.03-7.93 (M, 3H), 7.63 (d, IH); m/z 456. Example 165
2-Chloro-N-t6-rl.2-dihvdroxyethyl)t)yridin-3-yl1-5-{r3-rtfiflUofomethyl)benzoyl1 amino] benzamide
To a solution of N-(6-bromopyridin-3-yl)-2-chloro-5-{|>(trifluoromethyl)benzoylj amino} benzamide (Example 215; 100 mg) in NMP (3 ml) wefe added tributyl vinyl tin (0.4 ml), Pd(PPh3)4 (50 mg) under argon. The resulting mixture was heated to 80°C for 10 hours. The mixture was partitioned between M2O and EtOAc, and the organic layer was washed with brine, saturated aqueous NaF solution and dried with MgSθ4. Evaporation of the solvent gave a solid, which was dissolved in a mixture of acetone/H2O (1 :1 v/v, 2 ml). TV-methyl morpholiiie oxide (60 mg) was added followed by a solution of OSCM in t-βuθH (0.04 ml, 2.5 w/v) and the resulting mixture was stirred at ambient temperature for 12 hours. A solution of sodium thiosulphate (IN, l0 ml) was added and the resulting solution was stirred for 3 hours at room temperature. The mixture was partitioned between M2O and EtOAc, and the organic layer was washed with brine and dried with MgSθ4. Evaporation of the solvent gave a solid, which was purified by reverse phase HPLC (5-95% MeCN/H2O, 15 min). The title compound (1 1 mg) was collected by evaporation. NMR (300 MMz): 10.54 (s, IM), 10.34 (s, IH), 8.00- 8.55 (m, 4H), 7.80 - 7.95 (m, 3H), 7.08-7.55 (m, 3H), 3.23-3.51 (m, 3H); tti/z 480.
Example 166 2-FlUoro-5-f(3-fluorobenzoyl)amino1-7V-pyridin-3-ylbenzamide
A solution of 5-amino-2-flUoro-jV-pyridin-3-ylbenzattiide (Method 75; 30.5 mg, 0.132 mmol), 3-fluorobenzoic acid (20.5 mg, 0.145 mniol) and t)lEA (60 μL, 0.35 mmol) in t>MF (1.5 ml) was treated with HATU (60 mg, 0.1584 mmol). The reaction mixture was shaken overnight at 25 °C. Water (10 ml) was added slowly to precipitate the product. The resulting precipitate was washed with water (10 ml), isolated and dried overnight in a vacuum oven at 70 °C to give the title compound 32 mg, (68%) as a solid. NMR: 10.65 (s, IH), 10.52 (s, IH), 8.86 (s, IH), 8.33 (d, IH), 8.15 (d, IH), 8.09 (d, IH), 7.93-8.02 (m, IH), 7.75-7.84 (m, 2H), 7.56-7.66 (m, IH), 7.37-7.48 (m, 3H); m/z 353.
Examples 167-182
The following compounds were prepared by the procedure in Example 166 using 5- amino-2-flUoro-/V-pyriditt-3-ylbenzamide (Method 75) and the appropriate SM. In some cases, further purification was required (supercritical fluid, Gilson reverse phase preparatory HPLC or column chromatography utilizing an ISCO system).
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Example 183 5-ir3-(l -Cvaho-l-methylethyl)benzoyl1amiiio1 -2-methyl-N-(6-niethylpyridiii-3-yl)benzafflide
A solution of 5-[3-(cyaiio-dimethyl-methyl)-benzoylamino]-2-ttiethyl-benzoic acid (Method 20; 200 mg, 0.620 ttimol), 6-methylpyHdin-3-attiirte (65 mg, 0.602 mmol) and t)l£A (0.32 ml, 1.86 mmol) in DMF (1.3 ml) was treated with HATtJ (354 mg, 0.930 mmol). The reaction was stirred at 25 °C for 12 h. The reaction was then quenched with M2O (5 ml) and extracted with EtOAc (20 ml). The organics were washed with NaCl(sat) (50 ml) and dried with MgSθ4. The solvents were removed under reduced pressure to give a yellow solid (208 mg), which was purified by Gilson reverse phase preparatory HPLC (5-95% MeCN/H20, 20 min). The solvents were removed under reduced pressure to give a white solid (1 l6mg) of the title compound. NMR: 11.01-1 1.30 (s, IH), 10.37-10.68 (s, IH), 9.01-9.32 (s, IM), 8.48 (d, IH), 7.93-8.13 (m, 3H), 7.68-7.88 (m, 3H), 7.59 (t, IH), 7.28 (d, IH), 2.56-2.76 (s, 3H), 2.23- 2.43 (s, 3H), 1.45-1.92 (s, 6H); m/z 4l3.
Examples 184-317
The following compounds were prepared by the procedure in Example 183 using the appropriate SMs. In some cases, further purification was required (supercritical fluid, Gilson reverse phase preparatory HPLC or column chromatography utilizing an ISCO system).
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000107_0002
Example 318 jV-lβ-^Aminocarbonvhaniinoipyridin-S-vU-S-^ D-d-cvano-l-methylethvπbenzoyllamino}- 2-methylbenzamide
To a solution of 7V-(6-aminopyfidin-3-yl)-5-{t3-(l-cyano-l-methylethyl)betizoyl] amino }-2-methylbehzamide (Example 202; 314 mg, 0.760 mmpl) in THF (5ml), sodium hydride (145 mg, 3.04 lmnol) and trichloroacetyl isocyanate (0.14 ml, 1.14 mmol) were added and the reaction mixture was stirred overnight at 25°C. The mixture was partitioned between H2O and EtOAc, and the organic layer was washed with brine and dried with MgSθ4. Evaporation of the solvent gave a white solid that was dissolved in MeOH (10 ml) and purged with ammonia gas. Evaporation of the solvent gave a tan solid, which was purified by reverse phase HPLC (5-55% MeCN/H2O, 15 min). The title compound (65 mg) was collected by evaporation as a white solid. NMR (300 MHz): 10.41 (s, 2H), 9.20 (s, IH), 8.58 (s, IH), 7.99 - 8.08 (m, 2H), 7.96 (d, IH), 7.89 (s, IH), 7.83 (dd, IH), 7.75 (d, IH), 7.61 (t, I H), 7.48 (d, 1 H), 7.32 (d, 1 H), 6.85 (s, 1 H), 2.36 (s, 3H), 1.76 (s, 6H); m/z 457.
Example 319
2-Chloro-5-ir3-(l-cvano-l-methylethyl)benzoyl1aminol-jV-["5-(dimethylamino)-6- methylpyridin-3-yl'lbenzamide
To a solution of N-(5-amino-6-memylpyridin-3-yl)-2-chloro-5-{[3-(l-cyano-l- methylethyl)benzoyl]amino) benzamide (Example 312; 145 mg) in E)MF1 (2 ml) was added at O0C Cs2CO3 (317 mg) and the mixture was stirred at this temperature for 30 minutes. Mel (0.81 ml) was added and the mixture was stirred at room temperature for 4 hours. The mixture was cooled with an ice bath and H2O was added. The mixture was partitioned between EtOAc and H2O. The organics were washed with NaCl(Sat) and then dried with Na2Sθ4(S). Evaporation of the solvent gave a solid, which was purified by reverse phase HPLC (5-95% MeCN/H2O, 15 min using hexyl beiizene column). The title compound (3.4 mg) was collected by evaporation. NMR (300 MHz): 10.79 (s, IH), 10.23 (s, IH), 8.04 (s, I H), 8.01 (d, I H), 7.98- 7.95 (m, 2H), 7.84 (d, IH), 7.78 (d, I H), 7.52 - 7.66 (m, 3H), 2.83(s, 6H) 2.41 (s, 3H), 1.65 (s, 6H); m/z 478. Example 320
5-IY5-I f3-f 1 -Cvano-1 -methylethvDbenzovUamino] -2-methylbenzoyl)amino1-JV- methylt>yridine-2-carboxamide
A solution of methyl 5-[(5-{[3-(l-cyano-l-methylethyl)benzoyl]amino) -2- methylbenzoyl)amino]pyridine-2-carboxylate (Example 305; 100 mg) in THF" (1 ml) was cooled to -78°C and treated with a solution Of Me3Al-MeNH2 (the solution was made by adding slowly Me3Al (0.35 ml, 1 M in TMF) to a solution Of MeNH2 (0.35 ml, IM in THF) at -780C and allowing the solution to stir for 30 minutes at this temperature). The reaction mixture was stirred overnight at 25 °C. The mixture was partitioned between EtOAc and H2O. The organics were washed with TStaCl(sat) and then dried with
Figure imgf000109_0001
Evaporation of the solvent gave a solid, which was purified by reverse phase HPLC (5-95% MeCN/H2O, 15 mill). The title compound (2 mg) was collected by evaporation. NMR (300 MHz): 10.85 (s, IH), 10.44 (s, IH), 8.95 (s, IH), 8.20 - 8.50 (m, 2H), 7.70 - 8.18 (m, 6H), 7.51 - 7.66 (m, IH), 7.19 - 7.51 (m, I H), 2.87 (s, 3H), 2.30 (s, 3H) 1.70 (s, 6H); m/z 456
Example 321 5-f3-(Cvano-dimethyl-methyl)-benzoylamino1-"N-(6-cyano-pyridin-3-yl')-2-methyl-benzamide
A solution of 5-[3-(cyaiiodimethyl-methyl)-benzoylamino]-2-methyl-benzoic acid (Method 20; 300 mg, 0.928 mmol) in SOCl2 (5 ml) was refluxed at 80 °C for 2 h. Then a solution of 5-aminopyridine-2-carbohitrile (221 mg, 1.86 mmol) in THF (5 ml) was treated with NaH (50% in mineral oil) (111 mg, 2.32 mmol). This reaction was stirred at 25 °C for 1 h. After removing the SOCl2 from the first reaction, the resulting product was dissolved in THF1 and added to the second reaction and stirred at 25 0C for 30 min. The reaction was theft quenched with H2O (10 ml), extracted with EtOAc (25 ml), washed with brine (50 ml) and dried with MgSO4. the solvents were removed under reduced pressure to give an orange solid (637 mg) which was purified by Gilsoft reverse phase preparatory HPLC (5-95% MeCN/H2O, 20 min)to yield a yellow solid (10 mg). NMR (300 MHz): 11.07 (s, IH), 10.61 (s, I H), 9.02 (d, IH), 8.42 (dd, IH), 8.22-8.36 (m, 2H), 7.95-8.08 (m, 3H), 7.73-7.92 (m, 2H), 7.36 (d, IH), 2.48-2.51 (m, 6H), 2.38 (s, 3H); m/z 424. Examnle 322
S-US-fl -Cvano-l-methylethv^benzoyliammol^-methyl-N-rS-flH-pyrazol^-vDpyfidin-S- vUbenzamide
N-(5-BromopyHdin-3-yl)-5-{t3-(l-cyano-l -methylethyl)benzoyl]amino}-2- methylbenzamide (Example 192; 256mg, 0.54mmol), 1 //-pyrazol-4-ylboronic acid (l25mg, 0.64mmol), Cs2CO3 (352mgl .08mmol) and Pd(PPh3)4 (62mg, 0.054mmol) were put in a microwave tube, dioxane (4ml) and water (I mI) were added. The tube was heated in microwave (Smith, Personal Chemistry tM) and heated at 1800C for 2000 seconds, the solution was filtered, and separated between EtOAc and water. Organic layer was dried and evaporated Under reduced pressure. The crude product was purified by reverse phase HPLC (5-75% MeCN/H2O, 15 min) and the title compound (75.6 mg, 30%) was collected by evaporation. NMR (300 MHz) 10.88 (s, IH), 10.52 (s, IH), 8.54 (s, I H), 8.26 (s, I H), 8.13 (s, I H), 7.96 - 8.09 (in, 3H), 7.80 - 7.93 (m, 3H), 7.63 - 7.73 (m, 2H), 7.42 (d, IH), 2.20 (s 3H), 1.82 (s, 6H); m/z 466.
Examples 323-324
The following compounds were prepared by the procedure of Example 322, using the appropriate starting material
Figure imgf000110_0001
Figure imgf000111_0001
Example 325
2-Methyl-N-r5-r4-riiethylt)it)erazin-l-yl)t7yridiri-3-yl1-5-ir3-ftrifluorornethyl')benzoyl1aniinoi benzamide To a 10 ml round bottom flask equipped with a magnetic stirring bar was added
Pd2(dba)3 (34 mg, 0.038 mmol), BlNAP ( 47 mg, 0.075 mmol), and sodium fe/Y-butoxide (72 mg, 0.752 mmol). Toluene (2 ml) was added followed by 1 -methylpipetazine (56 mg, 0.564 mmol) and the reaction was allowed to stir at room temperature for l0 min before the addition of 7V-(5-bromopyridin-3-yl)-2-methyl-5-{t3-(trifluoromethyl)benzoyl]amino) benzamide (Example 193; 180 mg, 0.376 mmol). The resulting reaction mixture was warmed to 80 °C and was allowed to stir for 12 h before being cooled and diluted with EtOAc (~ 100 ml). The organic phase was poured into a separator funnel and washed with saturated aqueous NaMCO3 (~ lOO ml). The organic extract was dried with MgSO4, filtered, and concentrated in vacuo to yield the crude product, which was purified on a 40 g SiO2 column using MeOH/EtOAc (1 :10) as eluent giving 144 mg (77%) of the title compound as a white solid. NMR (300 MHz): 10.91 (s, IH), 10.65 (s, IH), 8.57 (s, IH), 8.32-8.26 (m, 3H), 8.10 (s, I H), 8.02 (d, IH), 7.99 (d, IH), 7.82-7.78 (m, 2H), 7.35 (d, IH), 3.99-3.93 (m, 2H), 3.55-3.50 (m, 2H), 3.32-3.12 (m, 4H), 2.82 (s, 3H), 2.37 (s, 3H); m/z 499.
Examples 326-336
The following compounds were prepared by the procedure in Example 325 using N- (5-bromopyridin-3-yl)-2-methyl-5-{t3-(trifluoromethyl)benzoyl]amino) benzamide (Example 193), N-(5-bromopyridin-3-yl)-5-{[3-(l-cyano-l-methylethyl)benzoyl]amino) -2- methylbenzamide (Example 192), N-(5-bromopyridin-3-yl)-2-chloro-5-t(3,5- dimethylbehzoyl)amino]beiizamide (Example 219) and the appropriate SM. In some cases, further purification was required (supercritical fluid, Gilson reverse phase preparatory HPLC or column chromatography utilizing an ISCO system).
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
Example 337
N-f5-r3-AmiHobt-ot)-l-vn-l -yl)t)yridin-3-yl1-2-methyl-5-it3-fti-ifltioromethyl)benzoyl1aminol benzamide to a 10 ml found bottom flask equipped with a magnetic stilting bar was added N-(5- bfomopyHdiH-3-yI)-2-methyl-5-{t3-(trifluoi-omethyl)benzoyl]amino} benzamide (Example 193; 200 mg, 0.418 mmol) and MeCN (1.75 ml). Et3N (0.293 ml, 2.10 mmol) was added followed by pfop-2-yli-l -amine (58 mg, 1.05 mmol), CuI ( 25 mg, 0.125 mmol), and Pd(I>l:>h3)4 (96 mg, 0.084 mmol). the reaction was wanned to 50 °C with stitting fof 12 h before being cooled to toom tempetatute, diluted with 50 ml of EtOAc, and filtered through a pad Of SiO2. the SiO2 was rinsed with an additional 50 ml of EtOAc and the combined filtrate was concentrated in vacuo to yield the crude product, which was purified on a 40 g SiO2 column Using MeOH/EtOAc (1 :10) as eluent giving 102 nig (55%) of the title compound as an off-white solid. NMR (300 MHz): 10.82 (s, IH), 10.62 (s, IH), 8.46-8.40 (m, 2H), 8.31- 8.27 (m, 3H), 7.98-7.95 (m, 2H), 7.84-7.77 (m, 2H), 7.34 (d, IH), 4.08-4.02 (m, 2H), 2.36 (s, 5 3H); m/z 453.
Examples 338-340
The following compounds were prepared by the procedure in LD29 using N-(5- bromopyridin-3-yl)-2-methyl-5-{t3-(trifluoromethyl)benzoyl]aniino] benzamide (Example 10 193) and the appropriate SM. In some cases, further purification was required (supercritical fluid, Gilson reverse phase preparatory Hl3LC or column chromatography utilizing an ISCO system).
Figure imgf000115_0001
Example 341 jV-fS-O-HvdfoxypfopyDDyridin-S-yli-Σ-inethyl-S-lfS-ftrifluofomethylibenzoylianiinoj benzamide
To a 25 ml round bottom charged with a magnetic stirring bar and JV-[5-(3- hydroxyrjrop-l-ytt-l-yl)pyridin-3-yl]-2-methyl-5-{t3-(trifluoromethyl)benzoyl]amino) benzamide (Example 338; 45 mg, 0.100 mmol) was added MeOH (10 ml). 10% Pd/C (15 mg) was carefully added and the reaction was placed under 1 atm of H2 using a balloon, the reaction was allowed to stir for 12 h at room temperature before being purged with argon, diluted with ~l 5 ml of EtOAc, and filtered through a pad of SiO2. The SiO2 pad was rinsed with an additional 25 ml of EtOAc and the combined filtrate was concentrated in vacuo to yield the crude product, which was purified on a 40 g SiO2 column using EtOAc as eluent giving 44 mg (98%) of the title compound as an off-white solid. NMR (300 MHz): 10.85 (s, IH), 10.60 (s, IH), 8.32-8.26 (m, 5H), 7.99-7.97 (m, 2H), 7.84-7.76 (m, 2H), 7.34 (d, IH), 3.43 (t, 2H), 2.75-2.69 (m, 2H), 2.37 (s, 3H), 1.78-1.71 (m, 2H); m/z 459.
Examples 342-343
The following compounds were prepared by the procedure in Example 341 and the appropriate SM. In some cases, further purification was required (supercritical fluid, Gilson reverse phase preparatory HPLC or column chromatography utilizing an ISCO system).
Figure imgf000116_0001
Example 344
2-Chloro-JV-i5-tf4-metliylt)bei-azin-l-yl)methyl1t)yri(liii-3-yl}-5-(r3- (ttifluoromethvhbenzoyliaminolbenzamide to a 10 ml round bottom flask charged with a magnetic stir bat and 2-chloro-N-[5- (hydtOxymethyl)pyridin-3-yl]-5-{[3-(trifluoromethyl)benzoyl]amino}benzainide (Example 304; 0.200 g, 0.444 mmol) was added Et3N (0.19 ml, 1.34 mmol). The reaction was cooled to 0 0C in an ice bath and methahesulfbnyl chloride (0.05 ml, 0.578 mmol) was added dropwise via syringe. The reaction was allowed to stir at this temperature for 15 min before 1- methylpiperazine (0.500 ml, 4.44 mmoi) was added via syringe. The reaction was allowed to stir to room temperature over 3 h before being poured over ~50 ml of saturated aqueous NaMCO3. The resulting mixture was poured into a separator funnel and extracted with -50 ml of EtOAc. The combined organic extract was dried with MgSθ4, filtered, and concentrated in vacuo to yield the crude product, which was purified by semi-preparative reverse phase HPLC giving 0.190 g (80%) of the title compound as a pale yellow solid NMR (300 MHz): 10.95 (s, IM), 10.78 (s, I H), 8.75 (d, IH), 8.33-8.26 (m, 4H), 8.10 (d, IH), 7.99 (d, IH), 7.88 (dd, IH), 7.80 (t, IH), 7.60 (d, IH), 3.74 (s, 2H), 3.42-3.32 (m, 4H), 3.1 1-3.00 (m, 4H), 2.78 (s, 3H), m/z 533.
Examples 345-351 The following compounds were prepared by the procedure in Example 344 using the appropriate SMs. In some cases, further purification was required (supercritical fluid, Gilson reverse phase preparatory HfLC or column chromatography utilizing an ISCO system).
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Example 352
2-Methyl-N-i5-rfPvitolidiii-3-ylmethvhamino1t)vfidin-3-vU-5-(t3- (tfifluofomethyl)benzoyliamihoibenzamide To a 25 ml round bottom flask charged with a magnetic stir bar and tert-butyl 3- fbrmylpytτolidine-1-carboxylate (0.121 g, 0.603 mniol) was added MeOH (3 ml) and glacial acetic acid (0.3 ml). To the reaction mixture was added iV-(5-aminopyridin-3-yl)-2-methyl-5- {[3-(trifluoromethyl)benzoyl]amiho) benzamide (Example 244; 0.25 g, 0.603 mmol) and the reaction was allowed to stir at room temperature for 10 min. To the resulting mixture was added a IM solution OfNaBH3CN in THF (1.21 ml), and the reaction was allowed to stir for 4 h at room temperature before being quenched with ~ 5 ml of saturated aqueous NaHCO3. The resulting mixture was poured into a separator funnel and extracted with -50 ml of EtOAc. The combined organic extract was dried with MgSO4, filtered, and concentrated in vacuo to yield the crude product, which was dissolved in MeOH (5 ml). A 4N solution of HCl in dioxane was added until a pH of 3 (~ 0.5 ml) was achieved. The reaction was allowed to stir at room temperature for 12 h before being concentrated in vacuo which was purified by semi- preparative reverse phase Hl3LC giving 0.09 g (30%) of the title compound as a white solid. NMR (300 MHz): 10.97 (s, I H), 10.67 (s, IH), 8.42 (s, IH)5 8.33 (s, IH), 8.29 (d, IH), 7.91 - 8.05 (m, 4H), 7.76 - 7.89 (m, 2H), 7.36 (d, IH), 3.27 - 3.38 (m, 2H), 3.20 (d, 2H), 2.86 - 2.99 (tti, 3H), 2.48 - 2.64 (m, 2H), 2.05 - 2.18 (m, 2H), 1.61 - 1.76 (m, IH); m/∑ 499.
Examples 353-356 the following compounds wefe prepared by the procedure in Example 352, using N- (5-aminopytidin-3-yl)-2-methyl-5-{t3-(trifluoromethyl)betizoyl]amino] benzamide (Example 244), and the appropriate SM. In some cases, further purification was required (supercritical fluid, Gilson reverse phase preparatory Hl3LC or column chromatography utilizing an ISCO system).
Figure imgf000120_0001
Figure imgf000121_0001
Example 357
2-Chlofo-N-(5-t(niethylsulfonyl)aiτiino1pyridin-3-vU-5-([3-ftrifluoroniethyl)benzoyl1amino} benzamide to a 10 ml found bottom flask equipped with a magnetic stil- bar was added N-(5- amiliopyddin-3-yl)-2-cliloi-o-5-{t3-(tfifluofomethyl)benzoyl]amitio}beiizamide (Example 243; 80 mg, 0.184 minol). Pyridine (2.0 ml) was added followed by methattesulfonyl chloride (0.018 ml, 0.23 mmol). the reaction was warmed to 50 °C and allowed to stir to for 12 h before being poured over -50 ml of saturated aqueous NaHCO3. the resulting mixture was poured into a separator funnel and extracted with -50 ml of EtOAc. the combined organic extract was dried with MgSθ4, filtered, and concentrated in Vacuo to yield the crude product, which was purified on a 40 g SiO2 column using EtOAc as eluent giving 50 mg (53%) of the title compound as an off-white solid. NMR (300 MHz): 10.90 (s, IH), 10.74 (s, IH), 10.14 (s, IH), 8.66 (s, IH), 8.26 (s, 3H), 8.15 (s, IH), 7.98 (s, 3H), 7.81 (s, IH), 7.60 (s, IH), 3.08 (s, 3H); m/z 514. >
Example 358 the following compound was prepared by the procedure in Example 357, using N-(6- aminopyridin-3-yl)-5-{t3-(l-cyano-l-methylethyl)benzoyl]amino}-2-methylbenzamide (Example 202) and the appropriate SM. Further purification was required (column chromatography utilizing an ISCO system). Ex Compound NMR M/z SM
358 5-{[3-(l-Cyaiio-l- 10.46 (c I, 2H), 8.60 (s, lH), 493 Methanesulfonyl ttiethylethyl)benzoyl] 8.06 (s, 2M), 7 94 (s, 2H), chloride amino}-2-inethyl-jV-{6- 7.85 (s, IH), 7 76 (s, 2H),
[(methylsulfonyl) 7.61 (d, IH), 7 .31 (d IH)5 aminσ]pyridin-3- 7.00 (d, IH), 3 .27 (s, 3H), yl}benzamide 2.35 (S5 3H), 1 74 (s, 6H)
Example 359
N-f5-(Acetylaniino)pyriditt-3-yl1-2-methyl-5-{f3-(trifluσfometliyl)benzoyl"laniiiiolbenzaniide
To a 10 ml found bottom flask equipped with a magnetic stir bat- was added N-(5- aminopyfidin-3-yl)-2-methyl-5-{t3-(trifluofomethyl)behzoyl]amiho}betizamide (Example 244; 200 mg, 0.482 mmol). Pyridine (5.0 ml) was added followed acetyl chloride (0.044 ml, 0.603 mmol). The reaction was allowed to stir to for 12 h at room temperature before being poured over -50 ml of saturated aqueous NaHCO3. The resulting mixture was poured into a separator funnel and extracted with -50 ml of EtOAc. The combined organic extract was dried with MgSθ4, filtered, and concentrated in vacuo to yield the crude product, which was purified by on a 40 g SiO2 column Using EtOAc as elueht giving 160 mg (73%) of the title ^compound as an off-white solid. NMR (300 MHz): 10.74 (s, IH), 10.57 (s, IH), 10.34 (s, IH)5 8.63 (d, 2H)5 8.59 (s, IH)5 8.31 (s, IH)5 8.27 (d, IH)5 7.90 - 8.00 (m, 2H), 7.76 - 7.86 (m, 2H)5 7.33 (d, IH)5 2.36 (s, 3H)5 2.09 (s5 3H); m/z 457.
Examples 360-361
The following compound was prepared by the procedure In Example 359, using N-(6- aminopyridin-3-yl)-5-{t3-(l -cyano-l-methylethyl)benzoyl]amino) -2-methylbenzamide (Example 202) and the appropriate SM. In some cases, further purification was required (supercritical fluid, Gilson reverse phase preparatory Hl3LC or column chromatography utilizing an ISCO system).
Figure imgf000123_0001
Example 362
ΛLl5-f(Aminocarboiiyl)amitio1pyridin-3-yll-2-rnethyl-5-(r3-(trifluorornethyl)berizoyl1amirioi benzamide To a 25 ml round bottom flask equipped with a magnetic stir bar was added 7V-(5- aminopyridin-3-yl)-2-methyl-5-{t3-(trifluoromethyl)benzoyl]amirio}benzamide (Example 244; 0.25 g, 0.603 mmol). Anhydrous THf (3.0 ml) was added followed trichloroacetyl isocyanate (0.286 ml, 2.40 mmol). The reaction was allowed to stir to for 1 h at room temperature before concentrated in vacuo. The resulting residue was dissolved in a 2N solution ofNH3 in MeOH (10 ml) and allowed to stir for 3 h at room temperature. The reaction mixture was concentrated in vacuo to yield the crude product, which was purified by semi-preparative reverse phase HPLC giving 0.132 g (49%) of the title compound as a white solid NMR (300 MHz): 10.75 (s, IH), 10.57 (s, IH), 9.10 (s, IH), 8.56 (s, 2H), 8.43 (s, I H), 8.25 - 8.32 (m, 2H), 7.92 - 8.00 (tit, 2H), 7.76 - 7.85 (m, 2H), 7.33 (d, IH), 6.13 (s, 2H), 2.36 (s, 3H); m/z 458. Examnlc 363
N-rS-fFormylaminolpyridin-S-yli-l-methyl-S-ifB-ftrifluofoniethvhbeiizoyliaminolbenzaniide
To a 25 ml found bottom flask equipped with a magnetic stir bar was added N-(5- aminopyHdin-3-yl)-2-methyl-5-{t3-(trifluoromethyl)beiizoyl]amiiio] benzamide (Example 5 244; 0.30 g, 0.723 mmol). Anhydrous t)CM (3.0 ml) was added followed Et3N (0.507 ml, 3.62 mmol), and acetic-formic anhydride (0.159 g, 1.80 mmol). The reaction was allowed to stir to for 4 h at room temperature before being poured over -50 ml of saturated aqueous NaMCO3. The resulting mixture was poured into a separator funnel and extracted with -50 ml of EtOAc. The combined organic extract was dried with MgSO4, filtered, and concentrated in O vacuo to yield the crude product, which was purified on a 40 g SiO2 column using EtOAc as eluent giving 171 mg (53%) of the title compound as a white solid. NMR (300 MHz): 10.73 (s, IM), 10.57 (s, 2M), 8.58 - 8.69 (m, 3H), 8.33 (d, 2H), 8.27 (d, IM), 7.90 - 8.00 (m, 2M), 7.76 - 7.87 (tti, 2H), 7.33 (d, IH), 2.36 (s, 3H); m/∑ 443.
5 Example 364
2-Methyl-N-f5-rmethylamino)ρyridin-3-yl1-5-(r3-(trifluoromethyl)benzoyl1aminolbenzamide
To a 25 ml round bottom flask equipped with a magnetic stir bar was added N-[5- (formylamino)pyridin-3-yl]-2-methyl-5-{[3-(trifiuoromethyl)benzoyl]amino) benzamide (Example 363; 0.12 g, 0.271 mmol). Anhydrous THF (3 ml) was added and the reaction 0 mixture was cooled to 0 °C with an ice bath. Lithium aluminium hydride (15 mg, 0.394 mmol) was added and the reaction was allowed to warm to room temperature with stirring over 3 h. The reaction was carefully quenched with - 10 ml of H2O and the resulting mixture was poured into a separator funnel and extracted with -50 ml of EtOAc. The combined organic extract was dried with MgSO4 1, filtered, and concentrated in vacuo to yield the crude 5 product, which was purified on a 40 g SiO2 column using EtOAc as eluent giving 68 mg (59%) of the title compound as a white solid. NMR (300 MHz): 10.86 (s, IH), 10.59 (s, IH), 8.38 (d, IH), 8.24 - 8.34 (m, 2H), 7.95 - 8.01 (m, 2H), 7.73 - 7.86 (m, 4H), 7.34 (d, IH), 2.76 (s, 3H), 2.36 (s, 3H); m/∑ 430. Example 365
N-IS-^.B-DihvdfoxypfopyhatninoitivHdin-S-yll^-methyl-S-irS-rtfifluofomethyllbenzoyli amino) benzamide to a 25 ml found bottom flask charged with a magnetic stir bar and iV-(5-{[(2,2- dimethyl-l ,3-dioxolaii-4-yl)methyl]amino}pyriditi-3-yl)-2-methyl-5-{t3-(trifluoromethyl) benzoyl]amino}behzamide (Example 331; 0.50 mg, 0.094 mmol) was added 3 ml of a 2 N MCl solution in Et2O. Water (0.05 ml) was added and the reaction was allowed to stir for 2 h at room temperature before being concentrated in Vacuo to yield the crude product which was purified by semi-preparative reverse phase HfLC giving 0.037 g (80%) of the title compound as a white solid. NMR (300 MMz): 1 1.00 (s, IM), 10.65 (s, IH), 8.59 (s, IM), 8.32-8.29 (m, 2H), 8.02 (dd, 2H), 7.99 (d, IH), 7.83- 7.78 (m, 3H), 7.34 (d, IH), 4.26-4.22 (m, IH), 3.79- 3.54 (m, 2M), 3.12-3.05 (m, 2M), 2.37 (s, 3H); m/z 489.
Example 366 2-Chloro-N-l6-tf3-methoxyprot)anoyl)amino1t)yridin-3-vU-5-if3-ftrifluoromethyl) benzoyliaminolbeiizamide
To Et solution of 2-chloro-N-{6-amino-pyridin-3-yl}-5-{[3-(trifluoromethyl) bettzoyl]amino}bettzamide (Example 317; 4θmg) in DCM (0.5 ml) at 0°C was added 3- methoxy propanoyl chloride (0.100 ml) followed by Et3N (0.80 ml) and the resulting mixture was stirred at room temperature for 3 hours, the mixture was partitioned between H2O and EtOAc, and the organic layer was washed with brine and dried with MgSO4. Evaporation of the solvent gave a solid, which was purified by reverse phase HPLC (5-95% MeCNVH20, 15 min). the title compound (4 mg) was collected by evaporation. NMR. (300 MHz): 10.64 (s, IH), 10.02 (s, IM), 8.18-8.47 (m, 3H), 7.82 - 7.96 (m, 3H), 7.43-7.66 (m, 3H), 7.07 (d, IH), 3.69 - 3.72 (m, 2H), 3.33 (s, 3H), 2.1 1-2.21 (m, 2H); m/z 520.
Example 367
5-ri3-f2-ft)imethylamino)-l J-dimethyl-2-oxoethyl1benzovUamino)-2-methyl-N-f6- methylpyridin-3-vhbenzamide A solution of 5-({3-t2-(dimethylamino)-l ,l -dimethyl-2-oxoethyl]behzoyl) amino)-2- methylbenzoic acid (Method 54, 71 mg, 0.193 mmol), 3-amino-6-picoline (21 mg, 0.193 mmol) and DlEA (O.lO ml, 0.58 mmol, 3.0 equiv) in DMF (2 ml) was treated with HAtU (88 mg, 0.232 mmol, 1.2 ecjuiv). the reaction mixture was stirred for 12 h at 40 °C. the reaction was quenched with 10% NaOH and extracted with EtOAc. The organics were dried with NaCl(sat) and then Na2Sθ4(S) and removed Under reduced pressure. The residue was purified directly by column chromatography (5% MeOH in EtOAc) to give 70 mg of product (73%). NMR: 1 1.16 (s, IH), 10.46 (s, IH), 9.15 (m, IH), 8.48 (d, IH), 8.02 (s, IH), 7.84 (m, 4H), 7.51 (t, IH), 7.34 (m, 2H), 2.78 (bs, 3H), 2.68 (s, IH), 2.46 (s, 3H), 2.37 (s, 3H), 1.48 (s, 6H); m/z 459.
Example 368
5-rrDimethylamiiio')sulforiyl1-iV-r4-m'ethyl-3-irr6-methylt)yridin-3- yl)amino1carbonyl}t)hetiyl)riicotinamide
A solution of 5-t({5-t(dimethylamiiio)sulfonyl]pyridin-3-yl}carbonyl)amino]-2- methylbenzoic acid (Method 55; 77 mg, 0.212 mmol), 3-amino-6-picoline (23 mg, 0.212 mmol) and DIEA (0.12 ml, 0.64 mmol, 3.0 equiv) in DME (2 ml) was treated with HATU (97 mg, 0.254 mmol, 1.2 equiv). The reaction mixture was stirred for 12 h at 40 °C. The reaction was quenched with 10% NaOH and extracted with EtOAc. The organics were dried with NaCl(Sat) and then Na2Sθ4(S) and removed under reduced pressure. The residue was purified directly by Gilsott reverse phase preparatory HPLC (5-95% MeCN/H2O) to give 18 mg of product (13%). NMR: 10.89 (s, 2H), 10.80 (s, IH), 9.39 (d, IH), 9.11 (d, IH), 9.02 (s, IH), 8.64 (t, I H), 8.29 (dd, IH), 7.96 (d, IH), 7.82 (dd, IH), 7.62 (d, IH), 7.37 (d, IH), 2.71 (s, 6H), 2.57 (s, 3H), 2.38 (s, 3H); m/z 454.
Example 369
7V-l6-f(2-Aniinoethyl)amino1pyridin-3-vU-5-{f3-fl-cvano-l-methytethyl)benzoyl"|aminol -2- methylbenzamide Tert-butyl {2-[(5-aminopyridin-2-yl)amino]ethyl}carbamate (Method 73; 331 mg,
1.24 mmol) was combined with 5-[3-(cyanodimethyi-methyt)-benzoylamitto]-2-methyl- benzoic acid (Method 20; 400 mg, 1.24 mmol), HATU (708 mg, 1.86 mmol) and DlEA (0.65 ml, 3.72 mmol) in 2.48 ml of DME and the reaction mixture was stirred overnight at 25°C. LC/MS confirmed the formation of tert-butyl t2-({5-t(5-{t3-(l-cyano-l- methylethyl)benzoyl]aniino}-2-methylbenzoyl)amino]pyridin-2-ylj amino)ethyl]carbamate, and the reaction was quenched with H2O. The mixture was partitioned between H2O and EtOAc, and the organic layer was washed with brine and dried with MgSθ4. Evaporation of the solvent gave a light brown solid (m/z 557), which was redissolved in 10 ml of HCl in 1,4- dioxane and stiffed overnight at 25°C. Evaporation of the solvent gave a brown gummy solid, which was purified by reverse phase Ml3LC (5-95% MeCN/H2O, 20 min). The title compound (44 mg) was collected by evaporation as a brown solid. NMR (300 MHz): 10.41 (s, IH), 10.18 (s, IH), 10.00 (s, IH), 8.28 - 8.50 (m, IH), 8.01 - 8.12 (m, IH), 7.88 - 8.00 (ni, 2H), 5 7.70 - 7.87 (in, 4H), 7.61 (t, IH), 7.32 (d, IH), 6.65 (s, 2H), 2.94 - 3.13 (m, IH), 2.85 - 2.96 (tti, IH), 2.68 - 2.80 (m, IH), 2.35 (s, 3H), 2.23 - 2.33 (in, IH), 1.76 (s, 6H); hi/z 457.
Example 370
5-{f3-(l-Cvano-l-methylethyl)benzoyl1amino}-7V-f5-(isopropylamino)pyridiri-3-yl1-2-
10 methylbenzamide
N-(5-Aminopyridifi-3-yl)-5-{t3-(l-cyano-l-methylethyl)beiizoyl]aniiiio}-2- methylbefizamide (Example 205; 164 mg, 0.398 mmol) was combined with acetone and sodium triacetoxyborohydfide (337 mg, 1.59 mmol) in 0.80 ml of THF and heated at 30°C in a sealed tube overnight. LC/MS confirmed the formation of the product and the mixture was
15 partitioned between H2O and EtOAc. The organic layer was washed with bfine and dried with MgSθ4. Evapofation of the solvent gave a yellow solid, which was purified by reverse phase HPLC (5-95% MeCNTH2O, 20 min). The title compound (40 mg) was collected by evaporation as a white solid. NMR (300 MHz): 10.91 (s, IH), 10.47 (s, IH), 8.39 (s, IH), 8.06 (t, IH), 7.93 - 8.01 (m, 2H), 7.74 - 7.85 (m, 5H), 7.63 (t, IH), 7.36 (d, I H), 2.37 (s, 3H), 1.76
20 (s, 6H), 1.18 (m, 7H); m/z 456.
Example 371
5-lf3-(l-Cvano-l-methylethyl)benzoyl1aminol-2-methyl-N-f5-pyrrolidin-2-ylpyridin- 3-yl)benzamide
25 /e/V-Butyl 2-{5-t(5-{t3-(l-cyano-l-methylethyl)benzoyl]amino) -2- methylbenzoyl)amino]pyridin-3-ylj pyrrolidine- 1 -carboxylate (Example 324; 50 mg) was dissolved in MeOH (3 ml) and 4N HCl in 1,4-dioxane (2.5 ml) was added at O0C and the resulting mixture was stirred for 2 hours at room temperature. Evapofation of the solvents afforded the title compound as an off-white solid (32 mg). NMR (300 MHz): 10.72 (s, IH),
30 10.46 (s, IH), 8.85 (s, IH), 8.43 - 8.54 (m, IH), 8.25 (s, IH), 8.06 (s, IH), 8.01 (t, IH), 7.96 (d, IH), 7.-3 - 7.81 (m, 2H), 7.61 (t, IH), 7.34 (d, IH), 4.23 (m, IH), 3.73 (m, 2H), 2.27 (s, 3H), 1.93-2.22 (m, 4H), 1.78 (s, 6H), m/z 469. Examples 372-373
The following examples were made by the procedure of Example 371 using the appropriate starting materials.
Figure imgf000128_0001
Pf eβaration of starting Materials
Method 1
3-Cvanomethyl-behzoic acid methyl ester
A suspension of methyl-3-(bromomethyl)benzoate (13.5 g, 58.9 mmol) arid sodium cyanide (4.33 g, 88.4 mmol) in DMf (25 ml) and water (1 ml) was stirred at 75 °C for 5 h. The reaction mixture was quenched with water (50 ml) and extracted with EtOAc (100 ml x 3). The combined orgaiiics were dried and concentrated under reduced pressure. The resulting residue was purified by column chromatography utilizing an ISCO system (hexane-EtOAc) to give 7.2 g (70%) of colourless oil. NMR: 7.90 (s, I H), 7.86 (d, IH), 7.60 (d, IH), 7.50 (m, IH), 4.10 (s, 2H), 3.80 (s, 3H); m/z 175. Methods 2-7
The following compounds wefe prepared by the procedure of Method 1 , Using the appropriate startihg material.
Figure imgf000129_0001
Method 8
3-fl-Cvano-l -methylethyl)benzoic acid methyl ester
A solution of 3-cyanomethyl-benzoic acid methyl ester (Method 1; 7.2 g, 41.1 himoi) in anhydrous t)MSO (80 ml) was treated with NaH (60% in mineral oil, 4.9 g, 123.3 mmol). Methyl iodide was added dropwise at 0 °C. The reaction mixture was stirred at 25 °C for 12 h. The reaction mixture was quenched with water (200 ml) and extracted with EtOAc. The combined organics were dried and concentrated under reduced pressure. The crude product was purified by column chromatography utilizing an ISCO system (hexane-EtOAc) to give 5.5 g (66%) of a colourless oil. NMR: 8.05 (s, IH), 7.90 (d, IM), 7.75 (d, IH), 7.55 (m, IH), 3.80 (s, 3H), 1.62 (s, 6H); m/z 203.
Methods 9-18
The following compounds were prepared by the procedure of Method 8, using the appropriate starting material.
Figure imgf000129_0002
Figure imgf000130_0001
Method 19
3-Cl-Cvano-l-rtiethylethyl)benzoic acid
A solution of 3-(l -cyano- l-methylethyl)benzoic acid methyl ester (Method 8; 5.5 g, 27.1 mmol) in 100 ml of THF/MeθH/H2O (3 : 1 : 1 ) was treated with lithium hydroxide ( 1.95 g) in 20 ml water. The mixture was stirred at 25 0C for 12 h. The solvent was removed under reduced pressure and the resulting solution was diluted with water, then acidified with 10% HCl to pH = 1-3. The resulting white solid (4.83 g, 94%) was filtered, washed with water and dried. NMR: 13.00 (s, IH), 7.95 (s, IH), 7.80 (d, IH), 7.65 (d, I H), 7.45 (m, IH), 1.60 (s, 6H); m/z 189.
Methods 20-55
The following compounds were prepared by the procedure of Method 19, Using the appropriate starting material.
Figure imgf000130_0002
Figure imgf000131_0001
Figure imgf000132_0001
Method 56
4-Methyl-3-trifluoromethyl-benzoic acid methyl ester
A solution of KOH (84 tug, 1.5 mmol) in DMSO (5 ml) was stilled fot- 30 min at 25 0C. The above slurry was then treated with 4-methyl-3-trifluoromethyl-benzoic acid (306 mg, 1.5 mmol) in H)MSO (5 ml) and the resulting mixture was stirred for 15 min, and iodottiethane (426 mg, 3 mmol) was then added to the mixture. The reaction was stirred for 2 h at 25 °C and then quenched with water. The resulting solution was extracted with βtOAc. The organic layer was washed with NaCl(sat) and dried with lsfa2Sθ4(S). The organics were removed under reduced pressure to give the title compound as an oil 327 mg (100%). NMR: 8.10 (m, 214), 7.60 (s, IH), 3.86 (s, 3H), 2.45 (s, 3H); tn/z 218.
Method 57
2-Methyl-5-nitro-N-pyridin-3-ylbenzaniide A solution of 2-methyl-5-nitrobenzoic acid (1.4 grams, 7.7 mmol) and 3-aminoaniline
(0.73 g, 7.7 mmol) in DMF1 (10 ml) was treated with HATU (2.2 grams, 7.7 mmol) and pyridine (5 equiv). The resulting solution was stirred at 25 °C for 48 h. The solvent was evaporated under reduced pressure and the residue was purified by column chromatography utilizing an ISCO system to afford 1.65 grams (84% yield) of the title compound as a white, crystalline solid. NMR (300 MHz): 10.82 (s, I H), 8.91 (d, IH), 8.35-8.39 (m, 2H), 8.26-8.29 (in, IH), 8.20 (d, IH), 7.95 (s, IH), 7.64 (d, 1 H), 7.43-7.48 (ni, IH), 2.68 (s, 3H); th/z 258. Methods 58-67
The following compound was prepared by the procedure of Method 57, using the appropriate starting material.
Figure imgf000133_0001
Method 68
5-Amirιo-2-methyl-N-pyriditi-3-ylbenzamide
A solution of 2-niethyl-5-nitro-jV-pyridin-3-ylbenzamide (Method 57; 1.65 grams, 6.4 nunol) in MeOH was treated with 10% Pd/C and hydrogenated for 45 min at l0 psi using a t»arr Hydrogenator. The catalyst was removed by filtration and the solvent evaporated. The crude product was purified by column chromatography utilizing an ISCO system to provide 975 mgs (67% yield) of white solid. ΝMR (300 MHz): 10.25 (s, I H), 8.71-8.72 (tti, I H), 8.1 1-8.14 (m, IH), 8.Ol (d, lH), 8.l 8-8.23 (m, IH), 6.79 (d, IH), 6.63-6.64 (m, IH), 6.42- 6.46 (m, IH), 4.96 (bs, 2H), 2.04 (s, 3H); m/z 228.
Methods 69-74 The following compounds were prepared by the procedure of Method 68, Using the appropriate starting material.
Figure imgf000134_0001
Method 75
5-Amino-2-fluoro-yV-pyridin-3-ylbeiizamide A solution of 2-fluoro-5-nitro-N-pyridin-3-ylbenzamide (Method 58; 127 nig, 0.487 mmol) in MeOH (2 ml) was treated with an excess of zirtc metal and acetic acid (150 μl, 2.5 mmol). The reaction was heated to reflux for 30 min then cooled to 25 0C. The solids were removed by filtration through a pad of diatomaceous earth and the solvents were removed under reduced pressure. The crude product was purified by column chromatography utilizing an 1 SCO system to provide the title compound (35 mgs, 31 % yield); m/z 231.
Methods 76-82
The following compounds were prepared by the procedure of Method 75, Using the appropriate startihg material.
Figure imgf000134_0002
Figure imgf000135_0001
Method 83
4-(5-Nitropyridin-2-yl)morpholine
A solution of 2-chloro-5-nitropyridine (400 rng, 1.52 mmol) and t)lEA (440 μL, 1.52 mmol) in EtOH (10 ml) was treated with morpholine (660 μL, 4.56 mmol). The solution was heated up at 70 °C for 12 h. the solvents were removed under reduced pressure. M/z 2l 1.
Method 84
6-Morpholin-4-ylpyridin-3 -amine A solution of 4-(5-nitropyridin-2-yl)morphoϋne (Method 83; 418 mg, 2 mmol) in
MeOH (5 ml) was treated with a solution of ammonium chloride (540 mg, 10 mmol) and iron powder in water (5 ml), the resulting solution was heated to 78 °C for 2 h. the solution was then filtered at 50 0C and the solvents were removed under reduced pressure, the crude product was dissolved in acetone and Filtered to remove any inorganic salts, the organic phase was then concentrated in vacuo to give the title compound material. M/z 179.
Method 85 the following compound was prepared by the procedure of Method 84, using the appropriate starting material.
Figure imgf000135_0002
Method 86
Methyl 2-methyl-5-nitrobenzoate
A solution of 2-methyl-5-nitrobenzoic acid (3.9 g, 21.5 mmol) in MeOH (20 mi) was treated with HCl(g) for 10 min. The reaction was then refluxed in a sealed tube at 65 0C for 24 h. The solvent was evaporated giving a cream coloured solid (4.8 g) which was dissolved in EtOAc (200 ml), washed with H2O (200 ml) and brine (200 ml), and dried with MgSO4. The solvents were removed under reduced pressure to give a white solid (3.4 g). M/z: 179.
Methods 87-91 The following compounds were prepared by the procedure of Method 86, Using the appropriate starting material.
Figure imgf000136_0001
Method 92
Methyl 5-amino-2-methylbenzoate A solution of methyl 2-niethyl-5-nitrobenzoate (Method 86; 3.4 g) and 10% palladium oh carbon (672 nig) in MeOH (20 ml) was treated with H2 for 48 h. The reaction mixture was then filtered through diatomaceous earth and washed with MeOH (20 ml) and EtOAc (10 ml). The solvents were removed under reduced pressure to give a brown oil (2.7 g). M/z 165.
Methods 93-95
The following compounds were prepared by the procedure of Method 92, using the appropriate starting material.
Figure imgf000136_0002
Figure imgf000137_0001
Method 96
Methyl 5-{[3-rl -cvano-l-methylethyl)benzoyl1amiiiol-2-methylbenzoate
A solution of methyl 5-amino-2-methylbenzoate (Method 92; 2.7 g, 16.4 mmol), 3- (cyano-dimethyl-methyl^benzoic acid (3.133 g, 16.6 mmol) and DIEA (8.67 ml, 49.8 mmol) in DMF (33 ml) at 0 0C was treated with HATU (9.466 g, 24.9 mmol). The reaction was stirred at 25 0C for 24 h. The reaction mixture was quenched with H2O (30 ml) and then extracted with EtOAc (100 ml). The organics were washed with tstaCl(sat) (200 ml) and dried with MgSO4. The solvents were removed under reduced pressure to give a reddish brown oil (5.58 g) of the title compound. M/z 336.
Methods 97-99
The following compounds were prepared by the procedure of Method 96, Using the appropriate starting material.
Figure imgf000137_0002
Method 100
5-Methylpyridin-3-amine
A solution of 6-chloro-5-methylpyridin-3-amitte (Method 85; 2 mmol) and 10% Pd on carbon (20% w/w) in MeOH (10 ml) was treated with H2. The solution was stirred at 25 °C for 12 h. The reaction mixture was filtered through a pad of diatomaceous earth and the solvents were removed under reduced pressure to yield the title compound which was Used without further purification. M/z 108. Method 101 te;V-Butyl(dit>henyl)f3-thienylmethoχy)silane
To 3-thienylmethanol (5.0 g, 43.8 mmol) was added 86 ml of DMF followed by imidazole (8.94 g, 131.4 mmol). The reaction mixture was cooled to 0 °C and treated with /erf-butylchlorodiphenylsilane (15.0 g, 54.7 mmol) and was allowed to stir 6 h to 25 °C before being quenched by the addition of 250 ml saturated aqueous NH4Cl. The resulting mixture was extracted with EtOAc (3 x 125 ml). The combined organic phase was washed Ix with brine (100 ml), dried with MgSθ4, and concentrated in vacuo. The crude reaction product was purified on 120 g SiO2 using hexanes/EtOAc 10:1 as eluent giving 14.8 g of the title compound as a colourless oil (96 %). MJz 353.
Method 102
The following compound was prepared by the procedure of Method 1 Ol , Using the appropriate starting material.
Figure imgf000138_0001
Method 103
2-(5-Formyl-2-thienyl)-2-methylpropanenitrile
THF (5.8 ml) was added to 2-methyl-2-(2-thienyl)ρropanenitrile (Method 9; 0.260 g, 1.71 mmol) and the reaction mixture was cooled to -78 0C. To the cooled reaction was added 1.26 ml of te/7-butyl lithium (1.7 M solution in pentanes) dropwise via syringe. The resulting bright yellow mixture was allowed to stir for 1 h before DMF (0.330 ml, 4.27 mmol) was added via syringe. The reaction was stirred for 6 h at -78 0C before being quenched by the addition of 25 ml of saturated aqueous NH4Cl. The resulting mixture was extracted with EtOAc (3 x 25 ml). The combined organic phase was washed l χ with brine (50 ml), dried with MgSO4, and concentrated in vacuo giving 0.271 g of the title compound (88 %) as a colourless oil. M/z 180.
Method 104
The following compound was prepared by the procedure of Method 103, Using the appropriate starting material.
Figure imgf000139_0001
Method 105 f4-({^e/7-Butylrdipheiiyl)silyl1oxylmethyl)-2-thienyl1methanol
4-({t/e77-Butyl(diphenyl)silyl]oxy}methyl)thiophene-2-carbaldehyde (Method 104; 3.99 g, 10.48 mmol) was dissolved in MeOH (50 ml). With stirring, NaBH4 (0.792 g, 20.96 niniol) was added in one portion. After 1 h, the reaction was carefully quenched with a solution of NH4Cl(sat) (-250 ml). The resulting mixture was extracted with EtOAc (3 x 125 ml), the combined organic phase was washed with brine (250 ml), dried with MgSO4, and concentrated in vacuo giving the crude reaction product which was purified on 120 g SiO2 using hexanes/EtOAc 5:2 as eluent giving 3.99 g of the title compound as a colourless oil (98 %) m/z 384.
Method 106 it5-(Bromomethyl)-3-thienyl1methoxyHfert-butyl)diphenylsilane Anhydrous THF (45 ml) was added to t4-({|7er/-butyl(diphenyl)silyl]oxy] methyl)-2- thienyl]methanol (Method 105; 4.2 g, 10.98 mmol). Phosphorous tribromide (3.56 g, 13.17 mmol) was added dropwise via syringe and the reaction was allowed to stir for 1 h. at 25 °C before being quenched by NaHCO3(sat) (250 ml). The reaction mixture was extracted with EtOAc (2 x 250 ml) and the combined organic phase was dried with MgSO4 and concentrated in vacuo to yield the crude reaction product which was purified on 120 g SiO2 Using hexanes/EtOAc 10:1 as eluent giving 3.70 g of the title compound as a yellow oil (76 %) m/z 447.
Method 107 2-r4-rHvdroxymethyl)-2-thienyl1-2-methylρropanenitrile
Anhydrous THF (25 ml) was added to 2-[4-({ttø/7-butyl(diρhenyl)silyl]oxy] methy])- 2-thienyl]-2-methylpropanenitrile (Method 1 1 ; 0.880 g, 2.10 mmol). A 1 M solution of tetrabutylammonium fluoride in THF (5.25 mmol) was added dropwise via syringe and the reaction was allowed to stir for 12 h at 25 °C before being quenched with NH4Cl(sat) (50 ml). The reaction mixture was extracted with EtOAc (2 x 50 ml) and the combined organic phase was dried with MgSO4 and concentrated in vacuo to yield the crude reaction product which was purified on 40 g SiO2 using hexanes/EtOAc 2:1 as eluent giving 0.270 g of the title compound as a colourless oil (71 %) m/z 182.
Method 108
2-(4-Pomiyl-2-thienylV2-methylprot>anenitrile
To DMSO (0.277 g, 3.55 mmol) was added lO ml of anhydrous t>CM. the reaction was cooled to -78 °C and oxalyl chloride (0.225 g, 1.78 mmol) was added dropwise via syringe and the reaction was allowed to stir for 30 min. at this temperature. A 1 M solution of 2-t4-(hydroxymethyl)-2-thienyl]-2-methylpropanenitrile (Method 107; 0.270 g, 1.48 mmol) in DCM was then added dropwise via syringe and the reaction was allowed to stir for 30 min. at this temperature. Triethylamine (0.718 g, 7.40 mmol) was then added and the reaction was allowed to warm to 25 °C with stirring over 1 h before being quenched with NaHCO3(sat) (250 ml). The reaction mixture was then extracted with EtOAc (2 x 50 ml) and the combined organic phase was dried with MgSO4 and concentrated in vacuo to yield the crude reaction product which was purified on 40 g SiO2 using hexanes/EtOAc 10:1 as eluent giving 0.262 g of the title compound as a colourless oil (99 %) m/z 180.
Method 109 5 -( 1 -Cyano- 1 -methylethyl)thiophene-2-carboxylic acid
To 2-(5-formyl-2-thienyl)-2-methylρropanenitrile (Method 103; 0.271 g, 1.51 mmol) was added 7.5 ml of tertiary butyl alcohol and 4.5 ml of 2-methyl-2-butene. The reaction mixture was treated dropwise with an aqueous pre-mixed solution OfNaClO2 (1.22 g, 13.60 mmol) and NaH2PO4 (1.45 g, 10.57 mmol) in 7 ml of H2O. The reaction mixture was stirred for 30 min. at 25 0C before the volatiles were removed on a rotary evaporator. The resulting crude product was washed with NaHCO3(sat) (1 x 50 ml) and extracted was extracted with EtOAc (3 x 25 ml). The combined organic phase was washed 1 x with brine (50 ml), dried with MgSO4 1, and cone, in vacuo giving 0.265 g of the title compound (90 %) as a white solid. JWz \ 96.
Method 110
The following compound was prepared by the procedure of Method 109, Using the appropriate starting material.
Figure imgf000141_0001
Method 111
2-Methyl-2-(4-methylpyridin-2-yl)propaneiiitrile
2-Fluoro-4-methylpyridine (1.00 g, 9.00 mmol), 2-methylpropanenitrile (2.48 g, 36 5 mmol), and anhydrous toluene (30 ml) were stirred. Potassium hexamethyldisilazide (13.5 mmol) was added and the reaction was refluxed for 1 h. before being cooled to 25 0C. The reaction was quenched with NH4Cl(sat) (50 ml) and the mixture was extracted with fetOAc (2 x 50 ml). The combined organic phase was dried with MgSO4 and concentrated in vacuo to yield the crude reaction product which was purified on 40 g SiO2 using hexaiies/EtO Ac 5:1 as 10 eluent giving 0.870 g of the title compound as a colourless oil (60 %). M/z 161.
Method 112
2-( 1 -Cyano- 1 -methylethyl)isonicotinic acid
Water (15 ml) was added to 2-methyl-2-(4-methylpyridin-2-yl)propanenitrile (Method
15 111 ; 0.870 g, 5.43 mmol). The reaction mixture was heated to 60 °C and KMnθ4 (4.3 g, 27 mmol) was added. The reaction was heated to reflux for 2 h, and was then filtered through a bed of diatomaceoUs earth. The pH was adjusted to 4 by the careful addition of 1 N ttCl and the aqueous phase was extracted with EtOAc (4 x 25 ml). The organic phase was dried with MgSO4 and concentrated in vacuo to yield the crude reaction product which was purified on
20 40 g SiO2 Using EtOAc/MeOH 10:1 as eluent giving 0.700 g of the title compound as a white solid (68 %); m/z 191.
Methods 113-114
The following compounds were prepared by the procedure of Method 112, using the 25 appropriate starting material.
Figure imgf000141_0002
Method 115
Ethyl 3-(33-dimetliylbυt-l-vn-l-yl)benzoate
MeCN (8.70 ml) was added to ethyl 3-bromobenzoate (0.500 g, 2.18 mmol). Triethylamine (1.53 nil, 10.9 mmol) was added followed by 3,3-dimethylbut-l-yne (0.27 g, 3.27 mmol). With stirring Pd(PPh3^ (0.25 g, 0.21 mmol) and CuI (0.083 g, 0.436 mmol) were added and the reaction was warmed to 60 0C for 4 h. The reaction was then diluted with EtOAc (~ 50 ml) and filtered through a pad of SiO2, and concentrated in vacuo. The crude product was purified on 40 g SiO2 using hexanes/EtOAc 10:1 as eluent giving 0.45 g of the title compound as a colourless oil (91 %); m/z 231.
Method 116
The following compound was prepared by the procedure of Method 115, using the appropriate starting material.
Figure imgf000142_0001
Method 117
5-Methoxynicotinic acid
A solution of methyl 5 -hydroxy nicotinate (633 mg, 4.1 mmol) in DMSO (7 ml) was treated with potassium hydroxide (918 mg, 16.4 mmol). The solution was stirred at 25 °C for 1 h. Methyl iodide (2.0 M in TMf, 2.25 ml, 4.5 mmol) was then added. The solution was stirred an additional 1 h. The reaction was quenched with H2O and extracted with EtOAc. The water layer was concentrated under reduced pressure to give 494 mg of crude product, 78.8%. M/z 153.
Method 118 5-Methoxypyridih-3-amine hydrochloride:
A solution of 5-methoxynicotinic acid (Method 1 17; 494 mg, 3.24 mmol) and C)IEA (1.1 ml, 6.5 mmol) in tert-BuOM (16 ml) was treated with diphenylphosphoryl azide (1.4 ml, 6.5 mmol). The resulting solution was heated at 85 °C for 5 h. The solution was then concentrated under reduced pressure and the crude product was dissolved in 4.0 M HCl in dioxane (20 ml). The solution was stirred at 25 0C for 12 h. The solvents were removed under reduced pressure to give 392 mg, 75.4% of the title compound as its hydrochloride salt. M/z 124.
Method 119 The following compounds were prepared by the procedure of Method 118, using the appropriate starting material.
Figure imgf000143_0001
Method 120
3-r(Dimethylamino)sulfonyl1benzoic acid A solution of 3-(chlorosulfoiiyl) benzoic acid (2.60 g, 12 mniol) in t)CM (20 ml) was treated with dimethylamine (2.0 M in THF, 20 ml, 40 mmol, 3.3 eqtiiv). After 30 mill, the reaction was quenched with 10% HCl and extracted with EtOAc. The organics were washed with NaCl(SHi) and then dried with Na2Sθ4(S). The organics were then removed under reduced pressure to give 1.80 g, 65%; m/z 229.
Methods 121-131
The following compounds were prepared by the procedure of Method 120, Using the appropriate starting material.
Figure imgf000143_0002
Figure imgf000144_0001
Method 132
N-Methyl-5-nitropyridin-2-arnine
A solution of 2-chloro-5-nitropyridine (400 mg, 1.52 mmol) was dissolved in 2.0 M methyl amine in MeOH (5 ml). The solution was heated Up at 70 °C for 12 h. The solvents were removed under reduced pressure; m/z 153.
Method 133
5-Amino-N-methylnicotinamide A solution of 5-aminonicotinic acid (414 mg, 3 mmol), DlEA (1.57 ml, 9 mmol) and methyl amine (2.0 M in THF, 4.5 ml, 9 mmol) in DMF (lθ ml) was treated with HATU (1.71 g, 4.5 mmol). The reaction was stirred for 5 h and then quenched with H2O (30 ml). The reaction mixture was extracted with EtOAc (50 ml), washed with ΝaCl(sat) (20 ml) and dried with MgSθ4. The organics were removed under reduced pressure; m/z 151.
Method 134
The following intermediate were prepared according to the procedure of Method 133 using the appropriate starting materials.
Figure imgf000144_0002
Method 135
4-Bromomethyl-3-trifluoromethyl-benzoic acid methyl ester
A suspension of 4-methyl-3-trifluoromethyl-benzoic acid methyl ester (Method 56; 327 mg, 1.5 mtnol), NBS (267 mg, 1.5 mmol) and catalytic amount of benzoyl peroxide in CCl4 (10 ml) was heated to reflux for 3 h. The reaction mixture was cooled to 25 °C, filtered through a pad of silica gel, and washed with £)CM. The organics were removed under reduced pressure and the crude product was purified by column chromatography utilizing an ISCO system (hexane-ktOAc) to give 252 mg (56.5%). NMR: 7.70-8.25 (m, 3H), 4.85 (s, 2H), 3.9l (s, 3H); m/z 297.
Methods 136-142
The following compounds were prepared by the procedure of Method 135, using the appropriate starting material.
Figure imgf000145_0001
Method 143
Methyl 4-lY4-ethylt>it>erazin- 1 -vhmethyl1-3-ftrifluoromethyl)benzoate
A mixture of 4-bromomethyl-3-trifiuoromethyl-benzoic acid methyl ester (Method 135; 252 mg, 0.85 rnniσl), N-ethyl piperazine (193 mg, 1.70 mmol) and potassium carbonate (235 mg, 1.70 mmol) in MeCN (10 ml) was stirred at 80 0C for 4 h. The reaction mixture was then loaded on silica gel and purified by column chromatography utilizing all ISCO system (hexane-EtOAc) to give 172 mg, (61.5%). NMR: 8.20 (d, I H), 8.15 (s, IH), 7.94 (d, I H), 3.89 (s, 3H), 3.68 (s, 2H), 2.40 (bs, 8H), 2.30 (q, 2H), 0.98 (t, 3H); m/z 330.
Methods 144-145
The following compounds were prepared by the procedure of Method 143, using the appropriate starting material.
Figure imgf000146_0001
Method 149 N-Cyclopropyl-5-riitropyridin-2-amine
To a 100 ml round bottom flask charged with a magnetic stir bar and 2-broino-5- nitropyridine (1.00 g, 4.92 mmol) was added EtOH (20 ml). Et3N (2.80 ml, 20 mmol) was added followed by cyclopropyl amine (0.86 g, 15 mmol) and the reaction was warmed to 70 0C with stirring for 4 h before being cooled to room temperature. The crude reaction mixture was then quenched with ~150 ml of saturated aqueous NaHCO3. The resulting mixture was poured into a separator funnel and extracted with -150 ml of EtOAc. The combined organic extract was dried with MgSO4, filtered, and concentrated in vacuo to yield the title compound as a yellow solid 0.850 g (96%), which was used without further purification; m/z 180. Methods 150-158
The following compounds were prepared by the procedure of Method 149, using the appropriate starting material.
Figure imgf000147_0001
Method 159
Methyl 3-irfdimethylamino)sulfoiiyl1methyl1 benzoate
To a solution of sodium [3-(methoxycarbonyl)phenyl]niethanesulfonate (Method 225; 3.3 g, 13.0 mmol) in DCM at -40 °C was added PCl5. The reaction was allowed to warm to room temperature with stirring over 4 hours. The crude reaction was filtered, and concentrated in \>acuo to yield the crude product that was subjected to ISCO purification Using
EtOAc/hexanes (3:1) as the eluent produced 372 mg of the sulfonyl chloride intermediate. The intermediate was then diluted in a solution of I1C2CO3, MNMe2 and t)CM. After allowing the reaction mixture to stir for lO minutes, the mixture was concentrated in vacuo to yield the crude product that was purified on an ISCO using EtOAc/hexanes (1 :4) which yielded 165 mg (5 %) of the title compound as a yellow solid. 1H NMR (300 MHz): 7.95 - 8.03 (m, 2H), 7.58 (d, IH), 7.42 (t, IH), 4.21 (s, 2H), 3.87 (s, 3H), 2.71 (s, 6H). Method l60
Methyl 3- j l-lfdimethylamino)sulfonyl1-l-methylethyl}benzoate
A solution of hiethyl 3-{[(dimethylamino)sulfonyl]methyljbenzoate (Method 159; 165 mg, 0.642 niniol) in anhydrous THF (5 ml) was treated with NaHMDS (1.4 ml, 1.41 mmol) at -78 °C. Immediately, iodomethane (0.1 ml, 1.61 mmol) was added and the reaction mixture was allowed to gradually warm to room temperature while stirring for an additional 2 h. The reaction mixture was then quenched with aqueous NH4Cl and extracted with EtOAc. The combined organic extracts were dried with MgSO4 and concentrated in vacuo to yield the crude product. The crude product was purified by column chromatography utilizing an ISCO system EtOAc/hexaiies (1:5) to give 85 mg (47%) of title compound. 1H NMR (300 MHz): 8.26 (s, IH), 7.97 - 8.09 (m, IH), 7.89 (d, IH), 7.47 (t, IH), 3.95 (s, 3H), 2.55 - 2.67 (m, 6H), 1.86 (s, 6H).
Method 161 The following compounds were prepared by the procedure of Method 160, using the appropriate starting material.
Figure imgf000148_0001
Method 162
Methyl 3-t3-ftrimethylsilyl)t>rot)-2-vn- 1 -ylibenzoate Trimethylsilyl acetylene (2.4 ml, 17.0 mmol) was added to a solution of methyl 3-
(bromomethyl)benzoate (3.0 g, 13.1 mmol), f»d2dba3 (300 mg, 0.3 mmol), triphenylphosphine (343 mg, 1.3 mmol), Cs2CO3 (6.0 g, 18.3 mmol), and CuI (187 mg, 1.0 mmol) in THF (50 ml). The reaction mixture was stirred overnight at 50 0C. After allowing the mixture to cool to room temperature, it was then diluted with EtOAc (~ lOO ml) and washed with brine. The mixture was then filtered through a pad of diatomaceoUs earth, dried over Na2Sθ4 and concentrated in vacuo. The crude product was purified on SiO2 using hexanes/EtOAc 4:1 as eluent giving 2.2 g (67 %) of the title compound. 1H NMR (300 MHz): 8.03 (s, IH), 7.92 (d, IH), 7.57 (d, IH), 7.40 (t, IH), 3.93 (s, 3H), 3.71 (s, 2H), 0.21 (s, 9H). Method 163
Methyl 3-(l,l -ditnethylpr op-2-vn- 1 -ypbeiizoate
To a solution of methyl 3-tl ,l-dimethyl-3-(tfimethylsilyl)prop-2-yn-l-yl]benzoate (Method 161; 170 mg, 0.62 mmol) in anhydrous MeOH (5 ml) was added potassium carbonate (1.2 g, 9.3 mmol). The reaction was stirred overnight at room temperature, filtered, and concentrated in vacuo. The crude product was subjected to ISCO purification using fitOAc/Hexaiies (1 :5) as eluent to yield 180 mg (70 %) of the title compound as a colourless oil. 1H NMR (300 MHz): 8.20 (s, IH), 7.91 (d, IH), 7.79 (d, IH), 7.39 (t, IH), 3.91 (s, 3H), 2.37 (s, IH), 1.61 (s, 6H).
Method 164
Methyl 3-( 1 , 1 -dimethylbut-2-vn- 1 -yl)benzoate
A solution of methyl 3-(l,l-dimethylprop-2-yn-l-yl)benzoate (Method 163; lOO mg, 0.495 mmol) in 1 ml of THf was cooled to -78 0C. A IM solution of LiHMDS in THF (0.55 ml, 0.55 mmol) was added, followed by methyl iodide (46 μL, 0.743 mmol). The reaction mixture was then allowed to warm to room temperature over 2 h and was then quenched with brine. The mixture was extracted with EtOAc, and the combined organic extract was dried over MgSO4, Filtered, and concentrated in vacuo to yield lOO mg (93%) of the title compound which was used without further purification. 1H NMR (300 MHz): 8.19 (s, IH), 7.89 (d, IH), 7.79 (d, IH), 7.39 (t, IH), 3.91 (s, 3H), 1.83 - 1.88 (m, 3H), 1.56 (s, 6H).
Method 165
Methyl 3-f 1 ,l-dimethylprop-2-en-l-yl)benzoate
To a solution of methyl 3-[l,l-dimethyl-3-(trimethylsilyl)prop-2-yrt-1 -yl]benzoate (Method 161 ; 300 mg, 1.49 mmol) and quirtoline (4 drops) in anhydrous toluene (5 ml) was added Lindlar's catalyst (50 mg) under an atmosphere of H2. The reaction mixture was allowed to stir for 5 h at room temperature before being filtered through diatottiaceous earth. The Filtrate was concentrated in vacuo which yielded 170 mg (56 %) of the title compound which was Used without further purification. 1H NMR (300 MHz): 8.03 (s, 1 H), 7.86 (d, 2H), 7.52 (d, 2H), 7.36 (t, 2H), 6.01 (dd, IH), 5.08 (s, IH), 5.03 (d, IH), 3.90 (s, 3H), 1.41 (s, 6H). Method 166
Methyl 3-(23-dihydroxy-l,l-dimethylpropyl)benzoate
A solution of methyl 3-(l,l-dimethylprop-2-en-l -yl)benzoate (Method 165; 0.273 g, 1.33 mmol) in 2 ml of tør/-BuθH and 2 ml of H2O was added NMO and K2Osθ4(H2O)2. The reaction mixture was allowed to stir at room temperature overnight before being quenched with 30 nig OfNa2SO3. The mixture was extracted with EtOAc and the combined extract was washed with brihe, dried over Na2Sθ4, and concentrated in vacuo to yield 240 mg (75 %) of the title compound crude was Used without further purification. 1H NMR (300 MHz): 8.06 (s, IH), 7.90 (d, IH), 7.59 (d, IH), 7.40 (t, IH), 3.82 (d, IH), 3.53 (d, IH), 3.37 (t, IH), 1.38 (d, 6H).
Method 167
3-fl.l-Dimethylρropyl)benzoic acid
A solution of 3-(l,l-dimethylprop-2-yn-l-yl)benzoic acid (Method 41 ; 170 mg, 0.90 mmol) in anhydrous MeOH (5 ml) was treated with fd/C (17 mg). The reaction mixture was placed under an atmosphere of H2 with a balloon and allowed to stir for 12 h at room temperature. The reaction mixture was then filtered through a pad of diatomaceous earth, and the filtrate was concentrated in vacuo which yielded 150 mg (86%) of the title compound which was used without further purification. M/z 192.
Method 168
Methyl 3-1 f(dimethylamino)carbonyl1amino1 benzoate
To a solution of methyl 3-isocyanatobenzoate (1.0 g, 5.64 mmol) in dichloroethane was added triethylamine (2.36 ml, 16.9 mmol) and dimethylamine hydrochloride (550 mg, 6.74 mmol). After allowing the reaction mixture to stir for 10 minutes, the solvent was removed in vacuo. The crude product was subjected to lSCO purification using
EtOAc/hexanes (1 :1) to yield 670 mg (54 %) of the title compound as a white crystalline solid. M/z 222.
Method 169
Ethyl 3-(cyclopropylcarbonyl)benzoate
To a solution of ethyl 3-iodobenzoate (1.8 ml, l O.O mmol) in THf (40 ml) at -78 °C was added isopropyl magnesium chloride (2.0M, 7.0 ml, 14.0 mmol). After 30 min. of stirring, CuCNt (1.1 g, 12.0 ttihiol) and LiCl (1.0 g, 24.0 mmol) were added simultaneously. After 20 minutes when reaction mixture colour changed to a orange colour, cyclopropane carbonyl chloride (3.0 ml, 33.0 mmol) was added, and then the reaction mixture was allowed to reach to room temperature over 1 hour with stirring. The mixture was diluted with EtOAc and added to aqueous solution OfNH4Cl. The organic extract was dried over Na2Sθ4, filtered, and concentrated in vacuo to yield the crude product which was chtomatographed with a ISCO system Using EtOAc/hexanes (1 :1) as eluent to yield 1.2 g (50%) of the title compound. 1M NMR (300 MHz): 8.66 (s, IH), 8.22 (d, IH), 8.17 (d, IH), 7.55 (t, I H), 4.40 (q, 2H), 2.76 - 2.67 (m, IH), 1.40 (t, 3H), 1.29 - 1.21 (m, 2H), 1.12 - 1.01 (m, 2H).
Method 170
Ethyl 3-f l-cyclopropyl-l -hydroxyethyllbenzoate
A solution of ethyl 3-(cyclopropylcarbσnyl)bettzoate (Method 169; 363 lttg, 1.66 mmol) in THF (6 nil) was cooled to -78 °C. To the reaction mixture was added methyl magnesium bromide (3. OM, 0.73 ml, 2.16 mmol). The reaction was allowed to stir for 3 h at this temperature before being quenched with saturated aqueous NH4Cl. The mixture was diluted with EtOAc and poured into a separator funnel. The organic extract was collected, dried over Na2SO4, and concentrated in vacuo to yield the crude product which was purified with an ISCO system using EtOAc/hexanes (1 : 1) as eluent to yield 1.2 g (50%) of the title compound. 1H NMR (300 MHz): 8.19 (s, IH), 7.92 (d, IH), 7.72 (d, I H), 7.40 (t, IH), 4.37 (q, 2H), 1.78 (s, IH), 1.51 (s, 3H), 1.38 (t, 3H), 1.32 - 1.21 (m, IH), 0.46-0.37 (m, 4H).
Method 171
Methyl 3-rU-difluoroethvhbenzoate A solution of methyl 3-acetylbenzoate (Method 87; 700 mg, 3.9 mmol) in 5 ml of
DeoxoFluor1 M was stirred overnight at 85 °C. The reaction was allowed to cool to room temperature and quenched with brine. The mixture was poured into a separator funnel and extracted with EtOAc. The organic extract was dried over Na2SO4 1, filtered, and concentrated in vacuo to yield the crude product. The crude oil was then subjected to ISCO purification Using EtOAc/hexanes (1 :4) as eluent to yield 396 mg (50%) of the title compound as a colourless oil. 1H NMR (300 MHz): 7.96 (s, IH), 7.86 (d, IH), 7.50 (d, IH), 7.31 - 7.22 (m, IH), 3.73 (s, 3H), 1.74 (t, 3H). Method 172
Ethyl 3-fcvclopropyl(hvdroxy)methyl1bettzoate to a solution of ethyl 3-(cyclopropylcatbonyl)benzoate (Method 169; 363 mg, 1.66 mmol) in anhydrous EtOH (5 ml) was added sodium borohydride (70 mg, 1.86 mmol). The 5 reaction was allowed to stir for 3 h at room temperature before being quenched by the addition of saturated aqueous NH4Cl. The mixture was diluted with EtOAc and poured into a separator funnel. The organic extract was dried over Na2Sθ4, filtered, and concentrated in vacuo. The crude product was purified with an ISCO system using EtOAc/hexanes (1 :1) as eluent which yielded 210 mg (77 %) of the title compound. 1M NMR (300 MMz): 8.07 (s, IH), 10 7.95 (d, IH), 7.61 (d, IH), 7.41 (t, I H), 4.36 (q, 2H), 4.04 (d, IH), 2.16 (s, IH), 1.38 (t, 3H), 1.27 - 1.15 (in, IH), 0.66 - 0.54 (m, 2H), 0.52 - 0.36 (m, 2H).
Method 173
Methyl 3-isopropenylbenzoate
15 A solution of methyl triphehylphosphoriium iodide in THf (5 ml) was cooled to 0 °C.
To the cooled mixture was added W-BuLi (2.5 M, 1.0 ml, 2.52 mmol) and the reaction was allowed to stir for 30 mitt at this temperature. To the mixture was added a solution of methyl 3-acetyibenzoate (Method 87; 375 mg, 2.10 mmol) in THf (15 ml). After stirring at 0 °C for one hour, the reaction was allowed to warm to room temperature and was stirred for an
20 additional 2 h. The mixture was then quenched with water and diluted with EtOAc and poured into a separator funnel. The organic extract was dried over Na2SO4 1, filtered and concentrated in vacuo giving the crude product which was purified using an ISCO system with EtOAc/hexanes (1 :9) as eluertt to yield 108 mg (29%) of the title compound as a colourless oil. 1H NMR (300 MHz): 8.15 (s, IH), 7.96 (d, IH), 7.67 (d, IH), 7.41 (t, IH), 5.45 (s, IH),
25 5.16 (s, IH), 3.94 (s, 3H), 2.19 (s, 3H).
Method 174
Methyl 3-(l-cyano-l -methylethyl)-5-ifmethoxy(niethyl)amino1methyl1 benzoate
To a solution of methyl 3-(bromomethyl)-5-(l-cyano-l-methylethyl)benzoate (Method 30 138; 176 mg, 0.595 mmol) in 5 ml of DMf was added R2CO3 (206 mg, 1.49 mmol) and NHMeOMe HCl (65 mg, 0.666 mmol). The reaction was warmed to 85 °C and stirred at this temperature for 12 h. The reaction was then cooled to room temperature and quenched with water. The mixture was poured into a separator funnel and extracted with EtOAc. The organic extract were dried over Na2SO4, Filtered, and concentrated in Vacuo. The crude residue was purified on an ISCO Using EtOAc/hexanes (1 :1) as the eluent giving 88 mg (54%) of the title compound as a colourless oil. 1H NMR (300 MHz): 8.02 (s, IH), 7.98 (s, IH), 7.74 (s, IH), 3.93 (s, 3H), 3.82 (s, 2H), 3.35 (s, 3H), 2.65 (s, 3H), 1.77 (s, 6H).
Method 175 3-rl-Cvano-l-niethylethyl)-5-t(methylsulfortyl)methvnbenzoic acid
To a solution of 3-(l-cyano-l-methylethyl)-5-[(methylthio)methyl]benzoic acid (Method 37; 58 mg, 0.23 mmol) in MeCN (5 ml) and H2O (3 ml) was added potassium peroxymonosulfate (358 mg, 0.582 mmol). The resulting reaction mixture was allowed to stir at room temperature overnight before being quenched with water. The mixture was poured into a separator funnel and extracted with fetOAc. The organic extract wds dried over Na2SO4, filtered, and concentrated in vacuo which yielded 60 mg (92%) of the title compound as a colourless oil which was Used without further purification. Wz 281.
Method 176
Methyl 3-fl .3-thiazol-2-vhbenzoate
To a round bottom flask equipped with a magnetic stir bar was added a solution of thiazole (461 μl, 6.51 mmol) in 15 ml of THf. The resulting mixture was cooled to -78 °C and «-BuLi (3.80 ml, 6.0 mmol) was added to the solution. The reaction was allowed to stir at this temperature for l0 min. and ZnCl2 (1.9 g, 13.95 mmol) was then added. The resulting mixture was allowed to stir for an additional 30 min. at this temperature followed by the addition of PdtPPh^ (269 mg, 0.233 mmol) and methyl 3-bromobenzoate (1.0 g, 4.65 mmol). The reaction was allowed to warm to room temperature, was Fitted with a reflux condenser, and was heated to 80 0C for 2 h. The mixture was then cooled to room temperature and quenched with saturated aqueous NH4CI. The reaction was poured into a separator funnel and with βtOAc. The organic extract was dried over Na2Sθ4, filtered, and concentrated in vacuo which provided 282 mg (28%) of the title compound as a colourless oil which was used without further purification. M/z 219. Mcthod 177
2-(Trifluoromethyl)pyrimidine-4-carboxylic acid
A solution of methyl 2-(trifluoroniethyl)pyrimidine-4-carboxylic acid (1.00 g, 4.85 mmol) in THf /H2O (3:1 , 8 ml) was treated with 2 N LiOH (2.5 ml, 4.85 mmol). After stirring the solution for 12 h, the solvents were removed under reduced pressure to give the desired product; m/z 193.
Method 178
3-(2-Jytethoxy-l ,1 -dimethylethyl)benzoic acid 2-(3-Bromophenyl)-2-methylpropyl methyl ether (Method 17; 281 mg, 1.16 mmol) in
THF (10 ml) at -78 °C under Ar was treated with tert-tiuU (1.7 M in pentane, 1.4 ml, 2.31 mmol, 2.0 equiv). The reaction stirred for 15 min and then CO2(g) was bubbled through the reaction mixture. After 10 min, the reaction was quenched with 10% NaOH and extracted with EtOAc. The aqueous layer was acidified with 10% HCl and extracted with EtOAc. The organics were dried with NaCl(sat) and Na2SO4^) and then removed under reduced pressure; m/z 209.
Method 179
2-(3 -Bromophenyl)-2-methylpropan- 1 -ol A solution of 2-(3-bromophenyl)-2-methylpropanoic acid (Method 52, 300 mg, 1.23 mmol) in anhydrous THE (10 ml) was treated with BH3 (1.0 M in THE, 2.49 ml, 2.49 mmol, 1.5 equiv) drop wise under argon at 0 °C. The ice bath was removed and the reaction was stirred for 12 h. The reaction was quenched with 10% HCl and extracted with EtOAc. The organics were washed with NaCl(Sat) and the dried with Na2Sθ4(S). The solvents were removed Under reduced pressure to give 265 mg (94%); m/z 230.
Method 180
2-(3-Bromobhenyl)-2-methylprot>anoyl chloride
A solution of 2-(3-bromophettyl)-2-methylpropanoic acid (Method 52, 564 mg, 2.32 mmol) in DCM (5 ml) was treated with oxalyl chloride (0.31 ml, 3.48 mmol, 1.5 equiv) and E)ME (0.10 ml), under argon at 25 °C. The reaction stirred for 4 h, and then the solvents were removed under reduced pressure to give 265 mg (94%); m/z 262. Method 181
2-(3-Bromodhenyl)-ΛUV.2-trimethylt>robanamide
2-(3-Broniophenyl)-2-methylproparioyl chloride (Method 180, 607 mg, 2.32 mmol) was treated with dimethylamine (2.0 M in THF1, 5 ml, 10 mmol, 4.3 equiv). The reaction stirred for 30 niin. The reaction was quenched with 10% HCl and extracted with EtOAc. The organics were washed with NaCl(sai) and the dried with Na2Sθ4(s). The solvents were removed under reduced pressure to give 539 mg (86%); m/z 271.
Method 182 Methyl 5-((3-[2-fdimethylamino)-lJ-dimethyl-2-oxoethyl1benzσyUamino)-2- ltiethylbenzoate
2-(3-Bromophenyl)-N,N,2-trittiethylpropanamide (Method 181 ; 200 mg, 0.740 mmol), methyl 5-amino-2-methylbettzoate (Method 92; 122 mg, 0.740 mmol, 1.0 equiv), Pd(OAc)2 (17 mg, 0.075 mmol, 10 mol%), Mo(CO)6 (293 mg, 1.1 1 mmol, 1.5 equiv), Cs2CO3 (362 mg, 1.11 mmol, 1.5 equiv) and BINAP (46 mg, 0.074 mmol, 10 mol%) in toluene-MeCN 1 : 1 (2 ml) was heated at 90 0C under Ar for 12 h. The reaction was quenched with 10% NaOti and extracted with EtOAc. The organics were dried with NaCl(sat) and Na2Sθ4(s) and then removed under reduced pressure. The residue was then purified by column chromatography utilizing an lSCO system (EtOAc-hexane) to give 75 mg (27%) of the desired product; m/z 383.
Method 183
The following compound was prepared by the procedure of Method 182, using the appropriate starting materials.
Figure imgf000155_0001
Method 184
5-f(Diphenylmethylene)amino1-MN-dimethvbyridine-3-sulfonamide
A stirred mixture of 5-bromo-N,jV-dimethylpyridine-3-sulfonamide (Method 230; 170 mg, 0.641 mmol), benzophenone imine (0.13 ml, 0.769 mmol, 1.2 equiv), Cs2CO3 (3 l3 mg, 0.962 mmol, 1.5 equiv), BlNAP (40 mg, 0.064 mmol, 10 mol%) in dioxane (3 ml) was treated with Pd2(dba)3 (30 mg, 0.032 mmol, 5 mol%). The reaction mixture was heated to 100 °C for 12 hours. The reaction was then quenched with 10% NaOH(aq) and extracted with EtOAc. The orgaiiics were dried with NaCl(sat) and then Na2SO4^5) and removed under reduced pressure. The resulting solid was purified by column chromatography utilizing an ISCO system (hexanes-EtOAc) to give 234 mg (99%); m/z 366.
Method 185
5 -Amino-NJV-dimethylpyridine-3 -sulfonamide
A solution of 5- [(diphenylmethylene)amino]-N,N-diniethylpyridine-3 -sulfonamide (Method 184; 234 mg, 0.640 mmol) in THF (3 ml) was treated with 10% HCl (5 ml). The reaction mixture was stirred for 10 min. The reaction was quenched with 10% HCl(aq) and extracted with EtOAc. The aqueous layer was saturated with K2CO3 and extracted with EtOAc and the solvents were removed under reduced pressure to give 129 mg (99%); m/z 202.
Method 186
3-Chloropyridine-2,5-diamine
Into a 300ml three-neck flask, l3.9g (O.lmol) of 2-amino-5-nitropyridine, (14.7g, 0.1 lhiol) of N-chlorosUccinimide and 150ml of toluene were added. The resulting reaction mixture was stirred at 80 °C for one hour. During the reaction, formation of 2-chloroamino-5- nitropyridine was confirmed. After completion of the reaction by LCMS, the reaction mixture was cooled to room temperature and lOO ml of H2O were added. The solution was filtered and the isolated solid was washed with H2O and toluene (50ml each). 2-amino-3-chloro-5- nitropyridine was obtained (10.8 g, 62%) and it was Used in the next step without further purification. M/z 175. Into a 500ml three-neck flask, 2-amino-3-chloro-5-nitropyridine (8.72g, 50mniol) was dissolved in MeOH (125 ml). A solution of ammonium chloride (13.5 g, 250mmol) in H2O (125 ml) were added, followed by 14g of iron powder. The solution was stirred with mechanic stirring at 78 °C for 2 hours. The solution was filtered at 50 °C and the isolated solid was washed by hot MeOH. The solvent was evaporated by vacuum and the crude product was extracted by acetone and filtered. The acetone solution was evaporated and dissolved in 50ml MeOH whereupon 50ml of a solution of 4N hydrogen chloride in dioxane was added slowly. The resulting solution was sonicated for 10 minutes, and then filtered. The solid was washed by acetone and dried in a vacuum oven. 3-chloropyridine-2, 5-diamine (7.5 g, HCl salt) was isolated as an off-white powder. M/z 145.
Method 187 The following compound was prepared by the procedure of Method 186, Using the appropriate starting material.
Figure imgf000157_0001
Method 188
N2-f2-(ftert-butylrdimethyl)silyl1oxylethvht)yridine-2.5-diamine To a solution of 2-chloro-5-nitro pyridine (400 mg, 2.5 mttiol) in EtOH (5ml) was added 2-((tert-butyl(dimethyl)silyl]oxy)ethyl amine (3 ml) and the resulting mixture was heated to reflux for 3 hours. Evaporation of the solvent under reduced pressure afforded 5- nitro-2-[2-hydroxy)ethylamino]pyridine (680 mg) that was Used in the next step without any further purification. N-(2-{ttert-butyl(dimethyl)silyl]oxy}ethyl)-5-nitropyridin-2-amine (Method 156; 1.29 g, 4.34 mmol) was dissolved in 20 ml of MeOH and 260 mg of palladium (lθ wt. % on activated carbon-Degussa®) was added. The reaction was subjected to 1 atmosphere of hydrogen overnight. LC/MS confirmed the formation of the product. The reaction mixture was filtered through diatomaceoUs earth and washed with MeOH and EtOAc. The title compound (970 mg) was collected by evaporation as a thick red oil. M/z 268.
Methods 189-199
The following compounds were prepared by the procedure of Method 188, using the appropriate starting material.
Figure imgf000157_0002
Figure imgf000158_0001
Method 197
(3-Brottio-5-fluorophenyl)niethanol
A solution of 3-bromo-5-fIuorobenzoic acid (1.14 g, 5.21 mmol) in anhydrous THf (10 ml) was treated with BM3 (1.0 M in THF, 8.0 ml, 8.0 mmol, 1.5 equiv) dropwise under nitrogen at 0 0C. The mixture was stirred at 0 °C for 30 mill then allowed to warm to 25 °C and stirred for 12 h. The reaction was quenched with 10% HCl and extracted with EtOAc. The organic layer was washed with 10% NaOH and then dried with NaCl(sat) and Na2Sθ4(S). The solvents were removed under reduced pressure. The resulting product was carried directly to the next step; m/z 284.
Method 198
3-Bromo-5-fluorobenzyl methanesulfonate
A solution of (3-bromo-5-fluorophetiyl)methanol (Method 197; 1.07 g, 5.22 mmol) in anhydrous DCM (20 ml) was cooled to 0 °C. To this solution, DlEA (1.4 ml, 7.83 mmol, 1.5 equiv) and methane sulfonyl chloride (0.5 ml, 6.26 mmol, 1.2 equiv) were added respectively. The mixture was stirred at 25 °C for 2 h. The reaction was quenched with 10% HCl and extracted with EtOAc. The organic layer was washed with NaHCO3(sat) and then dried with NaCl(sat, and Na2SO4^). The solvents were removed under reduced pressure. The resulting product was carried directly to the next step; m/z 208. Method 199
(3-Bromo-5-fluorophenyl)acetonitrile
A suspension of 3-bromo-5-fluoi-obenzyl methanesulfonate (Method 198; 1.27 g, 4.49 mmol) and sodium cyanide (0.264 g, 5.38 mmol, 1.2 equiv) in DMf (9 ml) and water (1 ml) was stilted at 40 °C for 5 h. The reaction mixture was quenched with water and extracted with EtOAc. The organic layer was dried with NaCl(sat) and Na2SO4(Sj. The solvents were removed under reduced pressure. The resulting product was purified by chromatography using 5% EtOAc in Hexane to give the desired product; m/z 2l5.
Method 200
2-Methyl-3,5-dinitropyridine
Diethyl malonate (1.52mL ,10mmol) was dissolved in 50 mL THE, sodium hydride (400 mg, 10 mmol) was added to the solution in portions. The solution was stirred until gas evolution ceased. 2-chloro-3,5-dinitropyridine (2.03g, lOmmol) was added and the resulting solution was stirred an additional 10 minutes. The solvent was evaporated in Vacuo. Sulfuric acid (20 mL, 6 N) was added to the crude intermediate and the resulting solution was heated to 1000C over night. The solution was cooled to room temperature and neutralized by the addition of 2N sodium hydroxide^). The solution was extracted with ethyl acetate and the combined orgahic layer was washed with water and dried with sodium sulfate. The solution was filtered and concentrated in Vacuo, yielding 680 mg of the title compound that was used without further purification (37.2 %).
Method 201
3-(4-Methyl-l//-imidazol-l-yl)-5-ftrifluoromethyl)benzoic acid To a solution of 3-(4-methyl- l//-imidazol- 1 -yl)-5-(trifluoromethyl)benzohitrile
(Method 206; 180 mg, 0.717 mmol) in 5 ml of dioxarte was added 7 ml of a IM NaOH solution. The reaction mixture was allowed to stir overnight at lOO °C. The reaction mixture was cooled to room temperature and quenched by the careful addition of concentrated HCl until a of pH 3 was obtained. The aqueous phase was extracted with EtOAc, dried over Na2Sθ4, filtered and concentrated in vacuo to yield 816 mg (74 %) of the title compound as a yellow solid which was Used without further purification. M/z 271. Method 202
5-f 1 H-Pyrrol- 1 -yl)pyridin-3-amine
To a solution of 5-(lH-pyrrol-l-yl)nicotinic acid (3.0 g, 15.9 liimol) in 80 ml of t- butanol, DPPA (6.89 ml, 31.9 mmol) and DlEA (5.56 ml, 31.9 mmol) were added and the reaction mixture was heated at 800C in a sealed tube overnight. The mixture was partitioned between H2O and EtOAc, and the organic layer was washed with brine and sodium bicarbonate and dried with MgSθ4. Evaporation of the solvent gave a brown solid m/z 260. This material was dissolved in MeOH (30 ml) and 4N HCl in 1,4-dioxane (25 ml) was added at 0°C and the resulting mixture stirred for 2 hours at room temperature. Ether was then added to the mixture and 5-(lH-pyrrol-l-yl)pyridin-3-amine (3.356g), a mustard yellow precipitate, was collected by Filtration. M/z 160.
Method 203
3-fl-Cyano-l,2-dimethylpropyl)benzoic acid To a solution of 3-(l -cyanoethyl)benzoic acid (500 mg) in THf (50ml) at -78°C was added slowly a solution of LiHMDS (60ml, 1.OM in THf) and the resulting red solution was allowed to stir at his temperature for 30 minutes, lsopropyl Iodide (10 ml) was added slowly and the resulting mixture was warmed up to room temperature and stirred for 10 hours. The mixture was partitioned between EtOAc and H2O and the aqueous layer was acidified with IN HCl until pH 3. The aqueous layer was extracted with EtOAc (3x) and dried with MgSθ4. Evaporation of the solvent under pressure afforded the desired compound as a white solid (300 mg). IH HMR (300 MHz) 8.03 (s, IH), 7.92 (d, 2H), 7.71 (d, 2H), 7.56 (t, IH), 2.20 (h, IH), 1.67 (s, 3H), 1.05 (d, 3H), 0.72 (d, 3H).
Methods 204-205
The following compounds were prepared by the procedure of Method 203, Using the appropriate starting material.
Method Compound m/z SM
204 3-(l-Cyano-l- IH NMR (300 MHz) 8.07 (s, iodoethane methylpropyl)bettzoic IH), 7.91 (d, IH), 7.73 (d, IM), acid 7.57 (t, IH), 1.98 (q, 2H), 1.69
(s, 3H), 0 82 (t, 3H)
Figure imgf000161_0001
Method 206
3-(4-Methyl-lH-imidazol-l-yl)-5-(trifluoroniethyl)benzonitrile
To a solution of 3-fluoro-5-(trifluoromethyl)benzonitrile (5.0 g, 26.4 mmol) in 25 ml of DMA was added 2-methyl imidazole (6.5 g, 79.3 mmol). The reaction mixture was stirred at 145 °C overnight. The reaction mixture was allowed to cool to room temperature and was quenched with -50 ml of brine and then extracted three times with EtOAc. The combined organic extracts were dried over Na2SO4, filtered and concentrated in Vacuo to yield the crude product. The crude sample was subjected to lSCO purification Using EtOAc as eluent to yield 4.O g (61%) of the title compound as a white solid. M/z 251.
Method 207 tert-Butyl (2-|Y5-nitropyridin-2-yl)amino1ethvUcarbaniate
To a solution of N-(5-nitropyridin-2-yl)ethane-l,2-diamine (1.0 g, 5.49 mmol) in THF (20 ml) at 0°C, sodium hydride (395 mg, 8.22 miiiol) and di-tert-butyl dicarbσttate (1.2Og, 5.49 mmol) were added. The reaction mixture was stirred overnight at 25°C. LC/MS confirmed the formation of the product so the reaction was quenched with H2O. The mixture was partitioned between H2O and EtOAc, and the organic layer was washed with brine and dried with MgSθ4. The title compound (1.1 Ig) was collected by evaporation as a yellow oily solid. M/z 284
Method 208
7V-(5-Aniinσ-3-bromopyridin-2-yl)acetamide
To a solution of 2-amino-3-broiiio-5-nitro pyridine (3.Og, 13.8 mmol) in pyridine (20 ml) at 0°C was added slowly acetyl chloride (2.5 ml) and the resulting mixture was stirred for 1 hour at ambient temperature. The mixture was partitioned between H2O and EtOAc, and the organic layer was washed with brine and dried with MgSO4 1. Evaporation under reduced pressure afforded the acetyl derivative, which was Used in the next step without further purification.
Into a three-neck flask, 2-acetylamino-3-bromo-5-nitropyridine (2.Og) was dissolved in MeOH (25 ml). A solution of ammonium chloride (1.3 g, 250mmol) in H2O (25 ml) was added, followed by 1.4g of iron powder. The solution was stirred by at 78 0C for 2 hours. The solution was filtered at 50 °C and the isolated solid was washed by hot MeOH. The solvent was evaporated under reduced pressure and the product was extracted by acetone and filtered. The acetone solution was evaporated to give the title compound (900 mg) as solid. M/z 231.
Methods 209-210
The following compounds were prepared by the procedure of Method 208, using the appropriate starting material.
Figure imgf000162_0001
Method 211 2,3-t)imethyl-pyridine-5-amine
To a solution of NaH (80 mg, 60% w/w) in ether (4 ml) at 0 °C was added slowly diethyl hialohate (0.3 ml). After the evolution of gas had ceased, 2-bromo-3-methyl-5-nitro pyridine (434 mg) was added portion-wise. After 30 min, the reaction was quenched with 10% HCl and extracted with EtOAc. The organics were washed with NaCl(Sat) and then dried with Na2SO4(S). The organics were then removed under reduced pressure to give the malonate adduct. The crude product was dissolved in 30 ml of 6N H2Sθ4 and heated to 1 10°C for 5 hours. The mixture was cooled in an ice bath and a solution of 2N NaOH was added until pH neutral. The desired product was collected by filtration (100 mg). M/z 154.
The 2,3-dimethyl-5-nitro-pyridine (100 mg) was dissolved in 10 ml of MeOH and lOO mg of palladium (10 wt. % on activated carbon-DegUssa®) was added. The reaction mixture was subjected to 1 atmosphere of hydrogen overnight. LC/MS confirmed the formation of the product and the reaction mixture was filtered through diatomaceous earth and washed with MeOH and fitOAc. The product (60 mg) was collected by evaporation. M/z 123. Methods 212-213
The following compounds were prepared by the procedure of Method 211, using the appropriate starting material.
Figure imgf000163_0001
Method 214
2-Hydroxypyridine-5 -amine
5-Nitropyrid-2-orie (420 mg, 3 mtiiol) was dissolved in MeOM (7 ml) and a solution of ammonium chloride (810 mg) in H2O (7 ml) was added, followed by 840 mg of iron powder. the solution was stirred at 78 °C for 2 hours. The solution was filtered at 50 °C and the isolated solid was washed by hot MeOH. The solvent was evaporated under reduced pressure and the desired product was isolated by filtration (170 mg). M/z 11 1.
Methods 215-217 The following compounds were prepared by the procedure of Method 214, using the appropriate starting material.
Figure imgf000163_0002
Method 218
Methyl 1 ,3.3-trimethyl-2-oxoindoline-5-carboxylate To a solution of methyl 2-oxoindoline-5-carboxylate (400 mg, 2.09 himol) in THF (10 ml) at -78 0C was added LiHMDS (1.0 M, 16.7 ml, 16.75 mmol) and Mel (1.3 ml, 20.9 mmol). The reaction was allowed to stir overnight to room temperature. The reaction was then quenched with -25 ml aqueous NH4Cl. After dilution with fetOAc, the mixture was washed with brine, and then dried over Na2Sθ4 and concentrated in Vactiϋ to yield the crude product that was purified on SiO2 using EtOAc/hexanes as eluent which yielded 81 mg (17%) the title compound as a yellow solid. M/z 233.
Method 219 5-lsopropoxypyridin-3-amine
5-Bromopyridin-3-ol (Ig, 5.75mmol) was dissolved in 20ml DMf, isopfopyl bromide (1.65ml, 17.2mmol) and Cs2CO3 (8.6gram, 25.9mmol) were added. The solution was stirred at room temperature overnight. The solution was filtered and separated between EtOAc and water. The organic layer was dried and evaporated under reduced pressure to afford the title compound (1.2 g).
Methods 220-222
The following compounds were prepared by the procedure of Method 2l9, using the appropriate starting material.
Figure imgf000164_0001
Method 223
5-(f3-(l-Cvano-l-methylethyl')benzoyl'|amino) -2-chlorobenzoic acid
3-(l -Cyano-l-methylethyl)behzoic acid (Method 19, 150 mg) was combined with methyl 5-amino-2-chlorobenzoate (Method 217, 120 mg)), HATU (400 mg) and DlEA (0.6 ml) in DMf (3 ml) and stirred overnight at 25°C. LC/MS confirmed the formation of the product, methyl 5-{t3-(l -cyano-l-methylethyl)benzoyl]aminoj -2-chlorobenzoate. The mixture was partitioned between H2O and EtOAc, and the organic layer was washed with brine and dried with MgSO4 1. Methyl 5-{[3-(l-cyatto-l-methylethyl)benzoyl]amino) -2- chlorobenzoate was collected by evaporation as a reddish-brown oil. Methyl S-ltS-Cl-cyano-l -methylethy^beiizoylJaniinoJ-Z-chlofobenzoate (120 mg) was dissolved in a 3:1 :1 (v/v/v) solution of THF/MeθH/H2O and lithium hydroxide (50 mg) was added slowly. The reaction was then stilted overnight at 25°C. LC/MS confirmed the formation of the product. The organic solvents were evaporated and the remaining material was separated between EtOAc and H2O. The aqueous layer was collected and acidified to a pH of between 3 and 4 with 2N HCl. The mixture was partitioned between H2O and EtOAc, and the organic layer was washed with brine and dried with MgSO4. The title compound (85 mg) was collected by evaporation as a white solid.
Method 224
The following compound was prepared by the procedure of Method 223, Using the appropriate starting material.
Figure imgf000165_0001
Method 225 Sodium r3-(methoxycarbonyl)phenyl1methanesulfonate
To a solution of methyl 3-(bromomethyl)beiizoate (2.5 g, 19.0 mmol) in 25 ml of acetone and 25 ml of H2O, was added sodium sulfite (1.5 g, 12.0 mmol) and tertabutylammonium iodide (4.4 g, 12.0 mmol). The reaction warmed to 75 0C and was allowed to stir for 12 h at this temperature. The reaction mixture was cooled to room temperature and concentrated in \>acuo to yield the title compound as a yellow solid 2.5 g (99%). M/z 230.
Method 226
3-Cyclopropyl-5-fluorobenzoic acid To a 50 ml round bottom flask charged with a magnetic stir bar was added 3-brottio-5- flUorobenzoic acid (0.500 g, 4.56 mmol) and cyclopropylboroiiic acid (0.590 g, 6.84 mmol). Toluene (15 ml) and H2O (0.75 ml) were added followed by K3PO4 (3.86 g, 18.24 mmol) and Pd(PPh3^ (1.05 g, 0.912 mmol). The resulting reaction mixture was heated to 100 °C for 12 h, was cooled to room temperature, and quenched with 10% aqueous MaOH (-100 ml). The reaction mixture was poured into a separator funnel and extracted with EtOAc (-100 ml). The resulting aqueous phase was isolated and brought to a pH of ~ 2 by the careful addition of 3M HCl at which time the desired product precipitated. The precipitate was collected via vacuum filtration, washed with ah additional portion of H2O (—100 ml), collected, and dried under vacuum for 24 h which yielded 0.310 g of the title compound (37%) as an off white solid. M/z 181.
Method 227
2,3-Dichloro-5-nitro-pyridine To a solution of 5-nitro-2-hydroxypyridine (700 mg, 5 mmol) in concentrated HCl
(3.3 ml) was heated to 50°C to facilitate dissolution. A solution of KClO3 (214 mg) in H2O (3ml) was added drop- wise to the above solution in such a way the internal temperature did not exceed 60°C. The resulting mixture was stirred at ambient temperature for 15 minutes, cooled to 0 °C and the product 3-chloro-5-nitro-2-hydroxypyridine was collected by Filtration (600 mg, 68%). The pyridine (600 mg) was dissolved in quinoline (0.4 ml) and I3OCl3 (0.35 ml). The resulting mixture was heated to l20°C for 2 hours. The mixture was partitioned between EtOAc and H2O. The orgahics were washed with NaCl(Sat) and then dried with Na2Sθ4(s). The organics were then removed under reduced pressure to give the title compound (358 mg, 55%) as a brown solid. M/z 194.
Method 228 3-f(2-Cvano-lH-pyrrol-l-yl)methvHbenzoic acid
To a solution of methyl 3-(brohiomethyl)benzoate (500 mg) in DMF (10 ml) was added a solution of 2-cyano pyrrole (350 mg) in DMF (5 ml) which had been previously treated with NaH (100 mg). The resulting mixture was stirred at ambient temperature for 3 hours. The mixture was partitioned between EtOAc and H2O. The organics were washed with NaCl(Sat) and then dried with Na2Sθ4(s). Evaporation of the solvent gave methyl 3-t(2-cyano- lH-pyrrol-l-yl)methyl]benzoate (300 mg). M/z 241.
Methyl 3-[(2-cyano-lH-pyrrol-l-yl)methyl]bertzoate (300 mg) was dissolved in MeOHVH2O (10 ml, 3 : 1 v/v) and LiOH (60 mg) was added. The resulting mixture was stirred at room temperature for 10 hours. The aqueous phase was filtered and washed with EtOAc. The basic aqueous layer was acidified by the addition of IN HCl until pH 3. The aqueous layer was extf acted with EtOAc (3x) and then dried with Na2SO4(S). Evaporation of the solvent afforded the title compound as a white solid (210 mg); m/z 226.
Method 229 3-( 1 -Cyafio- 1 -methylethyl)-5-flϋorobenzoic acid
2-(3-Bromo-5-fluorophenyl)-2-methylpropaneiiitrile (Method 18; 258 mg, 1.07 mmol) in TH? (10 ml) at -78 °C under Ar was treated with /BuLi (1.7 M in pentane, 2.13 mmol, 2.0 equiv). The reaction was stirred for 15 min and then CO2(g, was bubbled through the reaction mixture. After 10 min, the reaction was quenched with 10% NaOH and extracted with EtOAc. The aqueous layer was acidified with 10% HCl and extracted with EtOAc. The organics were dried with NaCl(sat) and Na2Sθ4(s) and then removed under reduced pressure; m/z 208.
Method 230
5-Bronio-jV,N-dimethylpyridine-3-sulfonamide A solution of N,N-dimethylρyridine-3 -sulfonamide (Method 129, 1.30 g, 6.98 mmol) and NaOAc (1.72 g, 20.9 mmol, 3.0 equiv) in HOAc (10 ml) was treated with Br2 (0.72 ml, 14.0 mmol, 2.0 equiv). The reaction was stirred for 12 h at 50 °C. The reaction was quenched with H2O and extracted with EtOAc. The organics were dried with NaCl(Sat) and Na2SO4(S) and then removed under reduced pressure. The residue was then purified by column chromatography Utilizing an ISCO system (EtOAc-hexane) to give 340 mg (18%) of the desired product; m/z 266.
Method 231
5-f luoronicotinic acid To a IL round bottom flask charged with a magnetic stir bar and 2,6-dichloro-5- fluσronicotinic acid (5.00 g, 23.8 mmol) was added MeOH (240 ml) and DlEA (8.30 ml, 48.0 mmol). To this solution was carefully added 500 mg of palladium on carbon (10 wt %). The resulting reaction mixture was purged with H2 and placed Under an atmosphere of H2 (1 atm) using a balloon. The reaction was allowed to stir at ambient temperature for 12 h before being filtered through a bed of diatomaceous earth. The filtrate was concentrated in vacuo to a volume of- 25 ml and diluted with -250 ml OfEt2O. A precipitate formed (DlPEA/HCl salt) which was filtered off using a Buchner funnel. The filtrate was concentrated in vacua to yield 3.2 g (98%) the title compound as a yellow oil which was used without further purification; m/∑ \ 4\ .
Method 232 5-Aminoiiicotiiionitrile
5-Bromonicotinonitrile (1.26g, 6.8mmol), Cs2CO3 (3.74g, 11.5mmol), BlNAP (7l6mg, 1.l5mmol), Pd2(dba)3 (526mg, 0.575mmol) were put in a round bottle, toluene 25mL and 1,1-diphenylmethanimine (1.43ml, 8.6mmoL) were added and the mixture was degassed for 5 minutes. The solution was heated at 100 °C over night. The crude product was filtered and evaporated, and dissolved in dioxatie (lOml) followed by the addition of 4N HCl in dioxahe 10ml. The solution was stirred at room temperature for 30 minutes. The residue left after evaporation was separated between water and ethyl acetate. Evaporation of the solvent gave the title compound (800 mg). M/z 120.
Method 233 jV-(5-Amitio-3-methylpyridin-2-ylV2-(berizyloxy)acetamide
To a solution of 2-amino-3-methyl-5-nitropyridine (1.Og) in pyridine (20 ml) at O0C was added slowly (benzyloxy)acetyl chloride (2.5 ml) and the resulting mixture was stirred for 1 hour at ambient temperature. The mixture was partitioned between H2O and EtOAc, and the organic layer was washed with brine and dried with MgSθ4. Evaporation under reduced pressure afforded the acetyl derivative which was Used in the next step without further purification, (m/z 302)
Into a three-neck flask, the residue (500 mg) was dissolved in MeOH (25 ml). A solution of ammonium chloride (1.3 g, 250mmol) in H2O (25 ml) was added, followed by 1.4g of iron powder. The solution was stirred by at 780C for 2 hours. The solution was filtered at 5O0C and the isolated solid was washed by hot methanol. The solvent was evaporated under reduced pressure and the product was extracted by acetone and filtered. The acetone solution was evaporated to give the title compound (lOO mg) as solid. M/z 272.
Method 234
Methyl 5-piperidin- 1 -ylnicotinate
A 25 ml round bottom flask was charged with a magnetic stir bar, methyl 5- bromonicotinate (0.500 g, 2.31 nitnol), piperidine (0.305 g, 3.46 mmol), and toluene (5 ml). Caesiuhi carbonate (2.25 g, 6.93 mmol), palladium (II) acetate (52 nig, 0.23 mmol), and BlNAP (0.287 g, 0.46 mmol) were then added. The reaction was heated to 80 °C for 8 h before being diluted with EtOAc (~ 50 ml), filtered tlirough a pad of SiO2, and concentrated in vacuo. The crude product was purified on 40 g SiO2 using EtOAc as eluent giving 0.376 g of the title compound as a colourless oil (74 %). M/z 221.
Methods 235-236
The following compounds were prepared by the procedure of Method 234., Using the appropriate starting material.
Figure imgf000169_0001
Method 237
Methyl 3-cyclopropylbenzoate
To a 100 ml round bottom flask charged with a magnetic stir bar and t)CM (20 ml) was added 12.3 ml of diethyl zinc (IM in hexanes). The reaction mixture was cooled to 0 °C and trifluoroacetic acid (1.40 g, 12.3 mmol) was added dropwise via syringe. The reaction was stirred at this temperature for 20 mins. followed by the addition of CH2I2 (3.30 g, 12.3 mmol). The reaction mixture was stirred for 20 mins. before methyl 3-vinylbeiizoate (1.00 g, 6.16 mmol) was added. The reaction was then allowed to warm to room temperature with stirring for 3 h. before being quenched by the addition of -50 ml of saturated aqueous NH4Cl. The mixture was poured into a separator funnel and the aqueous phase was further extracted with DCM (3 x 50 ml). The combined organic extract was dried with MgSθ4 and concentrated in vacuo to yield the crude reaction product which was purified on 120 g SiO2 Using hexanes/EtOAc 10:1 as eluettt giving 1.01 g of the title compound as a colourless oil (94 %) m/z 177.
Methods 238-239
The following compounds were prepared by the procedure of Method 237, using the appropriate starting material.
Figure imgf000169_0002
Figure imgf000170_0001
Method 240
(5-Bromopyridin-3-yl)methanol
To a 500 nil three neck flask Fitted with a reflux condenser was added with a magnetic stif bar and MeOM (65 ml). NaBHj (12.2 g, 324 mmol) was carefully added followed by methyl 5-bromonicotinate (7.0 g, 32.4 mmol). The reaction mixture was heated to reflux with stirring for 5 h before being cooled to room temperature and the reaction mixture was quenched by the slow addition of- 250 ml OfH2O. The MeOH was removed under reduced pressure and the resulting aqueous phase was extracted with -250 ml of EtOAc. The organic extract was dried with MgSO4, filtered, and concentrated in vacuo to yield the crude product, which was purified on a 120 g SiO2 column Using MeOH/EtOAc (1 :10) as eluent giving 2.3 g (37%) of the title compound as a white solid m/z 189.
Method 241 5-({ffey/-r3Utyl(diphenyl)silyl1oxylmethyl)-7V-(dit)henylmethylene)pyridin-3-amine
To a 200 ml round bottom flask charged with a magnetic stir bar was added 3-bromσ- 5-({t/e7V-butyl(dipheiiyl)silyl]oxy)methyl)pyridine (Method 102; 5.2 g, 12.2 mmol). Toluene (60 ml) was added followed by benzophenone imine (2.55 ml, 15.25 mmol), sodium teri- butoxide (2.00 g, 21.35 mmol), Pd2(dba)3 (0.558 g, 0.61 mmol), and BlNAP (1.13 g, 1.83 mmol). The reaction was heated to 80 °C with stirring for 5 h before being cooled to room temperature and quenched with -200 ml saturated aqueous NaHCO3. The mixture was poured into a separator funnel and extracted with -200 ml of EtOAc. The combined organic extract was dried with MgSO4, filtered, and concentrated in vacuo to yield the crude product, which was purified on a 120 g SiO2 column using hexanes/EtOAc (9:1) as eluent giving 5.26 g (82%) of the title compound as a white solid m/z 527.
Method 242
(5-Aniinopyridin-3-yl)methanol hydrochloride
To a 500 ml round bottom flask charged with a magnetic stir bar was added 5-({[tert- butyl(diphenyl)silyl]oxy j methyl)-N-(diphenylmethylene)pyHdin-3-amine (Method 241 ; 5.2 g, 9.87 mmol). MeOH (200 ml) was added followed by the addition of 50 ml of 3N HCl with stirring. The reaction was allowed to stir for 12 h at room temperature before being concentrated in vacuo. The crude oil diluted with EtOAc (-100 ml) and a precipitate formed. The solid was collected on a Buchner funnel to provide 1.24 g (79 %) of the title compound as an off white solid m/z 125.
Method 243 N2-Cvclopropylpyridine-2,5-diamine
To a 100 ml round bottom flask charged with a magnetic stir bar and N-cyclopropyl-5- nitropyridin-2-amine (Method 149; 0.800 g, 4.46 mmol) was added EtOH (15 ml). Tin (II) chloride dihydrate (4.03 g, 17.84 mmol) was added and the reaction was warmed to 70 °C with stirring for 4 h before being cooled to room temperature. The crude reaction mixture was then quenched with -150 ml of saturated aqueous NaHCO3. The resulting mixture was poured into a separator funnel and extracted with -150 ml of EtOAc. The combined organic extract was dried with MgSO4 1, filtered, and concentrated in vacuo to yield the title compound as a yellow solid 0.551 g (83%), which was Used without further purification; m/z 150.
Methods 244-250
The following compounds were prepared by the procedure of Method 243, using the appropriate starting material.
Figure imgf000171_0001
Method 251
/ert-Butyl (5-fluoropyridin-3-yl)carbaniate
To a 100 ml round bottom flask charged with a magnetic stir bar was added 5- fiuorotticotinic acid (Method 231; 1.00 g, 7.09 mmol). 7e/7-butyl alcohol was added (20 ml) followed by DlEA (3.08 ml, 17.7 mmol). t)iphenyl phosphoryl azide (3.83 ml, 17.72 mmol) was added and the flask was fitted with a reflux condenser. The reaction was heated to reflux for 12 h, cooled, and the crude reaction mixture was concentrated in vacuo. The resulting oil was dissolved in £tOAc (~ 200 ml) and the organic phase was washed 3 x 200 ml saturated aqueous NaHCO3. The organic phase was dried with MgSCM, filtered, and concentrated in vacuo yielding the crude product which was purified on SiO2 (120 g) using GtOAc/hexahes (1 :5) as eluent to yield 0.83 g (55%) of the title compound; m/z 213.
Method 252
5-t?luoropyriditi-3-amirie hydrochloride To a 100 ml round bottom flask charged with a magnetic stir bar and /erf-butyl (5- fluoropyridin-3-yl)carbamate (Method 251; 0.800 g, 3.77 mmol) was added MeOH (100 ml). A 4Kf solution of HCl in dioxane was then added until the reaction mixture reached a pH of ~ 3. The reaction was allowed to stir for 12 h before being concentrated in vacuo. The crude product was suspended in -250 ml of £t2θ. A white precipitate formed which was collected via vacuum filtration. The filter cake was washed with an additional 250 ml of Gt2O and dried on a vacuum to yield 0.5l 0 g (91%) of the title compound as a white solid; m/z 113.
Method 253
Methyl 3-(l -cyano-1 -methylethylV5-t(methylthio)niethyl1benzoate A solution of methyl 3-(bromoniethyl)-5-(l-cyano-l-methylethyl)benzoate (Method
138; 80 mg, 0.27 mmol) in 1 ml of EtOH was added sodium thioniethoxide. The mixture was stirred over open atmosphere at reflux. Evaporation the residual solvents yielded the product which was used without any further purification m/z 263.
Method 254
Sodium f3-(l-cvano-l-methylethyl)-5-(methoxycarbonyl)phenyl1methanesulfonate
To a solution of methyl 3-(bromomethyl)-5-(l-cyano-l-methylethyl)benzoate (Method 138; 230 mg, 0.777 mmol) in 5 ml of acetone and 5 ml of water was added sodium sulfite. The mixture was stirred over open atmosphere at reflux. The reaction was cooled to room temperature and the solvents were removed in vacuo to yield the title compoUhd which was used without any further purification. M/z 297.

Claims

Claim
1. A compound of formula (I):
Figure imgf000173_0001
(I) wherein:
Ring A Is phenyl of a monocyclic 5 or 6 membered fully-unsaturated hetefocyclic ring; whefein said phenyl of hetefocyclic ring may be optionally fused to a five of six membefed carbocyclyl of heterocyclyl foftning a bicyclic fiήg; and whefein if said hetefocyclyl of hetefocyclic ring contains an -NH- moiety that nitfogefi may be optionally substituted by a group selected from R5;
R1 is a substituefit on carbon and is selected from halo, nitro, cyano, hydroxy, tfifluofomethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, C|-6alkoxy, C|.6alkahoyl, Ci^alkanoyloxy, N-(C|.6alkyl)amino, jV,jV-(C|.6alkyl)2amino, Cι-6alkanoylamino, N-(C|-6alkyl)carbamoyl,
N,N-(C|-6alkyl)2carbamoyl, C|-6alkylS(O)a wherein a is 0 to 2, Cualkoxycarbonyl, Ci-ealkoxycarbonylamino, 7V-(Ci-6alkyl)sulphamoyl,
Figure imgf000173_0002
N-(C i -6alky I)-N-(C i -6alkoxy )sulphamoy 1, N, N'-(C i -5alky I)2Uf eido, N', N'-(C i -6alky l)2ureido, N-(Cι-6alkyl)-N'N-(Ci-6alkyl)2ureido, Ci-6alkylsulphonylamino, carbocyclyl-R6- or heterσcyclyl-R7-; whefein R1 may be optionally substituted on carbon by one or mofe R8; and whefein if said hetefocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R9; n is selected from 0-4; wherein the values of R1 may be the same or different;
R2 is selected from hydrogen, halo, nitro, cyano, hydroxy, trifluorottiethoxy, amino, carboxy, carbamoyl, mefcapto, sulphamoyl, Cι-6alkyl, C2-ealkenyl, C2-6alkynyl, C]-6alkoxy, Cualkattoyl, C|.6alkanoyloxy, N-(C|-6alkyl)amino, N,N-(Cι-6alkyl)2amino, Cι-6alkanoylamino, N-(Cι-6alkyl)carbanioyl, N,N-(Cι-6alkyl)2carbamσyl, Cι-6alkylS(O)d whefein a is 0 to 2, C|-6alkoxycafbonyl, N-(C|-6alkyl)sulphamoyl, N,N-(C|-6alkyl)2sulphamoyl, C|-6alkylsulphoiiylamino, cafbocyclyl-R10- of hetefocyclyl-R1 1-; whefein R2 may be optionally substituted oh carbon by one of mote R 2; and wherein if said hetefocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted by a group selected from R13; ft3 is selected from halo, hydroxy, cyano, methyl, methoxy or hydroxymethyl; ft is selected from halo, nitro, cyano, hydroxy, trifiuoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, ureido, Cualkyl, C2-6alkenyl, C2-6alkynyl, C|-6alkoxy, Ci-ealkanoyl, C|-6alkanoyloxy, N-(C|.6alkyl)amino, N,N-(C|-6alkyl)2amino, Cualkanoylamήio, N-(C|-6alkyl)carbamoyl, iV,N-(Ci-6alkyl)2carbamoyl, C|-6alkylS(O)a wherein a is 0 to 2, Cι-6alkoxycarbonyl, TV-(C i-6alkyl)sulphamoyl, N,N-(C|-6alkyi)2sulphattioyl, Ci-6alkylsulphonylamino, carbocyclyl-R14- or heterocyclyl-R15-; wherein R4 may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that hitrogen may be optionally substituted by a group selected from R'7; tti is selected from 0-4; wherein the values of R4 may be the same or different; ft8 and ft12 are independently selected from halo, hitro, cyano, hydroxy, trifiuoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C|-6alkyl, C2-6alkenyl, C2-6alkyhyl,
Figure imgf000174_0001
Cualkanoyi, Cualkahoyloxy, jV-(Ci-6alkyl)amino, N, N-(C i -6alky l)2amino, N-(C i -6alky I)-N-(C i -6alkoxy)amino, C i -6alkanoy lamino, N-(C|.6alkyl)carbamoyl, N,N-(C!-6alkyl)2carbamoyl, Cι-6alkylS(O)a wherein a is 0 to 2, C|-6alkoxycarbonyl, N-(Ci-6alkyl)sulphamoyl, N,N-(Ci-6alkyl)2sulphamoyl,
Cualkylsulphonylamiiiσ, carbocyclyl-R18- or heterocyclyl-R19-; wherein R8 and R12 independently of each other may be optionally substituted on carbon by ohe or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R2'; ft16 is selected from halo, nitro, cyano, hydroxy, trifiuoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, Cualkyl, C2-6alkenyl, C2-6alkynyl, Ci^alkoxy, Cualkanoyi, Cι-6alkanoyloxy, N-(C].6alkyl)amino, N,N-(C|-6alkyl)2amino, C ualkanoy lamino, N-(Cι-6alkyl)carbamoyl, N,N-(Ci-6alkyl)2carbamoyl, C|.6alkylS(O)a wherein a is 0 to 2, Cι-6alkoxycarbonyl, N-(Ci-6alkyl)sulphamoyl, N,N-(C|-6alkyl)2sUlphamoyl, Cualkylsulphonylaminσ, carbocyclyl-R22- or heterocyclyl-R23-; wherein R16 may be optionally substituted on carbon by one or more R24; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R25; R6, R7, R10, R", R14, R15, R18, R19, R22 and R23 are independently selected from a direct bond, -O-, -N(R26)-, -C(O)-, -N(R27)C(O)-, -C(O)N(R28)-, -S(O)8-, -SO2N(R29)- or
-N(R30)SO2-; wherein R26, R27, R28, R29 and R30 are independently selected from hydrogen or
C|-6alkyl and s is 0-2; R5, R9, R13, R17, R21 and R25 are independently selected from C|.6alkyl, Cι-6alkanoyl,
C|-6alkylsulphonyl, C|-6alkoxycarbonyl, carbamoyl, N-(Ci.6alkyl)carbamoyl,
N,N-(C|-6alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphottyl; R20 and R24 are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifiuoroiiiethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-iV-ethylamino, acetylamino, N-methylcarbamoyl, jV-ethylcarbamoyl,
N,jV-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-TV-ethylcarbamoyl, phenyl, methylthio, ethylthio, ttiethylsulphinyl, ethylsuiphinyl, mesyl, ethy Sulphonyl, methoxycarbonyl, ethoxycarbonyl, iV-methylsulphattioyl, N-ethylsulphamoyl, N,jV-dimethylsulphamoyl, N, jV-diethylsulphamoyl or iV-methyl-N-ethylsulphamoyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not: jV-t4-chloro-3-({|;6-(4-methylpiperazin-l-yl)pyridin-3-yl]amino] carbonyl)phenyl]-2- morpholin-4-ylisonicotinamide; 7V-t4-chloro-3-({t6-(4-ethylpiperazin-l-yl)pyridin-3-yl]amino] carbonyl)phenyl]-2-morρholin-
4-ylisonicotinamide;
N-{4-chloro-3-t({6-tt3-(dimethylamino)propyl](methyl)amino]pyridin-3-yl] amino)carbonyl] phenyl) -2-morpholin-4-ylisonicotinamide;
N-{4-chloro-3-t({6-tt2-(dimethylamino)ethyl](methyl)amino]pyridin-3-yl) amino)carbonyl] ρhenyl}-2-morpholin-4-ylisonicotinamide; or
N-t4-chloro-3-({t6-(4-methyl-l,4-diazepan-l-yl)pyridili-3-yl]amino}carbonyl)phenyl]-2- morpholin-4-ylisonicotinamide.
2. A compound of formula (1), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 wherein Ring A is phenyl, pyridyl, pyrazolyl, thienyl, indolyl, 2,3- dihydrobenzofurattyl, imidazotl,2-a]pyridinyl, isoxazolyl, beiizimidazolyl, 2-oxoindolinyl, furanyl, l ,3-thiazolyl, pyrimidinyl and pyrrolyl; wherein said pyrazolyl, indolyl, pyrrolyl may be optionally substituted oh nitrogen by a group selected from R5; wherein R5 is selected from Cualkyl.
3. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in either claim 1 or claim 2 wherein R is a substituent on carbon and is selected from halo, cyano, hydroxy, sulphamoyl,
Figure imgf000176_0001
C2-6alkynyl, C|-6alkoxy, N,N-(C|-6alkyl)2amino, Cι-6alkylS(O)a wherein a is 0 to 2, C]-6alkoxycarbonylamino, N-(Ci-6alkyl)sulphamoyl, N, N-(C i -6alky l)2sulphamoy 1, N-(Ci -6alky I)-N-(C i -6alkoxy)sulphamoy 1, N'N'-(C|-6alkyl)2ureido, C|.6alkylsulphonylamino, carbocyclyl-R6- or heterocyclyl-R7-; wherein R1 may be optionally substituted on carbon by one or more R8; wherein
R8 is selected from halo, cyano, hydroxy, Cualkyl, C|-6alkoxy, N,N-(C]-6alkyl)2amino, N,N-(C|-6alkyl)2carbamoyl, C|-6alkylS(O)a wherein a is 0 to 2, N,N-(C|-6alkyl)2sulphamoyl, N-(Ci-6alkyl)-N-(C|-6alkoxy)amino, carbocyclyl-R18- or heterocyclyl-R19-; wherein R8 may be optionally substituted on carbon by one or more R20; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R21;
R6, R7, R18 and R19 are independently selected from a direct bond, -O-, -S(O)5- or -Ν(R30)SO2-; wherein R30 is selected from hydrogen and s is 2;
R21 is selected from Cι-6alkyl; and R20 is selected from cyano or hydroxy.
4. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-3 wherein n is selected from 0-2; wherein the values of R1 may be the same or different.
5. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-4 wherein R2 is hydrogen.
6. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-5 wherein R3 is selected from halo, methyl or methoxy.
7. A compound of formula (1), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 -6 wherein R4 is selected from halo, cyano, hydroxy, amino, carbamoyl, ureido, Cualkyl, C2.6aikyhyl, Ci-6alkoxy, C|-6alkanoyl, N-(Cf -6alkyl)amino, N, TV-(C i-6alkyl)2animo, Ci-ealkanoylamino, N-(Ci-6alkyl)carbanioyl, C|.6alkoxycarboiiyl, . N,./V-(Cι-6alkyl)2sUlphamoyl, Cι-6alkylsulphonylamiho, carbocyclyl-R14- or heterocyclyl-R15-; wherein R4 may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an -NH- moiety that hitrogeti may be optionally substituted by a group selected from R17; wherein
R16 is selected from halo, hydroxy, amino, Cι-6alkoxy, /V-(Ci.6alkyl)amino, /V,/V-(C|-6alkyI)2amino, carbocyclyl-R22- or heterocyclyl-R23-; wherein R16 may be optionally substituted on carbon by one or more R2 ; and wherein if said heterocyclyl contains an -NW- moiety that nitrogen may be optionally substituted by a group selected from R25;
R14, R-15, R22 and R23 are independently selected from a direct bond, -N(R26)- or -C(O)N(R28)-; wherein R26 and R28 are hydrogen;
Rl ? and R25 are independently selected from Cualkyl and Cualkoxycarbonyl; and
R24 is methyl or phenyl.
8. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-7 wherein m is selected from 0-2; wherein the values of R4 may be the same or different.
9. A compound of formula (I):
Figure imgf000177_0001
(D wherein:
Ring A is phenyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, l-methylρyrazol-5-yl, 1-/- butylpyrazol-5-yl, thiert-2-yl, thiert-3-yl, indol-2-yl, l -methylittdol-2-yl, indol-4-yl, ihdol-5-yl, indo)-6-yl, indol-7-yl, 2,3-dihydrobenzofuran-7-yl, imidazo[l ,2-a]byridin-2-yl, isoxazol-3-yl, pyrrol-2-yl, benzimidazol-6-yl, l-methyl-2-oxoiiidσlin-5-yl, fUfdtt-2-yl, l ,3-thiazol-5-yl, pyrimidin-4-yl or 1 -methylpyrtol-2-yl; R is a substitUent on carbon and is selected from fiuoro, chloro, bromo, iodo, cyano, hydroxy, sulphamoyl, methyl, trifluoromethyl, 1 -cyano- 1 -methylethyl, methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, ΛζjV-dimethylamino, difluoromethylthio, N,jV-dimethylsulphamoyl, /-butyl, mesyl, cyclopropylaminosulphonyl, azetidin-1-ylsulphonyl, 5 tetrahydrofuran-2-ylmethylamitiosulphoriyl, N-methyl-N-(2,3-dihydroxypropyl)sulphamoyl, mesylamino, morpholinosυlphonyl, l -methylpiperazin-4-ylmethyl, 1 -ethylpiperazin-4- ylmethyl, 3,3-dimethylbut-l-yli-l-yl, morpholino, N,7V-dimethylaminomethyl, 3-methyl-3- hydroxybut-1-yn-l-yl, methylthiomethyl, mesylmethyl, jV-(methyl)-N-(methoxy)sulphamoyl, 2-hydroxymethy lpiperidin- 1 -ylsulphony 1, 3-hydroxymethylpiperidin- 1 -ylsulphonyl, A- l O hydroxymethylpiperidin-1-ylsulphoriyl, 1 , 1 -difluor oethy 1 , piperidin-1-yl, N,N-diethylamino, JV'N-dimethylureido, cyclopropyl, /-butoxycarboliylamino, pyrid-2-yl, phenoxy, 2-methoxy- 1 ,1 -dimethylethyl, mesylmethyl, l,3-thiazol-2-yl, 2-methyl-l,3-thiazol-5-yl, 1- methylcyclopropyl, 1 ,l-dimethylprop-2-yri-l-yl, l-(jV,N-dimethylsulphamoyl)-l -methylethyl, 1 , 1 -dimethylbut-2-yn- 1 -yl, jV-(methyl)-N-(methoxy)aminomethyl, 1 -
15 (N,N-dimethylcarbamoyl)-l -methylethyl, 4-methylimidazol-l-yl, 1 -(cyclopropyl)- 1- methylethyl, 2-methyl-3,4-dihydroxybut-2-yl, 2-methylbut-2-yl, 1 -hydroxy- 1- cyclopropylethyl, 1-cyaiioethyl, 2-cyario-3-methylbut-2-yl, 2-cyanobtit-2-yl, l-hydroxy-2- cyahoprop-2-yl and 2-cyanopyrrol-l -ylmethyl; ri is selected from 0-2; wherein the values of R1 may be the same or different; 0 R2 is hydrogen;
R3 is selected from fluoro, chloro, methyl or methoxy;
R is selected from fluoro, chloro, bromo, cyano, hydroxy, amino, carbamoyl, ureido, methyl, ethyl, methoxy, methylamino, isopropylamirio, morpholirio, 2- (dimethylamirio)ethylamitto, 2-(hydroxy)ethylamino, 2-(amino)ethylamino, 3-(pyrroliditi-l- 5 yl)propylamirio, 7V-methylcarbamoyl, acetylamino, 2-hydroxyacetylamino, trifluoromethyl, mesylamino, 2,2-dimethylpropanoylamino, 3-methoxypropanoylamino, cyclobutylcarbottylamino, cyclopropylamino, 2,3-dihydroxypropylamino, 1,3-dihydroxyprop- 2-ylamino, l-methylpiperazin-4-yl, l-methylρiperaziri-4-ylmethyl, acetyl, 7V-methyl-N-(3- dimethylaminopropyl)amirio, Λ/-methyl-N-(2-methoxyethyl)amiho, dimethylamino, 0 hydroxyniethyl, 1 ,2-dihydroxyethyl, pyrazol-5-ylamiho, 3-aminoprop-l-yn-l-yl, 3- hydroxyprop-1-yn-l-yl, 3-methylaminoprop-l-yn-l-yl, 3-dimethylaminoprop-l-yn-l-yl, A- aminobutylamino, pyrrolidin-2-ylamiiio, 3-methylaminopropyl, 3-dimethylamittopropyl, 3- hydroxypropyl, 3-dimethylamitiopropylainino, amiriomethyl, ρiperazin-1-yl, 1- ttiethylpiperazin-4-yl, 2,2-dimethyl-l ,3-dioxolan-4-ylmethylamino, pyrrolidin-3- ylmethylamino, piperidiii-4-ylmethylamino, imidazol-2-ylmetliylainino, methoxymethyl, ΛfN-dimethylsulphamoyl, formylamino, iiiorpholinomethyl, aminomethyl, 2- (dimethylamino)ethylamino, pyrrol- 1-yl, pytτol-2-yl, pyitolidin-2-yl, imidazol-4-yl, 5 cyclobutylamino, N-methyl-N-(2-dimethylaminoethyl)amino, 2-dimethylaminoethoxy, diniethylaminomethyl, cyclopfopylaminomethyl, piperidih-1-ylmethyl, methylaminomethyl, pyttolidin-2-ylmethoxy, 3-dimethylaniinopropoxy, methoxycafbonyl, l-(f- butoxycarbonyl)pyrrolidiii-2-yltτiethy lamino, 1 -(t-butoxycarbonyl)pyttoHdin-2-ylmethoxy, 2- phenoxyacetylamino and l-{7-butoxycarbonyl)pyiτolidih-2-yl; l O ill is selected from 0-2; whefein the values of R may be the same of different; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is hot:
N-t4-chloro-3-({t6-(4-methylpiperazin-l-yl)pyridin-3-yl]amino] carbonyl)phenyl]-2- morpholin-4-ylisorιicotiftamide;
15 N-{4-chloro-3-t({6-[t3-(dimethylamino)propyl](methyl)amiho]pyridin-3-yl}amino)carbonyl] phenyl } -2-frtorpholin-4-y lisonicotinamide; or
N-{4-chloro-3-t({6-tt2-(dimethylamino)ethylj(methyl)amino]pyridin-3-yl}amino)carbonyl] phenyl }-2-morpholin-4-ylisonicotinamide.
0 lO. A compound of fofinula (t):
Figure imgf000179_0001
(1) selected from:
N-(6-amino-5-chloropyridin-3-yl)-5-{t3-(l-cyano-l-methylethyl)benzoyl]amino}-2- 5 methylbenzamide;
N-(6-amino-5-chloropyridin-3-yl)-5-{t3-(l-cyano-l-methylethyl)-5-fluorobenzoyl]amino) -2- methylbettzamide;
S-JtS-Cl-cyano-l-methylethy^benzoylJaminoj -N-CS-methoxypyridin-S-yl^-methyl bettzamide; 7V-(6-amino-5-chlofopyridin-3-yl)-2-methyl-5-{[3-(trifluofomethyl)beiizoyl]amino} bertzamide;
S-ltS-Cl-cyano-l-methylethy^benzoylJaniinoJ-N-CS^-diniethylpyridin-S-yl)^- ttiethylbenzatnide; τV-(3-{t(6-amino-5-chloiOpyridih-3-yl)aitiino]cai-bonyl} -4-tnethylphenyl)-2-(l-cyano-l- methylethyl)isonicotinamide; jV-(6-amino-5-chloi-opyridin-3-yl)-2-chloi-o-5-{t3-(tfiflυofomethyl)benzoyl]amino} beiizamide;
7V-(6-acetylamino-pyfidin-3-yl)-5-t3-(cyaho-dimethyl-methyl)-benzoylaniino]-2-methyl- benzamide;
N-t6-(acetylamiiio)pyt-idin-3-yl]-2-chlofo-5-{t3-(tfifllioroiiiethyl)benzoyljamino}benzaniide; and yV-(6-amino-5-methylpyridin-3-yl)-2-chloiO-5-{t3-(l -cyaho-l-methylethyl)beHzoyl]amino} benzamide; of a pharmaceutically acceptable salt thereof.
11. A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof which process, wherein variable groups are, unless otherwise specified, as defined in claim 1, comprises of: Process a) reacting an amine of the formula (H)
Figure imgf000180_0001
(H) with an acid of formula (ill):
Figure imgf000180_0002
(111) or an activated acid derivative thereof; PrOcess b) feacting an acid of formula (IV):
Figure imgf000181_0001
(IV) with an amitte of formula (V):
Figure imgf000181_0002
of an activated acid derivative thereof; and thereafter if necessary: i) converting a coitφoUhd of the formula (I) into another compound of the formula (I); 10 ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt.
12. A pharmaceutical composition which comprises a compound of the formula (1), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-10, in association
15 with a pharmaceutically-acceptable diluent or carrier.
13. A compound of the formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims l-lθ for use as a medicament.
20 14. The use of a compound of the formula (1), of a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 -10, in the manufacture of a medicament for use in the production of a B-Raf inhibitory effect in a warm-blooded animal such as man.
15. The Use of a compound of the formula (1), of a pharmaceutically acceptable salt 25 thereof, as claimed in any one of claims 1 - 10, in the manufacture of a medicament for use in the production of an anti-calicer effect in a warm-blooded animal such as man. 16. The use of a compound of the formula (I), of a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-10, in the manufacture of a medicament for use in the treatment of melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries.
17. A method for producing a B-Raf inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-10.
18. A method for producing an anti-cancer effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims l-lθ.
19. A method of treating melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries, in a warm-blooded animal, sUch as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-10.
20. A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-10, in association with a pharmaceutically-acceptable diluent or carrier for use in the production of a B-Raf inhibitory effect in a warm-blooded animal such as man.
21. A pharmaceutical composition which comprises a compound of the formula (1), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims l-lθ, in association with a pharrtiaceutically-acceptable diluent or earner for use in the production of an anti-cancer effect in a warm-blooded animal such as man.
22. A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-10, in association with a pharmaceutically-acceptable diluent or carrier for use in the treatment of melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries in a warm-blooded animal such as man.
PCT/GB2005/004986 2004-12-22 2005-12-22 Pyridine carboxamide derivatives for use as anticancer agents WO2006067446A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2007547642A JP2008525406A (en) 2004-12-22 2005-12-22 Pyridine carboxamide derivatives for use as anticancer agents
MX2007007574A MX2007007574A (en) 2004-12-22 2005-12-22 Pyridine carboxamide derivatives for use as anticancer agents.
CA002589773A CA2589773A1 (en) 2004-12-22 2005-12-22 Pyridine carboxamide derivatives for use as anticancer agents
DE602005013819T DE602005013819D1 (en) 2004-12-22 2005-12-22 PYRIDINCARBOXYL ACID AMID DERIVATIVES FOR USE AS ANTICROBIAL AGENTS
BRPI0519181-5A BRPI0519181A2 (en) 2004-12-22 2005-12-22 compound or a pharmaceutically acceptable salt thereof, process for preparing it, pharmaceutical composition, use of a compound or a pharmaceutically acceptable salt thereof, and methods for producing a b-raf inhibitory effect on a warm-blooded animal to produce an anti-cancer effect on a warm-blooded animal and to treat a disease in a warm-blooded animal
EP05820952A EP1831198B1 (en) 2004-12-22 2005-12-22 Pyridine carboxamide derivatives for use as anticancer agents
AU2005317870A AU2005317870A1 (en) 2004-12-22 2005-12-22 Pyridine carboxamide derivatives for use as anticancer agents
IL183527A IL183527A0 (en) 2004-12-22 2007-05-29 Pyridine carboxamide derivatives for use as anticancer agents
NO20072784A NO20072784L (en) 2004-12-22 2007-05-31 Pyridene carboxamide derivatives for use as anticancer agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63923404P 2004-12-22 2004-12-22
US60/639,234 2004-12-22

Publications (1)

Publication Number Publication Date
WO2006067446A1 true WO2006067446A1 (en) 2006-06-29

Family

ID=35953912

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/004986 WO2006067446A1 (en) 2004-12-22 2005-12-22 Pyridine carboxamide derivatives for use as anticancer agents

Country Status (17)

Country Link
EP (1) EP1831198B1 (en)
JP (1) JP2008525406A (en)
KR (1) KR20070091675A (en)
CN (1) CN101128454A (en)
AR (1) AR054183A1 (en)
AT (1) ATE427946T1 (en)
AU (1) AU2005317870A1 (en)
BR (1) BRPI0519181A2 (en)
CA (1) CA2589773A1 (en)
DE (1) DE602005013819D1 (en)
IL (1) IL183527A0 (en)
MX (1) MX2007007574A (en)
NO (1) NO20072784L (en)
TW (1) TW200634003A (en)
UY (1) UY29300A1 (en)
WO (1) WO2006067446A1 (en)
ZA (1) ZA200705117B (en)

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022380A3 (en) * 2005-08-15 2007-06-21 Amgen Inc Bis-aryl amide compounds and methods of use
FR2903107A1 (en) * 2006-07-03 2008-01-04 Sanofi Aventis Sa IMIDAZOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
FR2925900A1 (en) * 2008-01-02 2009-07-03 Sanofi Aventis Sa New N-phenyl-imidazo(1,2-a)pyridine-2-carboxamide compounds are nuclear receptor related protein 1 modulators useful for preparing medicament to treat and prevent e.g. neurodegenerative diseases, brain injuries, epilepsy and cancer
WO2009111280A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
EP2175885A1 (en) * 2007-07-30 2010-04-21 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
KR100970670B1 (en) 2008-04-22 2010-07-15 계명대학교 산학협력단 Benzamide derivative as an inhibitor of cell proliferation and a process for preparing the same
EP2253617A1 (en) 2009-05-20 2010-11-24 Bayer CropScience AG Halogenated compounds as pesticides
US20110053905A1 (en) * 2009-09-03 2011-03-03 Allergan, Inc. Compounds as tyrosine kinase modulators
US7902219B2 (en) 2006-07-03 2011-03-08 Sanofi-Aventis 2-benzoylimidazopyridine derivatives, preparation and therapeutic use thereof
EP2352723A2 (en) * 2008-11-05 2011-08-10 Bayer CropScience AG Halogen-substituted compounds used as pesticides
US8067638B2 (en) 2005-06-21 2011-11-29 Mitsui Chemicals, Inc. Amide derivative and insecticide containing the same
EP2468717A1 (en) * 2006-10-27 2012-06-27 Bristol-Myers Squibb Company Heterocyclic Amide Compounds Useful as Kinase Inhibitors
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8314103B2 (en) 2007-08-07 2012-11-20 Piramal Enterprises Limited Pyridyl derivatives, their preparation and use
US8338452B2 (en) 2008-02-29 2012-12-25 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8394795B2 (en) 2008-02-29 2013-03-12 Array Biopharma Inc. Pyrazole [3, 4-B] pyridine Raf inhibitors
US8461189B2 (en) 2007-06-27 2013-06-11 Merck Sharp & Dohme Corp. Pyridyl derivatives as histone deacetylase inhibitors
US8486950B2 (en) 2009-06-11 2013-07-16 F. Hoffmann-La Roche Ag Janus kinase inhibitor compounds and methods
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
KR20140138602A (en) * 2011-12-21 2014-12-04 노비라 테라퓨틱스, 인코포레이티드 Hepatitis b antiviral agents
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
US9095581B2 (en) 2005-07-21 2015-08-04 Ardea Biosciences, Inc. Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
CN106187911A (en) * 2016-07-04 2016-12-07 烟台凯博医药科技有限公司 2 trifluoromethyl pyrimidine 4 carboxylic acids and derivant thereof and preparation method
EP2994454A4 (en) * 2013-12-09 2016-12-21 Unichem Lab Ltd An improved process for the preparation of (3r,4r)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine
EP3079682A4 (en) * 2013-12-13 2017-08-30 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US9884831B2 (en) 2015-03-19 2018-02-06 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
US9884818B2 (en) 2013-05-17 2018-02-06 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9895349B2 (en) 2013-04-03 2018-02-20 Janssen Sciences Ireland Us N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10071961B2 (en) 2013-10-23 2018-09-11 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10077239B2 (en) 2015-09-29 2018-09-18 Novira Therapeutics, Inc. Crystalline forms of a hepatitis B antiviral agent
US10112957B2 (en) 2014-10-22 2018-10-30 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
US10125094B2 (en) 2013-02-28 2018-11-13 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US10213420B2 (en) 2014-02-05 2019-02-26 Novira Therapeutics, Inc. Combination therapy for treatment of HBV infections
US10221192B2 (en) 2009-09-03 2019-03-05 Allergan, Inc. Compounds as tyrosine kinase modulators
US20190071400A1 (en) * 2016-03-09 2019-03-07 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
US10441589B2 (en) 2016-04-15 2019-10-15 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
US10450270B2 (en) 2013-07-25 2019-10-22 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10633348B2 (en) 2013-12-13 2020-04-28 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US10676429B2 (en) 2012-08-28 2020-06-09 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10919902B2 (en) 2015-07-06 2021-02-16 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US10954220B2 (en) 2016-03-09 2021-03-23 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US11078193B2 (en) 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US11560422B2 (en) 2013-12-27 2023-01-24 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
US11591405B2 (en) 2014-09-17 2023-02-28 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102140093A (en) * 2010-02-03 2011-08-03 上海源力生物技术有限公司 Pyridine amide derivatives, preparation method thereof and application thereof in medicines
US10428029B2 (en) * 2014-09-10 2019-10-01 Epizyme, Inc. Isoxazole carboxamide compounds
CN106632021A (en) * 2016-09-27 2017-05-10 中国药科大学 2-substitued isonicotinic acid type compound, and preparation method and application thereof
JP6755775B2 (en) * 2016-11-04 2020-09-16 富士アミドケミカル株式会社 4-Fluoroisoquinoline manufacturing method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055120A1 (en) * 1999-03-17 2000-09-21 Astrazeneca Ab Amide derivatives
US20040087626A1 (en) * 2002-03-29 2004-05-06 Renhowe Paul A. Substituted benz-azoles and methods of their use as inhibitors of Raf kinase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055120A1 (en) * 1999-03-17 2000-09-21 Astrazeneca Ab Amide derivatives
US20040087626A1 (en) * 2002-03-29 2004-05-06 Renhowe Paul A. Substituted benz-azoles and methods of their use as inhibitors of Raf kinase

Cited By (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067638B2 (en) 2005-06-21 2011-11-29 Mitsui Chemicals, Inc. Amide derivative and insecticide containing the same
US9095581B2 (en) 2005-07-21 2015-08-04 Ardea Biosciences, Inc. Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof
WO2007022380A3 (en) * 2005-08-15 2007-06-21 Amgen Inc Bis-aryl amide compounds and methods of use
US7704989B2 (en) 2006-07-03 2010-04-27 Sanofi-Aventis Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics
US8404848B2 (en) 2006-07-03 2013-03-26 Sanofi Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics
CN101484453B (en) * 2006-07-03 2012-07-04 赛诺菲-安万特 Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics
WO2008003856A1 (en) * 2006-07-03 2008-01-10 Sanofi-Aventis Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics
FR2903107A1 (en) * 2006-07-03 2008-01-04 Sanofi Aventis Sa IMIDAZOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
US7902219B2 (en) 2006-07-03 2011-03-08 Sanofi-Aventis 2-benzoylimidazopyridine derivatives, preparation and therapeutic use thereof
EP2468717A1 (en) * 2006-10-27 2012-06-27 Bristol-Myers Squibb Company Heterocyclic Amide Compounds Useful as Kinase Inhibitors
US8404689B2 (en) 2006-10-27 2013-03-26 Bristol-Myers Squibb Company Heterocyclic amide compounds useful as kinase inhibitors
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8461189B2 (en) 2007-06-27 2013-06-11 Merck Sharp & Dohme Corp. Pyridyl derivatives as histone deacetylase inhibitors
US9096559B2 (en) 2007-06-27 2015-08-04 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
EP2175885A4 (en) * 2007-07-30 2010-12-01 Ardea Biosciences Inc Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
EP2175885A1 (en) * 2007-07-30 2010-04-21 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
US8314103B2 (en) 2007-08-07 2012-11-20 Piramal Enterprises Limited Pyridyl derivatives, their preparation and use
WO2009106748A3 (en) * 2008-01-02 2009-12-30 Sanofi-Aventis Derivatives of n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof
WO2009106748A2 (en) 2008-01-02 2009-09-03 Sanofi-Aventis Derivatives of n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof
FR2925900A1 (en) * 2008-01-02 2009-07-03 Sanofi Aventis Sa New N-phenyl-imidazo(1,2-a)pyridine-2-carboxamide compounds are nuclear receptor related protein 1 modulators useful for preparing medicament to treat and prevent e.g. neurodegenerative diseases, brain injuries, epilepsy and cancer
WO2009111280A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
US8338452B2 (en) 2008-02-29 2012-12-25 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
US8394795B2 (en) 2008-02-29 2013-03-12 Array Biopharma Inc. Pyrazole [3, 4-B] pyridine Raf inhibitors
KR100970670B1 (en) 2008-04-22 2010-07-15 계명대학교 산학협력단 Benzamide derivative as an inhibitor of cell proliferation and a process for preparing the same
EP2352723A2 (en) * 2008-11-05 2011-08-10 Bayer CropScience AG Halogen-substituted compounds used as pesticides
EP2352723B1 (en) * 2008-11-05 2016-11-23 Bayer Intellectual Property GmbH Pesticidal n-aryl- or n-heteroaryl pyrazole carboxamide compounds
EP2253617A1 (en) 2009-05-20 2010-11-24 Bayer CropScience AG Halogenated compounds as pesticides
US8486950B2 (en) 2009-06-11 2013-07-16 F. Hoffmann-La Roche Ag Janus kinase inhibitor compounds and methods
US20110053905A1 (en) * 2009-09-03 2011-03-03 Allergan, Inc. Compounds as tyrosine kinase modulators
US9475801B2 (en) 2009-09-03 2016-10-25 Allergan, Inc. Compounds as tyrosine kinase modulators
US8614234B2 (en) * 2009-09-03 2013-12-24 Allergan, Inc. Compounds as tyrosine kinase modulators
US9725433B2 (en) 2009-09-03 2017-08-08 Allergan, Inc. Compounds as tyrosine kinase modulators
US10221192B2 (en) 2009-09-03 2019-03-05 Allergan, Inc. Compounds as tyrosine kinase modulators
US9328103B2 (en) 2009-09-03 2016-05-03 Allergan, Inc. Compounds as tyrosine kinase modulators
US11911371B2 (en) 2010-03-19 2024-02-27 Novartis Ag Pyridine and pyrazine derivative for the treatment of chronic bronchitis
USRE46757E1 (en) 2010-03-19 2018-03-20 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US10117858B2 (en) 2010-03-19 2018-11-06 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8476269B2 (en) 2010-03-19 2013-07-02 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US9365552B2 (en) 2010-03-19 2016-06-14 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US9751876B2 (en) 2011-09-01 2017-09-05 Novartis Ag Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US9751857B2 (en) 2011-12-21 2017-09-05 Novira Therapeutics, Inc. Hepatitis B antiviral agents
AU2016231615B2 (en) * 2011-12-21 2018-06-07 Novira Therapeutics, Inc. Hepatitis B antiviral agents
KR20140138602A (en) * 2011-12-21 2014-12-04 노비라 테라퓨틱스, 인코포레이티드 Hepatitis b antiviral agents
AU2012358332B2 (en) * 2011-12-21 2016-06-23 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US10196376B2 (en) 2011-12-21 2019-02-05 Novira Therapeutics, Inc. Hepatitis B antiviral agents
EP2794565A4 (en) * 2011-12-21 2015-06-24 Novira Therapeutics Inc Hepatitis b antiviral agents
US9676747B2 (en) 2011-12-21 2017-06-13 Novira Therapeutics, Inc. Hepatitis B antiviral agents
KR101699822B1 (en) * 2011-12-21 2017-01-25 노비라 테라퓨틱스, 인코포레이티드 Hepatitis b antiviral agents
AU2012358332C1 (en) * 2011-12-21 2017-01-19 Novira Therapeutics, Inc. Hepatitis B antiviral agents
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
US10995064B2 (en) 2012-08-28 2021-05-04 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US10676429B2 (en) 2012-08-28 2020-06-09 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US10125094B2 (en) 2013-02-28 2018-11-13 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US10941113B2 (en) 2013-02-28 2021-03-09 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
US10398677B2 (en) 2013-04-03 2019-09-03 Janssen Sciences Ireland Uc N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9895349B2 (en) 2013-04-03 2018-02-20 Janssen Sciences Ireland Us N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10457638B2 (en) 2013-05-17 2019-10-29 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9884818B2 (en) 2013-05-17 2018-02-06 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10450270B2 (en) 2013-07-25 2019-10-22 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US10071961B2 (en) 2013-10-23 2018-09-11 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10377709B2 (en) 2013-10-23 2019-08-13 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP2994454A4 (en) * 2013-12-09 2016-12-21 Unichem Lab Ltd An improved process for the preparation of (3r,4r)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine
EP3079682A4 (en) * 2013-12-13 2017-08-30 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US10633348B2 (en) 2013-12-13 2020-04-28 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
AU2014361800B2 (en) * 2013-12-13 2020-05-07 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US11560422B2 (en) 2013-12-27 2023-01-24 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
US9339510B2 (en) 2014-01-16 2016-05-17 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9505722B2 (en) 2014-01-16 2016-11-29 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9873671B2 (en) 2014-01-16 2018-01-23 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10213420B2 (en) 2014-02-05 2019-02-26 Novira Therapeutics, Inc. Combination therapy for treatment of HBV infections
US10632112B2 (en) 2014-02-05 2020-04-28 Novira Therapeutics, Inc. Combination therapy for treatment of HBV infections
US11078193B2 (en) 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
US11591405B2 (en) 2014-09-17 2023-02-28 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US10464949B2 (en) 2014-10-22 2019-11-05 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
US10844077B2 (en) 2014-10-22 2020-11-24 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
US10112957B2 (en) 2014-10-22 2018-10-30 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
US9884831B2 (en) 2015-03-19 2018-02-06 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
US10537580B2 (en) 2015-03-19 2020-01-21 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
US10919902B2 (en) 2015-07-06 2021-02-16 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US11858939B2 (en) 2015-07-06 2024-01-02 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US10077239B2 (en) 2015-09-29 2018-09-18 Novira Therapeutics, Inc. Crystalline forms of a hepatitis B antiviral agent
US20190071400A1 (en) * 2016-03-09 2019-03-07 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
US11014882B2 (en) 2016-03-09 2021-05-25 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
EP3426244A4 (en) * 2016-03-09 2019-11-06 Raze Therapeutics Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
US10954220B2 (en) 2016-03-09 2021-03-23 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
EP4234552A3 (en) * 2016-03-09 2023-10-18 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
US11634412B2 (en) 2016-03-09 2023-04-25 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
US11535593B2 (en) 2016-03-09 2022-12-27 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
US11129834B2 (en) 2016-04-15 2021-09-28 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
US10441589B2 (en) 2016-04-15 2019-10-15 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
CN106187911A (en) * 2016-07-04 2016-12-07 烟台凯博医药科技有限公司 2 trifluoromethyl pyrimidine 4 carboxylic acids and derivant thereof and preparation method
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10519149B2 (en) 2017-01-11 2019-12-31 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11225479B2 (en) 2017-01-11 2022-01-18 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US11286256B2 (en) 2017-01-11 2022-03-29 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US10793567B2 (en) 2017-01-11 2020-10-06 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10696673B2 (en) 2017-01-11 2020-06-30 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11912702B2 (en) 2017-08-07 2024-02-27 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Also Published As

Publication number Publication date
CA2589773A1 (en) 2006-06-29
EP1831198A1 (en) 2007-09-12
UY29300A1 (en) 2006-07-31
AR054183A1 (en) 2007-06-06
KR20070091675A (en) 2007-09-11
ZA200705117B (en) 2008-10-29
JP2008525406A (en) 2008-07-17
MX2007007574A (en) 2007-07-24
ATE427946T1 (en) 2009-04-15
BRPI0519181A2 (en) 2008-12-30
TW200634003A (en) 2006-10-01
NO20072784L (en) 2007-07-17
IL183527A0 (en) 2007-09-20
CN101128454A (en) 2008-02-20
EP1831198B1 (en) 2009-04-08
DE602005013819D1 (en) 2009-05-20
AU2005317870A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
EP1831198A1 (en) Pyridine carboxamide derivatives for use as anticancer agents
WO2006067445A2 (en) Csf-1r kinase inhibitors
AU2005293384A1 (en) Quinoxalines as B Raf inhibitors
US20070259849A1 (en) Azine-Carboxamides as Anti-Cancer Agents
NZ553087A (en) Quinazolinone derivatives and their use as B-raf inhibitors
MXPA06014696A (en) Substituted quinazolones as anti-cancer agents.
US20080146570A1 (en) Chemical Compounds
CA2577278A1 (en) Quinazolinone derivatives and their use as b-raf inhibitors
CN102964294A (en) Pyridyl inhibitors of hedgehog signalling
EP1966159A2 (en) Chemical compounds
MX2008008156A (en) Quinazoline derivatives, process for their preparation and their use as anti-cancer agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005317870

Country of ref document: AU

Ref document number: 183527

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2589773

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2005317870

Country of ref document: AU

Date of ref document: 20051222

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/007574

Country of ref document: MX

Ref document number: 2007547642

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2005317870

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005820952

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 5331/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 556637

Country of ref document: NZ

Ref document number: 1020077016841

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200580048590.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005820952

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0519181

Country of ref document: BR